



**Europäisches  
Patentamt**

**European  
Patent Office**

**Office européen  
des brevets**

03.12.03

REC'D 18 FEB 2004

WIPO

PCT

**Bescheinigung**

**Certificate**

**Attestation**

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

**Patentanmeldung Nr. Patent application No. Demande de brevet n°**

02102678.6

**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

**R C van Dijk**

**BEST AVAILABLE COPY**



Anmeldung Nr:  
Application no.: 02102678.6  
Demande no:

Anmeldetag:  
Date of filing: 04.12.02  
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:  
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.  
If no title is shown please refer to the description.  
Si aucun titre n'est indiqué se référer à la description.)

NOVEL IFNgamma-LIKE POLYPEPTIDES


In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)  
revendiquée(s)  
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/  
Classification internationale des brevets:

C07K14/00

Am Anmeldetag benannte Vertragsstaaten/Contracting states designated at date of  
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK



## **NOVEL IFNgamma-LIKE POLYPEPTIDES**

### **FIELD OF THE INVENTION**

The present invention relates to nucleic acid sequences identified in human  
5 genome as encoding for novel polypeptides, more specifically for novel polypeptides  
having at least one activity of human Interferon gamma.

### **BACKGROUND OF THE INVENTION**

Interferons (IFNs) are cytokines that play a complex and central role in  
10 mammalian immunological response to pathologic events such as infections,  
immunological disorders, and neoplastic degenerations.

There are two groups of IFNs: type I (IFNalpha and IFNbeta) and type II  
(IFNgamma, also known as immune interferon). IFNgamma is a cytokine produced by  
T-lymphocytes and natural killer cells and exists as a homodimer of two noncovalently  
15 bound polypeptide subunits, found in different glycosylated forms (Younes-HM and  
Amsden BG, 2002; Boehm U et al., 1997).

IFNgamma is a potent activator of mononuclear phagocytes, capable of affecting  
immune response by inducing the expression of several molecule, including tumor  
necrosis factor (TNF), class I / II major histocompatibility complex (MHC) molecules,  
20 and the enzymes mediating the respiratory burst which allow macrophages to kill  
phagocytosed microbes and tumor cells. IFNgamma triggers, by binding its cell surface  
receptor and activating intracellular signal transduction (JAK-STAT pathway, in  
particular), not only T and B-lymphocytes differentiation and the cytolytic activity of  
natural killer (NK) cells, but also the apoptosis or the proliferation of other cell types,  
25 such as vascular endothelial cells, also by modulating tryptophan metabolism.

The cellular responses to IFNgamma are particularly complex also because this protein coordinates many different cellular events. Moreover, IFNgamma may have agonistic, as well as antagonistic, properties which can be cell type-specific.

Important therapeutic properties of IFNgamma, alone or in combination with other compounds, have been suggested and/or demonstrated for a broad range of indications including Interstitial Pulmonary Fibrosis (Ziesche R et al., 1999), asthma (WO 01/34180), or septic shock (Docke WD et al., 1997). In cancer immunotherapy, IFNgamma is injected along with irradiated autologous tumor cell, since it acts as an adjuvant and enhances the immune response to the tumor cell challenge. IFNgamma is currently approved by the Food and Drug Administration (FDA) for limited clinical uses (such as for the reduction of infections associated with chronic granulomatous disease and for delaying progression in patients with malignant osteopetrosis), since this protein also yields significant side effects, such as fever, fatigue, nausea, and neurotoxicity.

These limitations, probably due to the expression of IFNgamma receptors on the surface of almost all types of human cells and the consequent excessive signaling activities (Bach EA et al., 1997), have prompted the development of alternative forms and delivering systems for this cytokine to achieve more acceptable results. Various naturally-occurring or synthetic forms of the human IFNgamma have been described, having longer or shorter N- / C-terminal sequences, or mutated in specific residues for improving specific properties such as heat-stability (WO97/11179) or glycosylation (WO 02/81507).

The literature provides many examples of different approaches for characterizing novel proteins by making use of bioinformatics analysis of transcripts, for example for chemokines (Wells TN and Peitsch MC, 2000). For example, GB patent application No.

0130720.6 discloses a novel polypeptide sequence, called INSP037, matching structural features of IFNgamma.

Since the actual content in DNA sequence in human genome encoding for IFNs (and for any other protein family) is still unknown, the possibility still exists to identify DNA sequence encoding polypeptide having IFNgamma-like structure and activity by  
5 applying alternative homology/structural criteria to the totality of Open Reading Frames (ORFs, that is, genomic sequences containing consecutive triplets of nucleotides coding for amino acids, not interrupted by a termination codon and potentially translatable in a polypeptide) present in human genome.

10

#### **SUMMARY OF THE INVENTION**

The invention is based upon the identification of Open Reading Frames (ORFs) in human genome encoding novel IFNgamma-like polypeptides on the basis of the homology with INSP037.

15 Accordingly, the invention provides identifies polypeptides having the amino acid sequence given by SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, and 40, their mature forms, variants, and fragments, as polypeptides having at least one activity of human IFNgamma. The invention includes also the nucleic acids encoding them, vectors containing such nucleic acids, and cell containing these vectors  
20 or nucleic acids, as well as other related reagents such as fusion proteins and ligands.

The invention provides methods for identifying and making these molecules, for preparing pharmaceutical compositions containing them, and for their use in the diagnosis, prevention and treatment of diseases where compounds having at least one activity of human IFNgamma may provide positive effects.

25

### DESCRIPTION OF THE FIGURES

Figure 1: alignment of IFNFH01 ORF (SEQ ID NO: 1) with pIFNFH01 protein sequence (SEQ ID NO: 2). The residues found identical in INSP037 are underlined (71% of Identity with INSP037). The arrows indicate the position of the primers CL\_IFNFH01\_5 (forward, SEQ ID NO: 41) and CL\_IFNFH01\_3 (reverse; SEQ ID NO: 42) in the ORF sequence.

Figure 2: alignment of IFNFH03 ORF (SEQ ID NO: 3) with pIFNFH03 protein sequence (SEQ ID NO: 4). The residues found identical in INSP037 are underlined (73.5% of Identity with INSP037). The arrows indicate the position of the primers CL\_IFNFH03\_5 (forward; SEQ ID NO: 43) and CL\_IFNFH03\_3 (reverse; SEQ ID NO: 44) in the ORF sequence.

Figure 3: alignment of IFNFH04 ORF (SEQ ID NO: 5) with pIFNFH04 protein sequence (SEQ ID NO: 6). The residues found identical in INSP037 are underlined (73.5% of identity with INSP037). The arrows indicate the position of the primers CL\_IFNFH04\_5 (forward; SEQ ID NO: 45) and CL\_IFNFH04\_3 (reverse; SEQ ID NO: 46) in the ORF sequence.

Figure 4: alignment of IFNFH08 ORF (SEQ ID NO: 7) with pIFNFH08 protein sequence (SEQ ID NO: 8). The residues found identical in INSP037 are underlined (78.5% of identity with INSP037). The arrows indicate the position of the primers CL\_IFNFH08\_5 (forward; SEQ ID NO: 47) and CL\_IFNFH08\_3 (reverse; SEQ ID NO: 48) in the ORF sequence.

Figure 5: alignment of IFNFH10 ORF (SEQ ID NO: 9) with pIFNFH10 protein sequence (SEQ ID NO: 10). The residues found identical in INSP037 are underlined (69.5% of identity with INSP037). The arrows indicate the

position of the primers CL\_IFNFH10\_5 (forward; SEQ ID NO: 49) and CL\_IFNFH10\_3 (reverse; SEQ ID NO: 50) in the ORF sequence.

Figure 6: alignment of IFNFH11 ORF (SEQ ID NO: 11) with pIFNFH11 protein sequence (SEQ ID NO: 12). The residues found identical in INSP037 are underlined (73.5% of identity with INSP037). The arrows indicate the position of the primers CL\_IFNFH11\_5 (forward; SEQ ID NO: 51) and CL\_IFNFH11\_3 (reverse; SEQ ID NO: 52) in the ORF sequence.

Figure 7: alignment of IFNFH12 ORF (SEQ ID NO: 13) with pIFNFH12 protein sequence (SEQ ID NO: 14). The residues found identical in INSP037 are underlined (73.5% of identity with INSP037). The arrows indicate the position of the primers CL\_IFNFH12\_5 (forward; SEQ ID NO: 53) and CL\_IFNFH12\_3 (reverse; SEQ ID NO: 54) in the ORF sequence.

Figure 8: alignment of IFNFH13 ORF (SEQ ID NO: 15) with pIFNFH13 protein sequence (SEQ ID NO: 16). The residues found identical in INSP037 are underlined (69.5% of identity with INSP037). The arrows indicate the position of the primers CL\_IFNFH13\_5 (forward; SEQ ID NO: 55) and CL\_IFNFH13\_3 (reverse; SEQ ID NO: 56) in the ORF sequence.

Figure 9: alignment of IFNFH14 ORF (SEQ ID NO: 17) with pIFNFH14 protein sequence (SEQ ID NO: 18). The residues found identical in INSP037 are underlined (71% of identity with INSP037). The arrows indicate the position of the primers CL\_IFNFH14\_5 (forward; SEQ ID NO: 57) and CL\_IFNFH14\_3 (reverse; SEQ ID NO: 58) in the ORF sequence.

Figure 10: alignment of IFNFH15 ORF (SEQ ID NO: 19) with pIFNFH15 protein sequence (SEQ ID NO: 20). The residues found identical in INSP037 are underlined (71% of identity with INSP037). The arrows indicate the position



of the primers CL\_IFNFH15\_5 (forward; SEQ ID NO: 59) and CL\_IFNFH15\_3 (reverse; SEQ ID NO: 60) in the ORF sequence.

Figure 11: alignment of IFNFH20 ORF (SEQ ID NO: 21) with pIFNFH20 protein sequence (SEQ ID NO: 22). The residues found identical in INSP037 are underlined (67% of identity with INSP037). The arrows indicate the position of the primers CL\_IFNFH20\_5 (forward; SEQ ID NO: 61) and CL\_IFNFH20\_3 (reverse; SEQ ID NO: 62) in the ORF sequence.

Figure 12: alignment of IFNFH23 ORF (SEQ ID NO: 23) with pIFNFH23 protein sequence (SEQ ID NO: 24). The residues found identical in INSP037 are underlined (72% of identity with INSP037). The arrows indicate the position of the primers CL\_IFNFH23\_5 (forward; SEQ ID NO: 63) and CL\_IFNFH23\_3 (reverse; SEQ ID NO: 64) in the ORF sequence.

Figure 13: alignment of IFNFH25 ORF (SEQ ID NO: 25) with pIFNFH25 protein sequence (SEQ ID NO: 26). The residues found identical in INSP037 are underlined (70% of identity with INSP037).

Figure 14: alignment of IFNFH27 ORF (SEQ ID NO: 27) with pIFNFH27 protein sequence (SEQ ID NO: 28). The residues found identical in INSP037 are underlined (68% of identity with INSP037). The arrows indicate the position of the primers CL\_IFNFH27\_5 (forward; SEQ ID NO: 65) and CL\_IFNFH27\_3 (reverse; SEQ ID NO: 66) in the ORF sequence.

Figure 15: alignment of IFNFH31 ORF (SEQ ID NO: 29) with pIFNFH31 protein sequence (SEQ ID NO: 30). The residues found identical in INSP037 are underlined (68% of identity with INSP037). The arrows indicate the position of the primers CL\_IFNFH31\_5 (forward; SEQ ID NO: 67) and CL\_IFNFH31\_3 (reverse; SEQ ID NO: 68) in the ORF sequence.

Figure 16: alignment of IFNFH32 ORF (SEQ ID NO: 31) with pIFNFH32 protein sequence (SEQ ID NO: 32). The residues found identical in INSP037 are underlined (70% of identity with INSP037). The arrows indicate the position of the primers CL\_IFNFH32\_5 (forward; SEQ ID NO: 69) and CL\_IFNFH32\_3 (reverse; SEQ ID NO: 70) in the ORF sequence.

Figure 17: alignment of IFNFH36 ORF (SEQ ID NO: 33) with pIFNFH36 protein sequence (SEQ ID NO: 34). The residues found identical in INSP037 are underlined (72% of identity with INSP037). The arrows indicate the position of the primers CL\_IFNFH36\_5 (forward; SEQ ID NO: 71) and CL\_IFNFH36\_3 (reverse; SEQ ID NO: 72) in the ORF sequence.

Figure 18: alignment of IFNFH37 ORF (SEQ ID NO: 35) with pIFNFH37 protein sequence (SEQ ID NO: 36). The residues found identical in INSP037 are underlined (76% of identity with INSP037). The arrows indicate the position of the primers CL\_IFNFH37\_5 (forward; SEQ ID NO: 73) and CL\_IFNFH37\_3 (reverse; SEQ ID NO: 74) in the ORF sequence.

Figure 19: alignment of IFNFH39 ORF (SEQ ID NO: 37) with pIFNFH39 protein sequence (SEQ ID NO: 38). The residues found identical in INSP037 are underlined (70% of identity with INSP037). The arrows indicate the position of the primers CL\_IFNFH39\_5 (forward; SEQ ID NO: 75) and CL\_IFNFH39\_3 (reverse; SEQ ID NO: 76) in the ORF sequence.

Figure 20: alignment of IFNFH42 ORF (SEQ ID NO: 39) with pIFNFH42 protein sequence (SEQ ID NO: 40). The residues found identical in INSP037 are underlined (67% of identity with INSP037). The arrows indicate the position of the primers CL\_IFNFH42\_5 (forward; SEQ ID NO: 77) and CL\_IFNFH42\_3 (reverse; SEQ ID NO: 78) in the ORF sequence.

Figure 21: alignment of the human IFN gamma-like INSP037 (SEQ ID NO: 155) with the protein sequences of the invention, grouped according to their length and homology. The region common to INSP037 and pIFNFHs is boxed (residues identical in INSP037 are underlined).

5 Figure 11: map of the expression vector pEAK12D.

### DETAILED DESCRIPTION OF THE INVENTION

The main object of the present invention are novel, isolated polypeptides having at least one activity of human IFN $\gamma$  selected from the group consisting of:

- 10 a) amino acid sequences SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, and 40;
- b) variants of the amino acid sequences SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, and 40, which are at least 80% identical to said sequences;
- 15 c) mature forms, active fragments, precursors, salts, or derivatives of the amino acid sequences given in a) or b).

The novel polypeptides pIFNFH01 (SEQ ID NO: 2), pIFNFH03 (SEQ ID NO: 4), pIFNFH04 (SEQ ID NO: 6), pIFNFH08 (SEQ ID NO: 8), pIFNFH10 (SEQ ID NO: 10), pIFNFH11 (SEQ ID NO: 12), pIFNFH12 (SEQ ID NO: 14), pIFNFH13 (SEQ ID NO: 16),  
20 pIFNFH14 (SEQ ID NO: 18), pIFNFH15 (SEQ ID NO: 20), pIFNFH20 (SEQ ID NO: 22), pIFNFH23 (SEQ ID NO: 24), pIFNFH25 (SEQ ID NO: 26), pIFNFH27 (SEQ ID NO: 28), pIFNFH31 (SEQ ID NO: 30), pIFNFH32 (SEQ ID NO: 32), pIFNFH36 (SEQ ID NO: 34), pIFNFH37 (SEQ ID NO: 36), pIFNFH39 (SEQ ID NO: 38), and pIFNFH42 (SEQ ID NO: 40) were identified on the basis of the comparable length and the sequence homology

with INSP037, a protein predicted to be an IFNgamma-like protein (GB patent application No. 0130720.6).

The totality of amino acid sequences obtained by translating the known ORFs in the human genome were challenged using INSP037 protein sequence, and the positive  
5 hits were further selected on the basis of sequence length and amino acid conservation comparable to INSP037 and/or human IFNgamma. Therefore, the novel polypeptides of the invention can be predicted to have at least one of the biological activities of human IFNgamma.

In addition to such sequences, a series of polypeptides forms part of the  
10 disclosure of the invention, such as variants of the amino acid sequences SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, and 40, which are at least 80% identical to said sequences. Similar variants can be identified and/or designed using commonly available bioinformatic tools (Mulder NJ and Apweiler R, 2002; Rehm BH, 2001), measuring the percentage over the entire amino acid  
15 sequences disclosed in figures 1-20, or in particular over a segment of at least 78 amino acids containing the region of homology with INSP037, as indicated in figure 21. The variants may correspond to naturally occurring allelic variants of the sequences SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, and 40, as the ones possibly resulting from the translation of a single nucleotide polymorphism.

20 In accordance with the present invention, any non-identical amino acid substitution should be preferably either an amino acid which is present in the same position in another of the protein sequence of the invention (figure 21), or a "conservative" or "safe" substitution, which introduces an amino acids having sufficiently similar chemical properties (eg a basic, positively charged amino acid

should be replaced by another basic, positively charged amino acid), in order to preserve the structure and the biological function of the molecule.

The literature provide many models on which the selection of conservative amino acids substitutions can be performed on the basis of statistical and physico-chemical studies on the sequence and/or the structure of proteins (Rogov SI and Nekrasov AN, 2001). Protein design experiments have shown that the use of specific subsets of amino acids can produce foldable and active proteins, helping in the classification of amino acid "synonymous" substitutions which can be more easily accommodated in protein structure, and which can be used to detect functional and structural homologs, orthologs, and paralogs (Murphy LR et al., 2000). The groups of synonymous amino acids and the groups of more preferred synonymous amino acids are shown in Table I.

Specific, non-conservative mutations can be also introduced in the polypeptides of the invention with different purposes, for example, the elimination of immunogenic epitopes, the alteration of binding properties, the alteration of the glycosylation pattern, or the improvement of protein stability (van den Burg B and Eijlsink V, 2002; Robinson CR, 2002; WO 02/05146; WO 00/34317; WO 98/52976).

Mature forms, active fragments, precursors, salts, or derivatives of the amino acid sequences SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, and 40, and of the variants defined before, are also part of the disclosure of the present invention when they have at least one of the biological activities of human IFN $\gamma$ .

Mature forms and active fragments can result from natural or artificial post-transcriptional or post-translational events. For example, truncated proteins can be generated by genetic engineering and expressed in host cells, or by a proteolytic processing leading to the removal of N-terminal sequences (by signal peptidases and

other proteolytic enzymes). Other alternative mature forms can also result from the addition of chemical groups such as sugars or phosphates.

Fragments should present deletions of terminal or internal amino acids not altering their function, and should involve generally a few amino acids, e.g., under ten, and preferably under three, without removing or displacing amino acids which are critical to the conformation of the active protein.

The "precursors" are compounds which can be converted into the compounds of present invention by metabolic and enzymatic processing prior or after the administration to the cells or to the body.

The term "salts" herein refers to both salts of carboxyl groups and to acid addition salts of amino groups of the polypeptides of the present invention. Salts of a carboxyl group may be formed by means known in the art and include inorganic salts, for example, sodium, calcium, ammonium, ferric or zinc salts, and the like, and salts with organic bases as those formed, for example, with amines, such as triethanolamine, arginine or lysine, piperidine, procaine and the like. Acid addition salts include, for example, salts with mineral acids such as, for example, hydrochloric acid or sulfuric acid, and salts with organic acids such as, for example, acetic acid or oxalic acid. Any of such salts should have substantially similar activity to the peptides and polypeptides of the invention or their analogs.

The term "derivatives" as herein used refers to derivatives which can be prepared from the functional groups present on the lateral chains of the amino acid moieties or on the amino- or carboxy-terminal groups according to known methods. Such molecules can result also from other modifications which do not normally alter primary sequence, for example *in vivo* or *in vitro* chemical derivatization of polypeptides (acetylation or carboxylation), those made by modifying the pattern of phosphorylation

(introduction of phosphotyrosine, phosphoserine, or phosphothreonine residues) or glycosylation (by exposing the polypeptide to mammalian glycosylating enzymes) of a peptide during its synthesis and processing or in further processing steps. Alternatively, derivatives may include esters or aliphatic amides of the carboxyl-groups and N-acyl derivatives of free amino groups or O-acyl derivatives of free hydroxyl-groups and are formed with acyl-groups as for example alkanoyl- or aryl-groups.

The generation of the derivatives may involve a site-directed modification of an appropriate residue, in an internal or terminal position. The residues used for attachment should they have a side-chain amenable for polymer attachment (i.e., the side chain of an amino acid bearing a functional group, e.g., lysine, aspartic acid, glutamic acid, cysteine, histidine, etc.). Alternatively, a residue having a side chain amenable for polymer attachment can replace an amino acid of the polypeptide, or can be added in an internal or terminal position of the polypeptide. Also, the side chains of the genetically encoded amino acids can be chemically modified for polymer attachment, or unnatural amino acids with appropriate side chain functional groups can be employed. The preferred method of attachment employs a combination of peptide synthesis and chemical ligation. Advantageously, the attachment of a water-soluble polymer will be through a biodegradable linker, especially at the amino-terminal region of a protein. Such modification acts to provide the protein in a precursor (or "pro-drug") form, that, upon degradation of the linker releases the protein without polymer modification.

Polymer attachment may be not only to the side chain of the amino acid naturally occurring in a specific position of the antagonist or to the side chain of a natural or unnatural amino acid that replaces the amino acid naturally occurring in a specific position of the antagonist, but also to a carbohydrate or other moiety that is attached to

the side chain of the amino acid at the target position. Rare or unnatural amino acids can be also introduced by expressing the protein in specifically engineered bacterial strains (Bock A, 2001).

All the above indicated variants can be natural, being identified in organisms other than humans, or artificial, being prepared by chemical synthesis, by site-directed mutagenesis techniques, or any other known technique suitable thereof, which provide a finite set of substantially corresponding mutated or shortened peptides or polypeptides which can be routinely obtained and tested by one of ordinary skill in the art using the teachings presented in the prior art.

The novel amino acid sequences disclosed in the present patent application can be used to provide different kind of reagents and molecules. Examples of these compounds are binding proteins or antibodies that can be identified using their full sequence or specific fragments, such as antigenic determinants. Peptide libraries can be used in known methods (Tribbick G, 2002) for screening and characterizing antibodies or other proteins binding the claimed amino acid sequences, and for identifying alternative forms of the polypeptides of the invention having similar binding properties.

The present patent application discloses also fusion proteins comprising any of the polypeptides described above. These polypeptides should contain protein sequence heterologous to the one disclosed in the present patent application, without significantly impairing the IFNgamma-related activity and possibly providing additional properties. Examples of such properties are an easier purification procedure, a longer lasting half-life in body fluids, an additional binding moiety, the maturation by means of an endoproteolytic digestion, or extracellular localization. This latter feature is of particular importance for defining a specific group of fusion or chimeric proteins



Included in the above definition since it allows the claimed molecules to be localized in the space where not only isolation and purification of these polypeptides is facilitated, but also where generally IFNs and their receptors interact.

Design of the moieties, ligands, and linkers, as well methods and strategies for the construction, purification, detection and use of fusion proteins are disclosed in the literature (Nilsson J et al., 1997; Methods Enzymol, Vol. 326-328, Academic Press, 2000). The preferred one or more protein sequences which can be comprised in the fusion proteins belong to these protein sequences: membrane-bound protein, immunoglobulin constant region, multimerization domains, extracellular proteins, signal peptide-containing proteins, export signal-containing proteins. Features of these sequences and their specific uses are disclosed in a detailed manner, for example, for albumin fusion proteins (WO 01/77137), fusion proteins including multimerization domain (WO 01/02440, WO 00/24782), immunoconjugates (Garrett MC, 2001), or fusion protein providing additional sequences which can be used for purifying the recombinant products by affinity chromatography (Constans A, 2002; Burgess RR and Thompson NE, 2002; Lowe CR et al., 2001; J. Bioch. Biophys. Meth., vol. 49 (1-3), 2001; Shelbani N, 1999).

The polypeptides of the invention can be used to generate and characterize ligands binding specifically to them. These molecules can be natural or artificial, very different from the chemical point of view (binding proteins, antibodies, molecularly imprinted polymers), and can be produced by applying the teachings in the art (WO 02/74938; Kuroiwa Y et al., 2002; Haupt K, 2002; van Dijk MA and van de Winkel JG, 2001; Gavilondo JV and Larrick JW, 2000). Such ligands can antagonize or inhibit the IFN $\gamma$ -related activity of the polypeptide of the invention against which they have been generated. In particular, common and efficient ligands are represented by

extracellular domain of a membrane-bound protein or antibodies, which can be in the form monoclonal, polyclonal, humanized antibody, or an antigen binding fragment.

The polypeptides and the polypeptide-based derived reagents described above can be in alternative forms, according to the desired method of use and/or production, such as active conjugates or complexes with a molecule chosen amongst radioactive labels, fluorescent labels, biotin, or cytotoxic agents.

Specific molecules, such as peptide mimetics, can be also designed on the sequence and/or the structure of a polypeptide of the invention. Peptide mimetics (also called peptidomimetics) are peptides chemically modified at the level of amino acid side chains, of amino acid chirality, and/or of the peptide backbone. These alterations are intended to provide agonists or antagonists of the polypeptides of the invention with improved preparation, potency and/or pharmacokinetics features.

For example, when the peptide is susceptible to cleavage by peptidases following injection into the subject is a problem, replacement of a particularly sensitive peptide bond with a non-cleavable peptide mimetic can provide a peptide more stable and thus more useful as a therapeutic compound. Similarly, the replacement of an L-amino acid residue is a standard way of rendering the peptide less sensitive to proteolysis, and finally more similar to organic compounds other than peptides. Also useful are amino-terminal blocking groups such as t-butyloxycarbonyl, acetyl, benzyl, succinyl, methoxysuccinyl, suberyl, adipyl, azeloyl, dansyl, benzyloxycarbonyl, fluorenylmethoxycarbonyl, methoxyazeloyl, methoxyadipyl, methoxysuberyl, and 2,4-dinitrophenyl. Many other modifications providing increased potency, prolonged activity, easiness of purification, and/or increased half-life are disclosed in the prior art (WO 02/10195; Villain M et al., 2001).

Preferred alternative, synonymous groups for amino acids derivatives included in peptide mimetics are those defined in Table II. A non-exhaustive list of amino acid derivatives also include aminoisobutyric acid (Aib), hydroxyproline (Hyp), 1,2,3,4-tetrahydro-isoquinoline-3-COOH, indoline-2carboxylic acid, 4-difluoro-proline, L-thiazolidine-4-carboxylic acid, L-homoproline, 3,4-dehydro-proline, 3,4-dihydroxy-phenylalanine, cyclohexyl-glycine, and phenylglycine.

By "amino acid derivative" is intended an amino acid or amino acid-like chemical entity other than one of the 20 genetically encoded naturally occurring amino acids. In particular, the amino acid derivative may contain substituted or non-substituted, linear, branched, or cyclic alkyl moieties, and may include one or more heteroatoms. The amino acid derivatives can be made de novo or obtained from commercial sources (Calbiochem-Novabiochem AG, Switzerland; Bachem, USA).

Various methodologies for incorporating unnatural amino acids derivatives into proteins, using both *in vitro* and *in vivo* translation systems, to probe and/or improve protein structure and function are disclosed in the literature (Dougherty DA, 2000). Techniques for the synthesis and the development of peptide mimetics, as well as non-peptide mimetics, are also well known in the art (Goleblowski A et al., 2001; Hruby VJ and Balse PM, 2000; Sawyer TK, in "Structure Based Drug Design", edited by Veerapandian P, Marcel Dekker Inc., pg. 557-663, 1997).

Another object of the present invention are isolated nucleic acids encoding for the polypeptides of the invention having at least one activity of human IFN $\gamma$ , or the corresponding fusion proteins, as disclosed above. Preferably, these nucleic acids should comprise a DNA sequence selected from the group consisting of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, and 39, or the complement of said DNA sequences.

Alternatively, the nucleic acids of the invention are the purified nucleic acids which hybridize under high stringency conditions, or exhibit at least about 85% identity over a stretch of at least about 30 nucleotides, with a nucleic acid selected from the group consisting of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, and 39, or a complement of said DNA sequences.

The wording "high stringency conditions" refers to conditions in a hybridization reaction that facilitate the association of very similar molecules and consist in the overnight incubation at 60-65°C in a solution comprising 50 % formamide, 5X SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10 % dextran sulphate, and 20 microgram/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1X SSC at the same temperature.

These nucleic acids, including nucleotide sequences substantially the same, can be comprised in plasmids, vectors and any other DNA construct which can be used for maintaining, modifying, introducing, or expressing the encoded polypeptide in a cell or a virus. In particular, vectors wherein said nucleic acid molecule is operatively linked to expression control sequences can allow expression in prokaryotic or eukaryotic host cells of the encoded polypeptide.

The wording "nucleotide sequences substantially the same" includes all other nucleic acid sequences which, by virtue of the degeneracy of the genetic code, also code for the given amino acid sequences. In this sense, the literature provides indications on preferred or optimized codons for recombinant expression (Kane JF et al., 1995).

The nucleic acids and the vectors can be introduced into cells or virus with different purposes, generating transgenic cells and organisms. For example, a process

for producing cells capable of expressing a polypeptide of the invention comprises genetically engineering cells with such vectors or nucleic acids.

In particular, host cells (e.g. bacterial cells) can be modified by transformation for allowing the transient or stable expression of the polypeptides encoded by the nucleic acids and the vectors of the invention. Alternatively, said molecules can be used to generate transgenic animal cells or non-human organisms (by non-/homologous recombination or by any other method allowing their stable integration and expression), having enhanced or reduced expression levels of the polypeptides of the invention, when the level is compared with the normal expression levels. Such precise modifications can be obtained by making use of the nucleic acids of the inventions and of technologies associated, for example, to gene therapy (Meth. Enzymol., vol. 346, 2002) or to site-specific recombinases (Kolb AF, 2002). Model systems based on the polypeptides disclosed in the present patent application can be also generated by gene targeting into human cell lines for the systematic study of their activities (Bunz F, 2002).

The polypeptides of the invention can be prepared by any method known in the art, including recombinant DNA-related technologies, and chemical synthesis technologies. In particular, a method for making a polypeptide of the invention may comprise culturing a host or transgenic cell as described above under conditions in which the nucleic acid or vector is expressed, and recovering the polypeptide encoded by said nucleic acid or vector from cell culture. For example, when the vector expresses the polypeptide as a fusion protein with an extracellular or signal-peptide containing proteins, the recombinant product can be secreted in the extracellular space, and can be more easily collected and purified from cultured cells in view of further processing or, alternatively, the cells can be directly used or administered.

The DNA sequence coding for the proteins of the invention can be inserted and ligated into a suitable episomal or non- / homologously integrating vectors, which can be introduced in the appropriate host cells or virus by any suitable means: (transformation, transfection, conjugation, protoplast fusion, electroporation, calcium phosphate-precipitation, direct microinjection, etc.). Factors of importance in selecting a particular plasmid or viral vector include: the ease with which recipient cells that contain the vector, may be recognized and selected from those recipient cells which do not contain the vector; the number of copies of the vector which are desired in a particular host; and whether it is desirable to be able to "shuttle" the vector between host cells of different species.

The vectors should allow the expression of the isolated or fusion protein including the polypeptide of the invention in the Prokaryotic or Eukaryotic host cells under the control of transcriptional initiation / termination regulatory sequences, which are chosen to be inducible or constitutively active in said cell. A cell line substantially enriched in such cells can be then isolated to provide a stable cell line.

Different transcriptional and translational regulatory sequences may be employed for Eukaryotic hosts, depending on the nature of the host (e.g. yeasts, insect, plant, or mammalian cells). They may be derived from viral sources, such as adenovirus, bovine papilloma virus, Simian virus or the like, where the regulatory signals are associated with a particular gene which has a high level of expression. Examples are the TK promoter of the Herpes virus, the SV40 early promoter, the yeast gal4 gene promoter, etc. Transcriptional initiation regulatory signals may be selected which allow for repression and activation, so that expression of the genes can be modulated. The cells stably transformed by the introduced DNA can be selected by introducing one or more markers allowing the selection of host cells which contain the expression vector. The

marker may also provide for phototrophy to an auxotrophic host, resistance to biocides (e.g. antibiotics) or to heavy metals (e.g. copper). The selectable marker gene can either be directly linked to the DNA sequences to be expressed in the same vector, or introduced into the same cell by co-transfecting another vector.

5           Host cells may be either prokaryotic or eukaryotic. Preferred are eukaryotic hosts, e.g. mammalian cells, such as human, monkey, mouse, and Chinese Hamster Ovary (CHO) cells, because they provide post-translational modifications to proteins, including correct folding and glycosylation. Also yeast cells can carry out post-translational peptide modifications including glycosylation. A number of recombinant  
10   DNA strategies exist which utilize strong promoter sequences and high copy number of plasmids which can be utilized for production of the desired proteins in yeast. Yeast recognizes leader sequences in cloned mammalian gene products and secretes peptides bearing leader sequences (i.e., pre-peptides).

          The above mentioned embodiments of the invention can be achieved by  
15   combining the disclosure provided by the present patent application on the sequence of novel polypeptides having IFNgamma-related activities with the knowledge of common molecular biology techniques.

          Many books and reviews provides teachings on how to clone and produce recombinant proteins using vectors and Prokaryotic or Eukaryotic host cells, such as  
20   some titles in the series "A Practical Approach" published by Oxford University Press ("DNA Cloning 2: Expression Systems", 1995; "DNA Cloning 4: Mammalian Systems", 1996; "Protein Expression", 1999; "Protein Purification Techniques", 2001).

          Moreover, literature also provides an overview of the technologies for expressing polypeptides in a high-throughput manner (Chambers SP, 2002; Coleman TA, et al.,  
25   1997), of the cell systems and the processes used industrially for the large-scale

production of recombinant proteins having therapeutic applications (Andersen DC and Krummen L, 2002, Chu L and Robinson DK, 2001), and of alternative eukaryotic expression systems for expressing the polypeptide of interest, which may have considerable potential for the economic production of the desired protein, such the ones based on transgenic plants (Giddings G, 2001) or the yeast *Pichia pastoris* (Lin Cereghino GP et al., 2002). Recombinant protein products can be rapidly monitored with various analytical technologies during purification to verify the amount and the quantity of the expressed polypeptides (Baker KN et al., 2002), as well as to check properties like bioequivalence and immunogenicity (Schellekens H, 2002; Gendel SM, 2002).

Totally synthetic proteins are disclosed in the literature (Brown A et al., 1996), and many examples of chemical synthesis technologies, which can be effectively applied for the polypeptides of the invention given their short length, are available in the literature, as solid phase or liquid phase synthesis technologies. For example, the amino acid corresponding to the carboxy-terminus of the peptide to be synthesized is bound to a support which is insoluble in organic solvents, and by alternate repetition of reactions, one wherein amino acids with their amino groups and side chain functional groups protected with appropriate protective groups are condensed one by one in order from the carboxy-terminus to the amino-terminus, and one where the amino acids bound to the resin or the protective group of the amino groups of the peptides are released, the peptide chain is thus extended in this manner. Solid phase synthesis methods are largely classified by the tBoc method and the Fmoc method, depending on the type of protective group used. Typically used protective groups include tBoc (t-butoxycarbonyl), Cl-Z (2-chlorobenzyloxycarbonyl), Br-Z (2-bromobenzyloxycarbonyl), Bzl (benzyl), Fmoc (9-fluorenylmethoxycarbonyl), Mbh (4,4'-dimethoxydibenzhydryl),



Mtr (4-methoxy-2,3,6-trimethylbenzenesulphonyl), Trt (trityl), Tos (tosyl), Z (benzyloxycarbonyl) and Cl<sub>2</sub>-Bzl (2,6-dichlorobenzyl) for the amino groups; NO<sub>2</sub> (nitro) and Pmc (2,2,5,7,8-pentamethylchromane-6-sulphonyl) for the guanidino groups); and tBu (t-butyl) for the hydroxyl groups). After synthesis of the desired peptide, it is subjected to the de-protection reaction and cut out from the solid support. Such peptide cutting reaction may be carried with hydrogen fluoride or trifluoromethane sulfonic acid for the Boc method, and with TFA for the Fmoc method.

The purification of the polypeptides of the invention can be carried out by any one of the methods known for this purpose, i.e. any conventional procedure involving extraction, precipitation, chromatography, electrophoresis, or the like. A further purification procedure that may be used in preference for purifying the protein of the invention is affinity chromatography using monoclonal antibodies or affinity groups, which bind the target protein and which are produced and immobilized on a gel matrix contained within a column. Impure preparations containing the proteins are passed through the column. The protein will be bound to the column by heparin or by the specific antibody while the impurities will pass through. After washing, the protein is eluted from the gel by a change in pH or ionic strength. Alternatively, HPLC (High Performance Liquid Chromatography) can be used. The elution can be carried using a water-acetonitrile-based solvent commonly employed for protein purification.

The disclosure of the novel polypeptides of the invention, and the reagents disclosed in connection to them (antibodies, nucleic acids, cells) allows also to screen and characterize compounds (proteins, as well as small organic molecules) that are capable to enhance or reduce their expression level into a cell or in an animal. Examples of compounds that can reduce or block the expression of polypeptides are antisense oligonucleotides (Stein CA, 2001) or small interfering, double stranded RNA

molecules that can trigger RNA interference-mediated silencing (Paddison PJ et al., 2002; Lewis DL et al., 2002). These compounds are intended as antagonists (in addition to the ones above described in connection to mutants and ligands) in the context of the possible mechanism of antagonism for blocking cytokine/chemokine-controlled pathways as defined in the literature (Choy EH and Panayi GS, 2001; Dower SK, 2000).

"Oligonucleotides" refers to either a single stranded polydeoxynucleotide or two complementary polydeoxynucleotide strands which may be chemically synthesized. Such synthetic oligonucleotides have no 5' phosphate and thus will not ligate to another oligonucleotide without adding a phosphate with an ATP in the presence of a kinase. A synthetic oligonucleotide will ligate to a fragment that has not been dephosphorylated.

The invention includes purified preparations of the products of the invention (polypeptides, nucleic acids, cells, ligands, peptide mimetics). Purified preparations, as used herein, refers to the preparations which containing at least 1%, preferably at least 5%, by dry weight of the compounds of the invention.

The present patent application discloses a series of novel polypeptides and of related reagents having one or more human IFNgamma-related activities which can be exploited for several possible applications. In particular, whenever the increase of a human IFNgamma-related activity of a polypeptide of the invention is desirable in the therapy or in the prevention of a disease, reagents such as the disclosed INS P037-like polypeptides, the corresponding fusion proteins and peptide mimetics, the encoding nucleic acids, the expressing cells, or the compounds enhancing their expression can be used.

Therefore, the present invention discloses pharmaceutical compositions for the treatment or prevention of diseases needing an increase in a human IFNgamma activity of a polypeptide of the invention, which contain one of the disclosed INSP037-like polypeptides, the corresponding fusion proteins and peptide mimetics, the encoding nucleic acids, the expressing cells, or the compounds enhancing their expression, as active ingredient. The process for the preparation of these pharmaceutical compositions comprises combining the disclosed INSP037-like polypeptides, the corresponding fusion proteins and peptide mimetics, the encoding nucleic acids, the expressing cells, or the compounds enhancing their expression, together with a pharmaceutically acceptable carrier. Methods for the treatment or prevention of diseases needing an increase in a human IFNgamma activity of a polypeptide of the invention, comprise the administration of a therapeutically effective amount of the disclosed INSP037-like polypeptides, the corresponding fusion proteins and peptide mimetics, the encoding nucleic acids, the expressing cells, or the compounds enhancing their expression.

Amongst the novel molecules disclosed in the present patent application, the ligands or the compounds reducing the expression or the activity of polypeptides of the invention have several applications, and in particular they can be used in the therapy or in the diagnosis of a disease associated to the excessive human IFNgamma activity of a polypeptide of the invention.

Therefore, the present invention discloses pharmaceutical compositions for the treatment or prevention of diseases associated to the excessive human IFNgamma activity of a polypeptide of the invention, which contain one of the ligands or compounds reducing the expression or the activity of such polypeptides, as active ingredient. The process for the preparation of these pharmaceutical compositions

comprises combining the ligand or the compound, together with a pharmaceutically acceptable carrier. Methods for the treatment or prevention of diseases associated to the excessive IFNgamma-related activity of the polypeptide of the invention, comprise the administration of a therapeutically effective amount of the antagonist, the ligand or of the compound.

The present patent application discloses novel INSP037-like polypeptides and a series of related reagents that may be useful, as active ingredients in pharmaceutical compositions appropriately formulated, in the treatment or prevention of diseases for which a compound having a human IFNgamma-related activity may provide beneficial effects, such as cell proliferative disorders, autoimmune/inflammatory disorders, cardiovascular disorders, neurological disorders, or bacterial and viral infections. A non-exhaustive lists of disorders include multiple sclerosis, graft-vs-host disease, lymphomas, leukaemia, Crohn's disease, asthma, septic shock, type I and type II diabetes, allergies, psoriasis, inflammatory bowel disease, ulcerative colitis, fibrotic diseases, rheumatoid arthritis, and neuroblastoma.

The therapeutic applications of the polypeptides of the invention and of the related reagents can be evaluated (in terms of safety, pharmacokinetics and efficacy) by the means of the *in vivo* / *in vitro* assays making use of animal cell, tissues and models developed for human IFNgamma and/or IFNgamma binding proteins (Younes HM and Amsden BG, 2002; Boehm U et al., 1997; Bach EA et al., 1997), including their orthologs, or by the means of *in silico* / computational approaches (Johnson DE and Wolfgang GH, 2000), known for the validation of IFNs and other biological products during drug discovery and preclinical development.

It is intended that any disclosed use or activity related to human IFNgamma (or its orthologs) disclosed in the prior art is also applicable to any corresponding

embodiment of the present invention, such as therapeutic uses and compositions, alone or in combination with another compounds (EP311616, WO 01/34180, EP 490250, EP203580, EP502997, EP886527, EP696639), formulations (EP697887, WO 01/36001), expression systems (WO 01/57218) known for human IFN $\gamma$ .

5       The pharmaceutical compositions of the invention may contain, in addition to INSP037-like polypeptide or to the related reagent, suitable pharmaceutically acceptable carriers, biologically compatible vehicles and additives which are suitable for administration to an animal (for example, physiological saline) and eventually comprising auxiliaries (like excipients, stabilizers, adjuvants, or diluents) which facilitate  
10      the processing of the active compound into preparations which can be used pharmaceutically.

      The pharmaceutical compositions may be formulated in any acceptable way to meet the needs of the mode of administration. For example, of biomaterials, sugar - macromolecule conjugates, hydrogels, polyethylene glycol and other natural or  
15      synthetic polymers can be used for improving the active ingredients in terms of drug delivery efficacy. Technologies and models to validate a specific mode of administration are disclosed in literature (Davis BG and Robinson MA, 2002; Gupta P et al., 2002; Luo B and Prestwich GD, 2001; Cleland JL et al., 2001; Pillai O and Panchagnula R, 2001).

20      Polymers suitable for these purposes are biocompatible, namely, they are non - toxic to biological systems, and many such polymers are known. Such polymers may be hydrophobic or hydrophilic in nature, biodegradable, non-biodegradable, or a combination thereof. These polymers include natural polymers (such as collagen, gelatin, cellulose, hyaluronic acid), as well as synthetic polymers (such as poly esters,  
25      polyorthoesters, polyanhydrides). Examples of hydrophobic non-degradable polymers

include polydimethyl siloxanes, polyurethanes, polytetrafluoroethylenes, polyethylenes, polyvinyl chlorides, and polymethyl methacrylates. Examples of hydrophilic non-degradable polymers include poly(2-hydroxyethyl methacrylate), polyvinyl alcohol, poly(N-vinyl pyrrolidone), polyalkylenes, polyacrylamide, and copolymers thereof.

5 Preferred polymers comprise as a sequential repeat unit ethylene oxide, such as polyethylene glycol (PEG).

Any accepted mode of administration can be used and determined by those skilled in the art to establish the desired blood levels of the active ingredients. For example, administration may be by various parenteral routes such as subcutaneous, intravenous, intradermal, intramuscular, intraperitoneal, intranasal, transdermal, oral, or buccal routes. The pharmaceutical compositions of the present invention can also be administered in sustained or controlled release dosage forms, including depot injections, osmotic pumps, and the like, for the prolonged administration of the polypeptide at a predetermined rate, preferably in unit dosage forms suitable for single administration of precise dosages.

15 Parenteral administration can be by bolus injection or by gradual perfusion over time. Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions, which may contain auxiliary agents or excipients known in the art, and can be prepared according to routine methods. In addition, suspension of the active compounds as appropriate oily injection suspensions may be administered. Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides. Aqueous injection suspensions that may contain substances increasing the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran.

Optionally, the suspension may also contain stabilizers. Pharmaceutical compositions include suitable solutions for administration by injection, and contain from about 0.01 to 99.99 percent, preferably from about 20 to 75 percent of active compound together with the excipient.

5       The wording "therapeutically effective amount" refers to an amount of the active ingredients that is sufficient to affect the course and the severity of the disease, leading to the reduction or remission of such pathology. The effective amount will depend on the route of administration and the condition of the patient.

10       The wording "pharmaceutically acceptable" is meant to encompass any carrier, which does not interfere with the effectiveness of the biological activity of the active ingredient and that is not toxic to the host to which is administered. For example, for parenteral administration, the above active ingredients may be formulated in unit dosage form for injection in vehicles such as saline, dextrose solution, serum albumin and Ringer's solution. Carriers can be selected also from starch, cellulose, talc, 15 glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol, and the various oils, including those of petroleum, animal, vegetable or synthetic origin (peanut oil, soybean oil, mineral oil, sesame oil).

20       It is understood that the dosage administered will be dependent upon the age, sex, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired. The dosage will be tailored to the individual subject, as is understood and determinable by one of skill in the art. The total dose required for each treatment may be administered by multiple doses or in a single 25 dose. The pharmaceutical composition of the present invention may be administered

alone or in conjunction with other therapeutics directed to the condition, or directed to other symptoms of the condition. Usually a daily dosage of active ingredient is comprised between 0.01 to 100 milligrams per kilogram of body weight per day. Ordinarily 1 to 40 milligrams per kilogram per day given in divided doses or in  
5 sustained release form is effective to obtain the desired results. Second or subsequent administrations can be performed at a dosage, which is the same, less than, or greater than the initial or previous dose administered to the individual.

Apart from the methods having a therapeutic or a production purpose, several other methods can make use of the INSP037-like polypeptides and of the related  
10 reagents disclosed in the present patent application.

In a first example, a method for screening candidate compounds effective to treat a disease related to a INSP037-like polypeptides of the invention, comprises:

- (a) contacting host cells expressing such polypeptide, transgenic non-human animals, or transgenic animal cells having enhanced or reduced expression  
15 levels of the polypeptide, with a candidate compound and
- (b) determining the effect of the compound on the animal or on the cell.

In a second example, a method for identifying a candidate compound as an antagonist/inhibitor or agonist/activator of a polypeptide of the invention comprises:

- (a) contacting the polypeptide, the compound, and a mammalian cell or a  
20 mammalian cell membrane; and
- (b) measuring whether the molecule blocks or enhances the interaction of the polypeptide, or the response that results from such interaction, with the mammalian cell or the mammalian cell membrane.



In a third example, methods for determining the activity and/or the presence of the polypeptide of the invention in a sample, can detect either the polypeptide or the encoding RNA/DNA. Thus, such a method comprises:

- (a) providing a protein-containing sample;
- 5 (b) contacting said sample with a ligand of the invention; and
- (c) determining the presence of said ligand bound to said polypeptide, thereby determining the activity and/or the presence of polypeptide in said sample.

Alternatively, the method comprises:

- (a) providing a nucleic acids-containing sample;
- 10 (b) contacting said sample with a nucleic acid of the invention; and
- (c) determining the hybridization of said nucleic acid with a nucleic acid into the sample, thereby determining the presence of the nucleic acid in the sample.

In this sense, primer sequences containing the sequences SEQ ID NO: 41-78 (Table III) can be used as well for determining the presence or the amount of a transcript or of a nucleic acid encoding a polypeptide of invention in a sample by  
15 means of Polymerase Chain Reaction amplification.

A further object of the present invention are kits for measuring the activity and/or the presence of INSP037-like polypeptide of the invention in a sample comprising one or more of the reagents disclosed in the present patent application: a INSP037-like  
20 polypeptide of the invention, a ligand, a peptide mimetic, an isolated nucleic acid or vector, a pharmaceutical composition, an expressing cell, a compound increasing or decreasing the expression levels, and/or primer sequences containing any of the sequences SEQ ID NO: 41-78.

Those kits can be used for *in vitro* diagnostic or screenings methods, and their  
25 actual composition should be adapted to the specific format of the sample (e.g.

biological sample tissue from a patient), and the molecular species to be measured. For example, if it is desired to measure the concentration of the INSP037-like polypeptide, the kit may contain an antibody and the corresponding protein in a purified form to compare the signal obtained in Western blot. Alternatively, if it is desired to measure the concentration of the transcript for the INSP037-like polypeptide, the kit may contain a specific nucleic acid probe designed on the corresponding ORF sequence, or may be in the form of nucleic acid array containing such probe, or the primer sequences disclosed as SEQ ID NO: 41-78 (Table III). The kits can be also in the form of protein-, peptide mimetic-, or cell-based microarrays (Templin MF et al., 2002; Pellois JP et al., 2002; Blagoev B and Pandey A, 2001), allowing high-throughput proteomics studies, by making use of the proteins, peptide mimetics and cells disclosed in the present patent application.

All publications, patents and patent applications cited herein are incorporated in full by reference for any purpose.

The invention will now be described with reference to the specific embodiments by means of the following Examples, which should not be construed as in any way limiting the present invention. The content of the description comprises all modifications and substitutions which can be practiced by a person skilled in the art in light of the above teachings and, therefore, without extending beyond the meaning and purpose of the claims.

## EXAMPLES

**Example 1: Selection of open reading frames (ORFs) encoding for polypeptides homologous to INSP037**

INSP037 was identified as an IFN $\gamma$ -like protein encoded by an ORF in human genome (GB patent application No. 0130720.6). The sequence of this ORF was used to search for homologous ORFs in human genome (Celera and GenBank databases). The homology was detected using the BLAST (Basic Local Alignment Search Tool; NCBI version 2), an algorithm which generates local alignments between a query and a hit sequence (Gish W and States DJ, 1993; Pearson WR and Miller W, 1992; Altschul SF et al., 1990). In this case the TBLASTN algorithm was used with the INSP037 protein sequence as a query. TBLASTN compares the query sequence to the database translated into 6 frames and can therefore identify a protein match to a DNA sequence in any reading frame. BLAST parameters used were: Comparison matrix = BLOSUM62; word length = 3; E value cutoff = 10; Gap opening and extension = default; No filter.

The pattern of the homologous regions were extracted from the BLAST output file using a script written in PERL (Practical Extraction and Report Language), a programming language having powerful pattern matching functions into large text data files allowing the extraction of information from genomic DNA sequences, starting from an alpha-numerical expression describing a defined consensus sequence (Stein LD, 2001). Another PERL script was used to retrieve the entire ORFs having such INSP037-like features, extending the sequence 5' to the first potential start methionine and 3' to the first stop codon.

A total of 20 ORFs out of the 93 hits matching the original query generated on the basis of INSP037 protein sequence were selected since they have a start Methionine and a stop codon separated by between 75 and 150 codons. IFNFHs selected DNA

sequences (SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, and 39), belong to different human chromosomes, potentially encode for protein sequences (SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, and 40) having a significant homology with INSP037 (BLAST E value minor or equal to  $7e^{-23}$ ), with level of identity comprised between 67% and 78.5% (figures 1-20). The novelty of the protein sequences was assessed by searching protein databases (SwissProt/Trembl and Derwent GENESEQ) using BLAST.

Amongst these sequences characterized as novel INSP037-like polypeptides, three of them (pIFNFH04, pIFNFH32, and pIFNFH20) are less than 10% longer than INSP037, while all the other sequences more than 10% longer due to an extended C-terminal region (pIFNFH08, pIFNFH12, pIFNFH25, pIFNFH36, pIFNFH37, pIFNFH23, pIFNFH27, pIFNFH14, pIFNFH01, pIFNFH10, pIFNFH11, pIFNFH13, pIFNFH31, pIFNFH03, and pIFNFH15), or to extended N-terminal and C-terminal regions (pIFNFH39 and pIFNFH42). The extended C-terminal regions present some significant local homologies amongst the different IFNFHs (figure 21). Even if not directly identified in figures 1-20, at least some of the selected polypeptides contain a functional signal peptide (Example 3).

#### **Example 2: Cloning of the novel INSP037-like ORFs from human genomic DNA**

The selected IFNFH sequences (with the exception of IFNFH25) were cloned from human genomic DNA into a cloning vector, and then transferred into an expression vector using Polymerase Chain Reaction (PCR), with pairs of forward/reverse primers specific for each ORF (see arrows in figures 1-12 and 14-20).

The cloning primers (CL series; SEQ ID NO: 41-78, Table III), containing from 21 to 30 nucleotides, were designed for amplifying each ORF using human genomic DNA

as template, since all ORFs are uninterrupted on human chromosomes. The forward primers start from three nucleotides before initial ATG. The reverse primers are complementary to the 3' end of the ORF, including the stop codon. Being the N-terminal sequences very similar amongst the different IFNFHs, the reverse primers actually are actually responsible for the specificity of the amplification reaction.

The PCR was performed by mixing the following components in each ORF-specific reaction (total volume of 50  $\mu$ l in double-distilled water):

150 ng human genomic DNA (Clontech)

1.2  $\mu$ M primers (0.6  $\mu$ M each primer)

240  $\mu$ M dNTP (Invitrogen)

0.5  $\mu$ l AmpliTaq (2.5 Units; Applied Biosystems)

5 AmpliTaq buffer 10X (Applied Biosystems)

The PCR reactions were performed using an initial denaturing step of 94 °C for 2 minutes, followed by 30 cycles:

94 °C for 30 seconds

55 °C for 30 seconds

72 °C for 30 seconds

After a final elongation step of 72 °C for 10 minutes, the PCR products were directly subcloned into the pCRII-TOPO vector using the TOPO™ cloning system (Invitrogen), according to manufacturer's standard protocol. The TOPO cloning system is a variation of the TA cloning system allowing the rapid cloning of PCR products, taking advantage from the fact that Taq polymerase leaves a single Adenosine at the 3' end of PCR products. Since the TOPO vector has single-stranded Thymine overhangs, Topoisomerase I enzyme is able to join the T-ends of the vector to the A-overhangs of the PCR product, which can be used without any purification step.

The resulting plasmids (pCRTOPO-ORF series) were used to transform *E. coli* cells (TOP10F', Invitrogen, supplied with the TOPO TA Cloning Kit), obtaining several clones for each ORF. Plasmid DNA was isolated using a commercial kit (WIZARD Plasmid Minipreps: Promega) and sequenced to verify the identity of the amplified and  
5 cloned sequence with the originally selected human genomic DNA sequence.

The plasmids containing the desired sequences were used in a further round of PCR reactions necessary for transferring the ORFs into the expression vector pEAK12D (figure 22), which allows the expression of the cloned insert under the control of EF-1 $\alpha$  promoter and in frame with a 6-His Tag sequence, using the Gateway  
10 cloning system (Invitrogen).

The expression vector pEAK12D was constructed by modifying pEAK12 (Edge Biosystems). This vector was digested with HindIII and NotI, made blunt ended with Klenow and dephosphorylated using calf-intestinal alkaline phosphatase. After dephosphorylation, the vector was ligated to blunt ended Gateway reading frame  
15 cassette C (Gateway vector conversion system, Invitrogen cat no. 11828-019) which contains AttR recombination sites flanking the *ccdB* gene (marker for negative selection of non-recombinant plasmids) and chloramphenicol resistance. The resulting plasmids were used to transform DB3.1 *E. coli* cells, which allow propagation of vectors containing the *ccdB* gene. Miniprep DNA was isolated from several of the resultant  
20 colonies and digested with AseI / EcoRI to identify clones yielding a 670 bp fragment, obtainable only when the cassette had been inserted in the correct orientation. The resultant plasmid was called pEAK12D.

Two series of primers were designed to add the ATTB1 and ATTB2 recombination sites (necessary for the integration in the expression vector) at the 5'  
25 and 3' end, respectively, of the ORF-containing insert. In the first series of primers

(EX1 series; SEQ ID NO: 79-116, Table IV), the original ORF-specific CL primers were modified by adding, at the 5' end, the sequence AAGCAGGCTTCGCCACC (for forward primers) or GTGATGGTGATGGTG (for reverse primers, but after eliminating the nucleotides complementary to the stop codon). In the second series of primers  
5 (EX2 series; SEQ ID NO: 117-154, Table V), the original ORF-specific CL primers were modified by adding, at the 5' end, the sequence GGGGACAAGTTTGTACAAAAAAGC AGGCTTCGCCACC (for forward primers) or GGGGACCACTTTGTACAAGAAAGCTG GGTTCATGGTGATGGTGATGGTG (for reverse primers, but after eliminating the nucleotides complementary to the stop codon). These reverse primers contain the  
10 codons for the 6-His tag which result fused in frame with the ORFs at their C-terminal end.

The PCR amplification was performed in 2 consecutive reactions. The first one was performed by mixing the following components (total volume 50 µl in double-distilled water):

- 15                    25 ng pCRTPOPO-ORF vector  
                     5mM dNTP (Invitrogen)  
                     0.5 µl Pfx DNA polymerase (Invitrogen)  
                     0.5 µl each EX1 primer (100µM)  
                     5µl 10X Pfx polymerase buffer(Invitrogen)

20                    The PCR reactions were performed using an initial denaturing step of 95°C for 2 minutes, followed by 10 cycles:

- 94°C for 15 seconds  
                     68°C for 30 seconds

The PCR products were purified using the Wizard PCR prep DNA purification system (Promega), and added as templates in a second PCR reaction including the following components (total volume 50  $\mu$ l in double-distilled water):

- 10  $\mu$ l purified PCR product
- 5 5mM dNTP (Invitrogen)
- 0.5  $\mu$ l Pfx DNA polymerase (Invitrogen)
- 0.5  $\mu$ l each EX2 primer (100 $\mu$ M)
- 5 $\mu$ l 10X Pfx polymerase buffer (Invitrogen)

The PCR reactions were performed an initial denaturing step of 95°C for 1 minute, followed by 4 cycles:

- 94°C for 15 seconds
- 50°C for 30 seconds
- 68°C for 3 minutes 30 seconds

Then the following conditions were applied for 25 cycles:

- 15 94°C for 15 seconds
- 55°C for 30 seconds
- 68°C for 3 minutes 30 seconds.

The DNA fragments resulting from the PCR reactions were purified as described before and recombined into the pEAK12D vector using the Gateway system.

20 First, the following 10  $\mu$ l reactions were assembled:

- |                                  |             |
|----------------------------------|-------------|
| pDONR-201 (0.1 $\mu$ g/ $\mu$ l) | 1.5 $\mu$ l |
| PCR product                      | 5 $\mu$ l   |
| BP buffer                        | 2 $\mu$ l   |
| BP enzyme mix                    | 1.5 $\mu$ l |



After being incubated at room temperature for 1 hour, the reaction was stopped by adding proteinase K (1  $\mu$ l, 2  $\mu$ g) and incubating at 37°C for further 10 minutes.

An aliquot of this reaction (2  $\mu$ l) was used for transforming *E. coli* cells (strain DH10B) by electroporation. Plasmid DNA was prepared for 4 clones for each ORF and

5 used for parallel 10  $\mu$ l recombination reactions containing:

|                                 |             |
|---------------------------------|-------------|
| pEAK12D (0.1 $\mu$ g / $\mu$ l) | 1.5 $\mu$ l |
| Plasmid DNA                     | 1.5 $\mu$ l |
| ddH <sub>2</sub> O              | 3.5 $\mu$ l |
| LR buffer                       | 2 $\mu$ l   |
| 10 LR enzyme mix                | 1.5 $\mu$ l |

After being incubated at room temperature for 1 hour, the reaction was stopped by adding proteinase K (1  $\mu$ l, 2  $\mu$ g) and incubating at 37°C for further 10 minutes. An aliquot of this reaction (1  $\mu$ l) was used for transforming DH10B *E. coli* cells by electroporation. The clones containing the correct insert were identified first by  
15 performing colony PCR on 3 colonies using the forward and reverse vector primers pEAK12D F1 (GCCAGCTTGGCACTTGATGT) and pEAK12D R1 (GATGGAGGTGGA CGTGTCAG), then confirmed by sequencing the insert with the same primer.

### 20 **Example 3: Expression and purification of the His-tagged INSP037-like polypeptides in Mammalian cells**

The vectors generated in Example 2 were used to express pIFNFHs in Human Embryonic Kidney cells expressing the Epstein-Barr virus Nuclear Antigen (cell line HEK293-EBNA).

The cells were seeded in T225 flasks (50 ml at a density of  $2 \times 10^5$  cells/ml) from  
25 16 to 20 hours prior to transfection, which was performed using the cationic polymer

reagent JetPEI™ (PolyPlus-transfection; 2 µl/µg of plasmid DNA). For each flask, 113 µg of the ORF-specific pEAK12D plasmid, which were prepared using CsCl (Sambrook, J et al. "Molecular Cloning, a laboratory manual"; 2nd edition. 1989; Cold Spring Harbor Laboratory Press), were co-transfected with 2.3 µg of a plasmid acting  
5 as positive control since it expresses Green Fluorescent Protein (GFP) in a constitutive manner. The plasmids, diluted in 230 µl of JetPEI™ solution, were added to 4.6 ml of NaCl 150 mM, vortexed and incubated for 30 minutes at room temperature. This transfection mix was then added to the T225 flask and incubated at 37 °C for 6 days. An aliquot of the cultures was then exposed to UV irradiation to check the transfection  
10 efficiency by evaluating GFP fluorescence.

Culture medium from HEK293-EBNA cells transfected with the ORF-specific pEAK12D plasmids were pooled and 100 ml of the medium were diluted to 200 ml with 100 ml of ice-cold buffer A (50 mM NaH<sub>2</sub>PO<sub>4</sub>; 600 mM NaCl; 8.7 % (w/v) glycerol, pH 7.5), which is the same buffer used for equilibrating the affinity column on which His -  
15 tagged proteins were subsequently immobilized and eluted. The solution was filtered through a 0.22 µm sterile filter (Millipore) and kept at 4°C in 250 ml sterile square media bottles until further processing.

Two consecutive chromatography procedures were applied to the samples using an HPLC-based system (Perfusion Chromatography™, PerSeptive Biosystems)  
20 including a VISION workstation (BioCAD™ series), POROS™ chromatographic media, and an external 250 ml-sample loader (Labomatic), all kept at 4°C.

In the first chromatography step, a Ni-metal affinity column (0.83 ml, POROS 20 MC) was first regenerated with 30 column volumes of EDTA solution (100 mM EDTA; 1 M NaCl; pH 8.0), and then recharged with Ni ions through washing with 15 column  
25 volumes of the Ni solution (100 mM NiSO<sub>4</sub>). The column is subsequently washed with

10 column volumes of buffer A, 7 column volumes of buffer B (50 mM  $\text{NaH}_2\text{PO}_4$ ; 600 mM NaCl; 8.7 % (w/v) glycerol, 400 mM Imidazole, pH 7.5), and finally equilibrated with 15 column volumes of buffer A containing 15 mM imidazole. The sample loader charged the protein-containing solution onto the Ni metal affinity column at a flow rate of 10 ml/min. The column was then washed with 12 column volumes of Buffer A, followed by 28 column volumes of Buffer A containing a concentration of imidazole (20 mM) allowing the elution of contaminating proteins that are loosely attached to the Ni-column. The His-tagged protein is finally eluted with 10 column volumes of Buffer B at a flow rate of 2 ml/min, collecting collected 1.6 ml fractions.

10 In the second chromatography step, a gel-filtration column (10 ml G-25 Sephadex) was regenerated with 2 ml of buffer D (137 mM NaCl; 2.7 mM KCl; 1.5 mM  $\text{KH}_2\text{PO}_4$ ; 8 mM  $\text{Na}_2\text{HPO}_4$ ; 1 M NaCl; pH 7.2), and then equilibrated with 2 column volumes of buffer C (137 mM NaCl; 2.7 mM KCl; 1.5 mM  $\text{KH}_2\text{PO}_4$ ; 8 mM  $\text{Na}_2\text{HPO}_4$ ; 20 % (w/v) glycerol; pH 7.4) before injecting the Ni-column peak fractions onto this column. The sample is eluted with buffer C and the desalted sample is recovered in 2.2 ml fractions.

The peak fractions from the gel-filtration column were then analyzed for their protein content using SDS-PAGE and the parallel detection by Coomassie staining and by Western blot with antibodies recognizing His-tags.

20 The fractions were filtered through a 0.22  $\mu\text{m}$  sterile centrifugation filter (Millipore) and aliquots (20  $\mu\text{l}$ ) were analyzed on SDS-PAGE (4-12 % NuPAGE gel; Novex). Protein concentrations were determined in the samples that show detectable protein bands by Coomassie staining, using the BCA Protein Assay kit (Pierce) and Bovine Serum Albumin as standard. The gel for the Western blot analysis was  
25 electrotransferred to a nitrocellulose membrane at 290 mA at 4°C for 1 hour. The

membrane was blocked with 5 % milk powder in PBS (137 mM NaCl; 2.7 mM KCl; 1.5 mM  $\text{KH}_2\text{PO}_4$ ; 8 mM  $\text{Na}_2\text{HPO}_4$ ; pH 7.4), and subsequently incubated with a mixture of 2 rabbit polyclonal anti-His antibodies (G-18 and H-15, 0.2  $\mu\text{g/ml}$  each; Santa Cruz) at 4°C overnight. After a further 1 hour incubation at room temperature, the membrane  
5 was washed with PBS containing 0.1% Tween-20 (3 x 10 min), and then exposed to a secondary Horse-Radish Peroxidase (HRP)-conjugated anti-rabbit antibody (DAKO) at room temperature for 2 hours. After washing in PBS containing 0.1% Tween-20 (3 x 10 minutes), the ECL kit (Amersham Pharmacia) was used to detect the antibodies immobilized onto the membrane, comparing the film with the image of the Coomassie  
10 stained gel.

By making use of the above described protocol of protein expression and purification, the presence of sequences allowing secretion into the protein sequences encoded from the cloned ORFs was demonstrated for pIFNFH15, pIFNFH23, pIFNFH32, and pIFNFH42, which were efficiently purified from the culture medium of  
15 the transfected mammalian cells as His-tagged proteins.

**Example 4: Cell- and Animal-based assay for the validation and characterization of the INSP037-like polypeptides.**

Several assays have been developed for testing specificity, potency, and  
20 efficacy of IFN $\gamma$  using cell cultures or animal models, as extensively reviewed (Younes HM and Amsden BG, 2002; Boehm U et al., 1997). Other examples of literature providing examples of human IFN $\gamma$  activities are the patent applications disclosing IFN $\gamma$  variants (WO 02/81507) or the several therapeutic activities of IFN $\gamma$ , alone or in combination with other compounds (WO 95/22328, WO  
25 01/34180, WO 90/03189, EP607258, EP696639, EP490250, EP502997). This prior art

provides reliable guidance on how to identify any human IFNgamma activity of the polypeptides of the invention.

Many assays and technologies for generating useful tools and products (antibodies, transgenic animals, radiolabeled proteins, etc.) have been also described  
5 in connection to human IFNgamma and/or its receptor (Aral C et al., 1999; Dow SW et al., 1999; Akbar S et al., 1999; Popko B and Baerwald KD, 1999; Zanti N et al., 1998; Sethi SK et al., 1997; Young HA, 1997; Bach EA et al., 1997). They can be used to verify the expression and the mechanisms of action of the polypeptides of the invention homologous to INSP037 and related reagents, in connection with possible therapeutic  
10 or diagnostic methods and uses.

**TABLE I**

| <b>Amino Acid</b> | <b>Synonymous Groups</b> | <b>More Preferred Synonymous Groups</b> |
|-------------------|--------------------------|---|
| <b>Ser</b>        | Gly, Ala, Ser, Thr, Pro  | Thr, Ser                                |
| <b>Arg</b>        | Asn, Lys, Gln, Arg, His  | Arg, Lys, His                           |
| <b>Leu</b>        | Phe, Ile, Val, Leu, Met  | Ile, Val, Leu, Met                      |
| <b>Pro</b>        | Gly, Ala, Ser, Thr, Pro  | Pro                                     |
| <b>Thr</b>        | Gly, Ala, Ser, Thr, Pro  | Thr, Ser                                |
| <b>Ala</b>        | Gly, Thr, Pro, Ala, Ser  | Gly, Ala                                |
| <b>Val</b>        | Met, Phe, Ile, Leu, Val  | Met, Ile, Val, Leu                      |
| <b>Gly</b>        | Ala, Thr, Pro, Ser, Gly  | Gly, Ala                                |
| <b>Ile</b>        | Phe, Ile, Val, Leu, Met  | Ile, Val, Leu, Met                      |
| <b>Phe</b>        | Trp, Phe, Tyr            | Tyr, Phe                                |
| <b>Tyr</b>        | Trp, Phe, Tyr            | Phe, Tyr                                |
| <b>Cys</b>        | Ser, Thr, Cys            | Cys                                     |
| <b>His</b>        | Asn, Lys, Gln, Arg, His  | Arg, Lys, His                           |
| <b>Gln</b>        | Glu, Asn, Asp, Gln       | Asn, Gln                                |
| <b>Asn</b>        | Glu, Asn, Asp, Gln       | Asn, Gln                                |
| <b>Lys</b>        | Asn, Lys, Gln, Arg, His  | Arg, Lys, His                           |
| <b>Asp</b>        | Glu, Asn, Asp, Gln       | Asp, Glu                                |
| <b>Glu</b>        | Glu, Asn, Asp, Gln       | Asp, Glu                                |
| <b>Met</b>        | Phe, Ile, Val, Leu, Met  | Ile, Val, Leu, Met                      |
| <b>Trp</b>        | Trp, Phe, Tyr            | Trp                                     |

TABLE II

| Amino Acid | Synonymous Groups   |
|------------|---|
| Ser        | D-Ser, Thr, D-Thr, allo-Thr, Met, D-Met, Met(O), D-Met(O), L-Cys, D-Cys   |
| Arg        | D-Arg, Lys, D-Lys, homo-Arg, D-homo-Arg, Met, Ile, D-Met, D-Ile, Orn, D-Orn   |
| Leu        | D-Leu, Val, D-Val, AdaA, AdaG, Leu, D-Leu, Met, D-Met   |
| Pro        | D-Pro, L-l-thioazolidine-4-carboxylic acid, D-or L-1-oxazolidine-4-carboxylic acid  |
| Thr        | D-Thr, Ser, D-Ser, allo-Thr, Met, D-Met, Met(O), D-Met(O), Val, D-Val   |
| Ala        | D-Ala, Gly, Alb, B-Ala, Acp, L-Cys, D-Cys   |
| Val        | D-Val, Leu, D-Leu, Ile, D-Ile, Met, D-Met, AdaA, AdaG   |
| Gly        | Ala, D-Ala, Pro, D-Pro, Alb, .beta.-Ala, Acp  |
| Ile        | D-Ile, Val, D-Val, AdaA, AdaG, Leu, D-Leu, Met, D-Met   |
| Phe        | D-Phe, Tyr, D-Thr, L-Dopa, His, D-His, Trp, D-Trp, Trans-3,4, or 5-phenylproline, AdaA, AdaG, cis-3,4, or 5-phenylproline, Bpa, D-Bpa |
| Tyr        | D-Tyr, Phe, D-Phe, L-Dopa, His, D-His   |
| Cys        | D-Cys, S-Me-Cys, Met, D-Met, Thr, D-Thr   |
| Gln        | D-Gln, Asn, D-Asn, Glu, D-Glu, Asp, D-Asp   |
| Asn        | D-Asn, Asp, D-Asp, Glu, D-Glu, Gln, D-Gln   |
| Lys        | D-Lys, Arg, D-Arg, homo-Arg, D-homo-Arg, Met, D-Met, Ile, D-Ile, Orn, D-Orn   |
| Asp        | D-Asp, D-Asn, Asn, Glu, D-Glu, Gln, D-Gln   |
| Glu        | D-Glu, D-Asp, Asp, Asn, D-Asn, Gln, D-Gln   |
| Met        | D-Met, S-Me-Cys, Ile, D-Ile, Leu, D-Leu, Val, D-Val   |

TABLE III

| SEQ ID NO: | NAME         | DIRECTION | 5'-3' SEQUENCE                  |
|------------|--------------|-----------|---------------------------------|
| 41         | CL_IFNFH01_5 | Forward   | AACATGACCTCACCAAATAAAC          |
| 42         | CL_IFNFH01_3 | Reverse   | TCATTTTATTCCTTTTCTTTGTC         |
| 43         | CL_IFNFH03_5 | Forward   | AACATGACATCACCAAATGAG           |
| 44         | CL_IFNFH03_3 | Reverse   | TTACAGGTGCCTGCCACTGCAC          |
| 45         | CL_IFNFH04_5 | Forward   | AACATGACCTCACCAAATGAAC          |
| 46         | CL_IFNFH04_3 | Reverse   | TCAAGAGACTGATGCATTCTTTAG        |
| 47         | CL_IFNFH08_5 | Forward   | AACATGACCTCACCAAATGAAC          |
| 48         | CL_IFNFH08_3 | Reverse   | CTAATCCGATTAATTCTACTATG         |
| 49         | CL_IFNFH10_5 | Forward   | AACATGACCTCACCAAATGAG           |
| 50         | CL_IFNFH10_3 | Reverse   | TCATTGTTTTTGTGTTTTTGGTC         |
| 51         | CL_IFNFH11_5 | Forward   | CACATGACCTCAGGAAATGA AG         |
| 52         | CL_IFNFH11_3 | Reverse   | TTATTGTTTTTATCTTTTCTTTTG        |
| 53         | CL_IFNFH12_5 | Forward   | AACATGACCTCACCAAATGAAC          |
| 54         | CL_IFNFH12_3 | Reverse   | TCAATCAGTTCTGCTATTAATAAATCTC    |
| 55         | CL_IFNFH13_5 | Forward   | AACATGACCTCACCAAATGAAC          |
| 56         | CL_IFNFH13_3 | Reverse   | TTAGGTGTGCTTCATTCTTTTATATT TTTT |
| 57         | CL_IFNFH14_5 | Forward   | AACATGACATCAACAAAGGAAC          |
| 58         | CL_IFNFH14_3 | Reverse   | TTATATTCTTTTTCTCTCTGACTG        |
| 59         | CL_IFNFH15_5 | Forward   | AATATGACCTCACCAAATGAAC          |
| 60         | CL_IFNFH15_3 | Reverse   | CTATTTAAGGCCAATAACTTTTAG        |
| 61         | CL_IFNFH20_5 | Forward   | AACATGCCCTTACCAAATGAGC          |
| 62         | CL_IFNFH20_3 | Reverse   | CTATGATGCATTCTTCATTATAC         |
| 63         | CL_IFNFH23_5 | Forward   | AACATGACCTCACCAAATGAAC          |
| 64         | CL_IFNFH23_3 | Reverse   | CTATATACTTTCAAATAGCCTGTC        |
| 65         | CL_IFNFH27_5 | Forward   | AACATGACCTCGCCTAATGAAC          |
| 66         | CL_IFNFH27_3 | Reverse   | TTAGTTTGCTTCCTCTGACTG           |
| 67         | CL_IFNFH31_5 | Forward   | AATATGACCTCACCAAATGAAC          |
| 68         | CL_IFNFH31_3 | Reverse   | CTAATACATGCTTCTTTTTTTGTTTG      |
| 69         | CL_IFNFH32_5 | Forward   | AACATGACCTCACCAAATAAAC          |
| 70         | CL_IFNFH32_3 | Reverse   | TCAGTATGCCAGTTGATTTTTCAGC       |
| 71         | CL_IFNFH36_5 | Forward   | AACATGACCTCACCAAACAAAC          |
| 72         | CL_IFNFH36_3 | Reverse   | TTATTCTGCTTGCTCAATTCTGC         |
| 73         | CL_IFNFH37_5 | Forward   | AACATGACCTCACTAAATGAAC          |
| 74         | CL_IFNFH37_3 | Reverse   | CTAATCTTTTTTCTGCTCCATAAATTC     |
| 75         | CL_IFNFH39_5 | Forward   | TCAATGGCCAGACACCTACAAC          |
| 76         | CL_IFNFH39_3 | Reverse   | TCATTCTTCTACTTGATTAATTCTAC      |
| 77         | CL_IFNFH42_5 | Forward   | TCAATGCCAAGACACCAAAGAAC         |
| 78         | CL_IFNFH42_3 | Reverse   | CTAATTCTTTTCTACTCGATCC          |



TABLE IV

| SEQ ID NO: | NAME          | DIRECTION | 5'-3' SEQUENCE                                  |
|------------|---------------|-----------|---|
| 79         | EX1_IFNFH01_5 | Forward   | AAGCAGGCTTCGCCACC AACATGACCTCACCAAATAAAC        |
| 80         | EX1_IFNFH01_3 | Reverse   | GTGATGGTGATGGTG TTTT TTTT TTTTATTCCTTTTCTTTTGTC |
| 81         | EX1_IFNFH03_5 | Forward   | AAGCAGGCTTCGCCACC AACATGACATCACCAAATGAG         |
| 82         | EX1_IFNFH03_3 | Reverse   | GTGATGGTGATGGTG CAGGTGCCTGCCACTGCAC             |
| 83         | EX1_IFNFH04_5 | Forward   | AAGCAGGCTTCGCCACC ATGACCTCACCAAATGAAC           |
| 84         | EX1_IFNFH04_3 | Reverse   | GTGATGGTGATGGTG AGAGACTGATGCATTCTTTAG           |
| 85         | EX1_IFNFH08_5 | Forward   | AAGCAGGCTTCGCCACC AACATGACCTCACCAAATGAAC        |
| 86         | EX1_IFNFH08_3 | Reverse   | GTGATGGTGATGGTG ATTCCGATTAATTCTACTATG           |
| 87         | EX1_IFNFH10_5 | Forward   | AAGCAGGCTTCGCCACC AACATGACCTCACCAAATGAG         |
| 88         | EX1_IFNFH10_3 | Reverse   | GTGATGGTGATGGTG TTGT TTTT TTTTGT TTTT TTTGTC    |
| 89         | EX1_IFNFH11_5 | Forward   | AAGCAGGCTTCGCCACC CACATGACCTCAGGAAATGAAG        |
| 90         | EX1_IFNFH11_3 | Reverse   | GTGATGGTGATGGTG TTGT TTTT TTTTATTC TTTT TTTTG   |
| 91         | EX1_IFNFH12_5 | Forward   | AAGCAGGCTTCGCCACC AACATGACCTCACCAAATGAAC        |
| 92         | EX1_IFNFH12_3 | Reverse   | GTGATGGTGATGGTG ATCAGTTCTGCTATTAAAA AACTC       |
| 93         | EX1_IFNFH13_5 | Forward   | AAGCAGGCTTCGCCACC AACATGACCTCACCAAATGAAC        |
| 94         | EX1_IFNFH13_3 | Reverse   | GTGATGGTGATGGTG GGTGTGCTTCATTCTTTTATATTTTTT     |
| 95         | EX1_IFNFH14_5 | Forward   | AAGCAGGCTTCGCCACC AACATGACATCAACAAAGGAAC        |
| 96         | EX1_IFNFH14_3 | Reverse   | GTGATGGTGATGGTG TATTCTTT TTTCTCTCTGACTG         |
| 97         | EX1_IFNFH15_5 | Forward   | AAGCAGGCTTCGCCACC AATATGACCTCACCAAATGAAC        |
| 98         | EX1_IFNFH15_3 | Reverse   | GTGATGGTGATGGTG TTTAAGGCCAATAACTTTTAG           |
| 99         | EX1_IFNFH20_5 | Forward   | AAGCAGGCTTCGCCACC AACATGCCCTTACCAAATGAGC        |
| 100        | EX1_IFNFH20_3 | Reverse   | GTGATGGTGATGGTG TGATGCATTCTTCATTATAC            |
| 101        | EX1_IFNFH23_5 | Forward   | AAGCAGGCTTCGCCACC AACATGACCTCACCAAATGAAC        |
| 102        | EX1_IFNFH23_3 | Reverse   | GTGATGGTGATGGTG TATACTTTCAAATAGCCTGTC           |
| 103        | EX1_IFNFH27_5 | Forward   | AAGCAGGCTTCGCCACC AACATGACCTCGCCTAATGAAC        |
| 104        | EX1_IFNFH27_3 | Reverse   | GTGATGGTGATGG TG G TTTGCTTCCTCTGACTG            |
| 105        | EX1_IFNFH31_5 | Forward   | AAGCAGGCTTCGCCACC AATATGACCTCACCAAATGAAC        |
| 106        | EX1_IFNFH31_3 | Reverse   | GTGATGGTGATGGTG ATACATGCTTCTTTT TTTT TTTG       |
| 107        | EX1_IFNFH32_5 | Forward   | AAGCAGGCTTCGCCACC AACATGACCTCACCAAATAAAC        |
| 108        | EX1_IFNFH32_3 | Reverse   | GTGATGGTGATGGTG GATGCCAGTTGATTTTTCAGC           |
| 109        | EX1_IFNFH36_5 | Forward   | AAGCAGGCTTCGCCACC AACATGACCTCACCAAACAAAC        |
| 110        | EX1_IFNFH36_3 | Reverse   | GTGATGGTGATGGTG TTCTGCTTGCTCAATTCTGC            |
| 111        | EX1_IFNFH37_5 | Forward   | AAGCAGGCTTCGCCACC AACATGACCTCACTAAATGAAC        |
| 112        | EX1_IFNFH37_3 | Reverse   | GTGATGGTGATGGTG ATTCTTTT TTTCTGCTCCATAAATTC     |
| 113        | EX1_IFNFH39_5 | Forward   | AAGCAGGCTTCGCCACC TCAATGGCCAGACACCTACAAAC       |
| 114        | EX1_IFNFH39_3 | Reverse   | GTGATGGTGATGGTG TTCTTCTACTTGATTAATTCTAC         |
| 115        | EX1_IFNFH42_5 | Forward   | AAGCAGGCTTCGCCACCTCAATGCCAAGACACCAAAGAAC        |
| 116        | EX1_IFNFH42_3 | Reverse   | GTGATGGTGATGGTG ATTCTTCTTTTCTACTCGATCC          |

TABLE V

| SEQ ID NO: | NAME          | DIRECTION | 5' - 3' SEQUENCE   |
|------------|---------------|-----------|--|
| 117        | EX2_IFNFH01_5 | Forward   | GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGCCACC AACATG<br>ACCTCACCAAATAAAC                     |
| 118        | EX2_IFNFH01_3 | Reverse   | GGGGACCACTTTGTACA AGAAAGCTGGGTTTCAATGGTG ATGG<br>TGATGGTGTTTTTTTTTATTCTTTTCTTTTGTGTC |
| 119        | EX2_IFNFH03_5 | Forward   | GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGCCACC AACATG<br>ACATCACCAAATGAG                      |
| 120        | EX2_IFNFH03_3 | Reverse   | GGGGACCACTTTGTACA AGAAAGCTGGGTTTCAATGGTGATGG<br>TGATGGTG CAGGTGCCTGCCACTGCAC         |
| 121        | EX2_IFNFH04_5 | Forward   | GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGCCACC AACATG<br>ACCTCACCAAATGAAC                     |
| 122        | EX2_IFNFH04_3 | Reverse   | GGGGACCACTTTGTACA AGAAAGCTGGGTTTCAATGGTGATGG<br>TGATGGTGAGAGACTGATGCATTCTTTAG        |
| 123        | EX2_IFNFH08_5 | Forward   | GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGCCACC AACATG<br>ACCTCACCAAATGAAC                     |
| 124        | EX2_IFNFH08_3 | Reverse   | GGGGACCACTTTGTACA AGAAAGCTGGGTTTCAATGGTGATGG<br>TGATGGTGATTCCGATTAAATCTACTATG        |
| 125        | EX2_IFNFH10_5 | Forward   | GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGCCACC AACATG<br>ACCTCACCAAATGAG                      |
| 126        | EX2_IFNFH10_3 | Reverse   | GGGGACCACTTTGTACAAGAAAGCTGGGTTTCAATGGTGATG<br>GTGATGGTGTTGTTTTTGTGTGTTTTGGTTC        |
| 127        | EX2_IFNFH11_5 | Forward   | GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGCCACC CACATG<br>ACCTCAGGAAATGAAG                     |
| 128        | EX2_IFNFH11_3 | Reverse   | GGGGACCACTTTGTACAAGAAAGCTGGGTTTCAATGGTGATG<br>GTGATGGTGTTGTTTTTATTCTTTTCTTTTGTG      |
| 129        | EX2_IFNFH12_5 | Forward   | GGGGACAAGTTTGTACAAAAAAG CAGGCTTCGCCACC AACATG<br>ACCTCACCAAATGAAC                    |
| 130        | EX2_IFNFH12_3 | Reverse   | GGGGACCACTTTGTACA AGAAAGCTGGGTTTCAATGGTGATGG<br>TGATGGTGATCAGTTCTGCTATTAAAAAACTC     |
| 131        | EX2_IFNFH13_5 | Forward   | GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGCCACC AACATG<br>ACCTCACCAAATGAAC                     |
| 132        | EX2_IFNFH13_3 | Reverse   | GGGGACCACTTTGTACA AGAAAGCTGGGTTTCAATGGTGATGG<br>TGATGGTGGGTGTGCTTCATTCTTTTATATTTTTT  |
| 133        | EX2_IFNFH14_5 | Forward   | GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGCCACC AACATG<br>ACATCAACAAAGGAAC                     |
| 134        | EX2_IFNFH14_3 | Reverse   | GGGGACCACTTTGTACAAGAAAGCTGGGTTTCAATGGTGATG<br>GTGATGGTGTTATCTTTTCTCTTCTGACTG         |
| 135        | EX2_IFNFH15_5 | Forward   | GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGCCACC AATATG<br>ACCTCACCAAATGAAC                     |
| 136        | EX2_IFNFH15_3 | Reverse   | GGGGACCACTTTGTACA AGAAAGCTGGGTTTCAATGGTGATGG<br>TGATGGTGTTAAGGCCAATAACTTTTAG         |
| 137        | EX2_IFNFH20_5 | Forward   | GGGGACAAGTTTGTACAAAAAAGCAGGCTTCG CCACCAACATG<br>CCCTTACCAAATGAGC                     |
| 138        | EX2_IFNFH20_3 | Reverse   | GGGGACCACTTTGTACA AGAAAGCTGGGTTTCAATGGTGATGG<br>TGATGGTGTGATGCATTCTTATTATAC          |
| 139        | EX2_IFNFH23_5 | Forward   | GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGCCACCAACATG<br>ACCTCACCAAATGAAC                      |
| 140        | EX2_IFNFH23_3 | Reverse   | GGGGACCACTTTGTACA CAAGAAAGCTGGGTTTCAATGGTGATGG<br>TGATGGTGATACTTTCAAATAGCCTGTC       |
| 141        | EX2_IFNFH27_5 | Forward   | GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGCCACCAACATG<br>ACCTCGCCTAATGAAC                      |
| 142        | EX2_IFNFH27_3 | Reverse   | GGGGACCACTTTGTACA AGAAAGCTGGGTTTCAATGGTGATGG<br>TGATGGTGGTTTGCTTCTCTGACTG            |
| 143        | EX2_IFNFH31_5 | Forward   | GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGCCACCAATATG<br>ACCTCACCAAATGAAC                      |
| 144        | EX2_IFNFH31_3 | Reverse   | GGGGACCACTTTGTACA AGAAAGCTGGGTTTCAATGGTGATGG<br>TGATGGTGATACATGCTTCTTTTTTGTGTTG      |

TABLE V (cont.)


| SEQ ID NO: | NAME          | DIRECTION | 5' -3' SEQUENCE   |
|------------|---------------|-----------|---|
| 145        | EX2_IFNFH32_5 | Forward   | GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGCCACCAACATG<br>ACCTCACCAAATAAAC                   |
| 146        | EX2_IFNFH32_3 | Reverse   | GGGGACCACTTTGTACA AGAAAGCTGGGTTTCAATGGTGATGG<br>TGATGGTGGTATGCCAGTTGATTTTTCAGC    |
| 147        | EX2_IFNFH36_5 | Forward   | GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGCCACC AACATG<br>ACCTCACCAAACAAAC                  |
| 148        | EX2_IFNFH36_3 | Reverse   | GGGGACCACTTTGTACA AGAAAGCTGGGTTTCAATGGTGATGG<br>TGATGGTGGTCTGCTTGCTCAATTCTGC      |
| 149        | EX2_IFNFH37_5 | Forward   | GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGCCACC AACATG<br>ACCTCACTAAATGAAC                  |
| 150        | EX2_IFNFH37_3 | Reverse   | GGGGACCACTTTGTACA AGAAAGCTGGGTTTCAATGGTGATGG<br>TGATGGTGATTCTTTTTTCTGCTCCATAAATTC |
| 151        | EX2_IFNFH39_5 | Forward   | GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGCCACC TCAATG<br>GCCAGACACCTACAAAC                 |
| 152        | EX2_IFNFH39_3 | Reverse   | GGGGACCACTTTGTACA AGAAAGCTGGGTTTCAATGGTGATGG<br>TGATGGTGGTCTTCTACTTGATTAATTCTAC   |
| 153        | EX2_IFNFH42_5 | Forward   | GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGCCACCTCAAT<br>GCCAAGACACCAAAGAAC                  |
| 154        | EX2_IFNFH42_3 | Reverse   | GGGGACCACTTTGTACA AGAAAGCTGGGTTTCAATGGTGATGG<br>TGATGGTGATTCTTCTTTTCTACTCGATCC    |

## REFERENCES

- Altschul SF et al., J Mol Biol, 215: 403-10, 1990.
- Akbar S et al., Biochem Biophys Res Commun, 259: 294-9, 1999
- Arai C et al., In Vivo, 13:445-51, 1999.
- 5 Andersen DC and Krummen L, Curr Opin Biotechnol, 13: 117-23, 2002.
- Bach EA et al., Annu Rev Immunol, 15:563-91, 1997.
- Baker KN et al., Trends Biotechnol, 20: 149-56, 2002.
- Blagoev B and Pandey A, Trends Biochem Sci, 26: 639-41, 2001.
- Bock A, Science, 292: 453-4, 2001.
- 10 Boehm U et al., Annu Rev Immunol, 15:749-795, 1997
- Brown A et al., J Pept Sci, 2: 40-46, 1996.
- Bunz F, Curr Opin Oncol, 14: 73-8, 2002.
- Burgess RR and Thompson NE, Curr Opin Biotechnol, 12: 450-4, 2001.
- Chambers SP, Drug Disc Today, 14: 759-765, 2002.
- 15 Choy EH and Panayi GS, N Engl J Med, 344: 907-16, 2001.
- Chu L and Robinson DK, Curr Opin Biotechnol, 13: 304-8, 2001.
- Cleland JL et al., Curr Opin Biotechnol, 12: 212-9, 2001.
- Coleman TA et al., Gene 190:163-171, 1997.
- Constans A, The Scientist, 16(4): 37, 2002.
- 20 Davis BG and Robinson MA, Curr Opin Drug Discov Devel, 5: 279-88, 2002.
- Docke WD et al., Nat Med, 3:678-681,1997.
- Dow SW et al., Hum Gene Ther, 10: 1905-14, 1999
- Dower SK, Nat Immunol, 1: 367-8, 2000.
- Dougherty DA, Curr Opin Chem Biol, 4: 645-52, 2000.
- 25 Garnett MC, Adv Drug Deliv Rev, 53: 171-216, 2001.

- Gavilondo JV and Larrick JW, *Biotechniques*, 29: 128-136, 2000.
- Gendel SM, *Ann N Y Acad Sci*, 964: 87-98, 2002.
- Giddings G, *Curr Opin Biotechnol*, 12: 450-4, 2001.
- Gish W and States DJ, *Nat Genet*. 1993 Mar;3(3):266-72.
- 5 Golebiowski A et al., *Curr Opin Drug Discov Devel*, 4: 428-34, 2001.
- Gupta P et al., *Drug Discov Today*, 7: 569-579, 2002.
- Haupt K, *Nat Biotechnol*, 20 : 884-885, 2002.
- Hruby VJ and Balse PM, *Curr Med Chem*, 7: 945-70, 2000.
- Johnson DE and Wolfgang GH, *Drug Discov Today*, 5: 445-454, 2000.
- 10 Kane JF, *Curr Opin Biotechnol*, 6: 494-500, 1995.
- Kolb AF, *Cloning Stem Cells*, 4: 65-80, 2002.
- Kuroiwa Y et al., *Nat Biotechnol*, 20: 889-94, 2002.
- Lewis DL, *Nat Genet*, 32: 107-8, 2002.
- Lin Cereghino GP et al., *Curr Opin Biotechnol*, 13: 329-332, 2001.
- 15 Lowe CR et al., *J Biochem Biophys Methods*, 49: 561-74, 2001.
- Luo B and Prestwich GD, *Exp Opin Ther Patents*, 11: 1395-1410, 2001.
- Mulder NJ and Apweiler R, *Genome Biol*, 3(1):REVIEWS2001, 2002
- Murphy LR et al., *Protein Eng*, 13:149-52, 2000.
- Nilsson J et al., *Protein Expr Purif*, 11: 1-16, 1997.
- 20 Paddison PJ, *Proc Natl Acad Sci U S A*, 99: 1443-8, 2002.
- Pearson WR and Miller W, *Methods Enzymol*, 210: 575-601, 1992.
- Pellois JP et al., *Nat Biotechnol*, 20: 922-6, 2002.
- Pillai O and Panchagnula R, *Cur Opin Chem Biol*, 5: 447-451, 2001
- Popko B and Baerwald KD, *Neurochem Res*, 24: 331-8, 1999
- 25 Quinn-Senger KE et al., *Curr Opin Chem Biol*, 6: 418-26, 2002.

- Rehm BH, Appl Microbiol Biotechnol, 57: 579-92, 2001.
- Robinson CR, Nat Biotechnol, 20: 879-880, 2002.
- Rogov SI and Nekrasov AN, Protein Eng, 14: 459-463, 2001.
- Schellekens H, Nat Rev Drug Discov, 1: 457-62, 2002
- 5 Sethi SK et al., Clin Exp Immunol, 110: 362-9, 1997
- Sheibani N, Prep Biochem Biotechnol, 29: 77-90, 1999.
- Stein CA, J Clin Invest, 108: 641-4, 2001.
- Stein LD, Methods Biochem Anal, 43: 413-49, 2001.
- Templin MF et al., Trends Biotechnol, 20: 160-6, 2002.
- 10 Tribbick G, J Immunol Methods, 267: 27-35, 2002.
- van den Burg B and Eijssink V, Curr Opin Biotechnol, 13: 333-337, 2002.
- van Dijk MA and van de Winkel JG, Curr Opin Chem Biol, 5: 368-74, 2001.
- Villain M et al., Chem Biol, 8: 673-9, 2001.
- Wells TN. and Peitsch MC. Methods Mol Biol, 138: 65-73, 2000.
- 15 Younes HM and Amsden BG, J Pharm Sci, 91:2-17, 2002
- Young HA, Methods, 11: 112-5, 1997
- Zantl N et al., Infect Immun, 66: 2300-9, 1998
- Ziesche R et al., N Engl J Med, 341:1264-9, 1999.



**CLAIMS**

1. An isolated polypeptide at least one activity of human IFN $\gamma$  selected from:  
the group consisting of:
  - a) amino acid sequences SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24,  
5 26, 28, 30, 32, 34, 36, 38, and 40;
  - b) variants of the amino acid sequences SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16,  
18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, and 40, which are at least 80%  
identical to said sequences;
  - c) mature forms, active fragments, precursors, salts, or derivatives of the  
10 amino acid sequences given in a) or b).
2. The polypeptide of claim 1 that is a naturally occurring allelic variant of the  
sequences SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32,  
15 34, 36, 38, and 40.
3. The polypeptide of claim 2, wherein the variant is the translation of a single  
nucleotide polymorphism.
4. A fusion protein comprising a polypeptide according to any of the claims from 1 to  
20 3.
5. The fusion proteins of claim 4 wherein said proteins further comprise one or more  
amino acid sequence belonging to these protein sequences: membrane-bound  
protein, immunoglobulin constant region, multimerization domains, extracellular  
25 proteins, signal peptide-containing proteins, export signal-containing proteins.



- 6     A ligand binding specifically to a polypeptide according to claim 1.
- 7     The ligand of claim 6 that antagonizes or inhibits the IFNgamma-related activity  
5     of a polypeptide according to any one of claims 1 to 3.
- 8     A ligand according to claim 7 which is a monoclonal antibody, a polyclonal  
antibody, a humanized antibody, an antigen binding fragment, or the extracellular  
domain of a membrane-bound protein.
- 10
- 9     The polypeptides of any of the claims from 1 to 8, wherein said polypeptides are  
in the form of active conjugates or complexes with a molecule chosen amongst  
radioactive labels, fluorescent labels, biotin, or cytotoxic agents.
- 15   10   A peptide mimetic designed on the sequence and/or the structure of a  
polypeptide according to any one of claims 1 to 3.
- 11   An isolated nucleic acid encoding for an isolated polypeptide selected from the  
group consisting of:
- 20   a)   the polypeptides having at least one of the activity of human IFNgamma of  
any of the claims from 1 to 3;
- b)   the fusion proteins of claim 4 or 5.

12. The nucleic acid of Claim 11, comprising a DNA sequence selected from the group consisting of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, and 39, or the complement of said DNA sequences.

5 13. A purified nucleic acid which:

- a) hybridizes under high stringency conditions; or
- b) exhibits at least about 85% identity over a stretch of at least about 30 nucleotides

10 with a nucleic acid selected from the group consisting of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, and 39, or a complement of said DNA sequences

14. A vector comprising a nucleic acid of any of Claims from 11 to 13.

15 15. The vector of claim 14, wherein said nucleic acid molecule is operatively linked to expression control sequences allowing expression in prokaryotic or eukaryotic host cells of the encoded polypeptide.

20 16. A process for producing cells capable of expressing a polypeptide of any the claims from 1 to 3, comprising genetically engineering cells with a vector or a nucleic acid according to any of the claims from 11 to 15.

17. A host cell transformed with a vector or a nucleic acid according to any of the claims from 11 to 15.

18. A transgenic animal cell that has been transformed with a vector or a nucleic acid according to any of the claims from 11 to 15, having enhanced or reduced expression levels of a polypeptide according to any one of claims from 1 to 3.
- 5 19. A transgenic non-human organism that has been transformed to have enhanced or reduced expression levels of a polypeptide according to any one of claims from 1 to 3.
- 10 20. A method for making a polypeptide of any the claims from 1 to 3 comprising culturing a cell of claim 17 or 18 under conditions in which the nucleic acid or vector is expressed, and recovering the polypeptide encoded by said nucleic acid or vector from cell culture.
- 15 21. A compound that enhances the expression level of a polypeptide according to any one of claims from 1 to 3 into a cell or in an animal.
22. A compound that reduces the expression level of a polypeptide according to any one of claims from 1 to 3 into a cell or in an animal.
- 20 23. The compound of claim 22 that is an antisense oligonucleotide or a small interfering RNA.
24. Purified preparations containing a polypeptide of any of the claims from 1 to 5 or claim 9, a ligand of any of the claims from 6 to 8, a peptide mimetic of claim

10, a nucleic acid of any of the claims from 11 to 15, a cell of claim 17 or 18, or a compound of any of the claims from 21 to 23.

- 5 25. Use of a polypeptide of any of the claims from 1 to 5 or claim 9, a peptide mimetic of claim 10, a nucleic acid of any of the claims from 11 to 15, a cell of claim 17 or 18, or a compound of claim 21, in the therapy or in the prevention of a disease when the increase in a human IFNgamma-related activity of a polypeptide of any of the claims from 1 to 3 is needed.
- 10 26. Pharmaceutical compositions for the treatment or prevention of diseases needing an increase in a human IFNgamma-related activity of polypeptide of any of the claims from 1 to 5 or claim 9, a peptide mimetic of claim 10, a nucleic acid of any of the claims from 11 to 15, a cell of claim 17 or 18, or a compound of claim 21, as active ingredient.
- 15 27. Process for the preparation of pharmaceutical compositions, which comprises combining polypeptide of any of the claims from 1 to 5 or claim 9, a peptide mimetic of claim 10, a nucleic acid of any of the claims from 11 to 15, a cell of claim 17 or 18, or a compound of claim 21, together with a pharmaceutically acceptable carrier.
- 20 28. Method for the treatment or prevention of diseases needing an increase in a human IFNgamma-related activity of a polypeptide of any of the claims from 1 to 3, comprising the administration of a therapeutically effective amount of
- 25 polypeptide of any of the claims from 1 to 5 or claim 9, a peptide mimetic of

claim 10, a nucleic acid of any of the claims from 11 to 15, a cell of claim 17 or 18, or a compound of claim 21.

29. Use of a ligand of any of the claims from 6 to 8, or of a compound of claim 22 or 23, in the therapy or in the prevention of a disease associated to the excessive human IFNgamma-related activity of a polypeptide of any of the claims from 1 to 3.
30. Pharmaceutical compositions for the treatment or prevention of a disease associated to the excessive human IFNgamma-related activity of a polypeptide of any of the claims from 1 to 3, containing a ligand of any of the claims from 6 to 8, or of a compound of claim 22 or 23, as active ingredient.
31. Process for the preparation of pharmaceutical compositions for the treatment or prevention of diseases associated to the excessive human IFNgamma-related activity of a polypeptide of any of the claims from 1 to 3, which comprises combining a ligand of any of the claims from 6 to 8, or of a compound of claim 22 or 23, together with a pharmaceutically acceptable carrier.
32. A method for the treatment or prevention of diseases related to the polypeptide of any of the claims from 1 to 3, comprising the administration of a therapeutically effective amount of a ligand of any of the claims from 6 to 8, or of a compound of claim 22 or 23.

33. A method for screening candidate compounds effective to treat a disease related to the polypeptides of any of the claims from 1 to 3, comprising:

- (a) contacting a cell of claim 17 or 18, or a transgenic non-human organism according to claim 19, having enhanced or reduced expression levels of the polypeptide, with a candidate compound; and
- (b) determining the effect of the compound on the animal or on the cell.

34. A method for identifying a candidate compound as an antagonist/inhibitor or agonist/activator of a polypeptide of any of the claims 1 to 3 comprising:

- (a) contacting said polypeptide, said compound, and a mammalian cell or a mammalian cell membrane capable of binding the polypeptide; and
- (b) measuring whether the molecule blocks or enhances the interaction of the polypeptide, or the response that results from such interaction, with the mammalian cell or the mammalian cell membrane.

35. A method for determining the activity and/or the presence of the polypeptide of any the claims from 1 to 34 in a sample, the method comprising:

- (a) providing a protein-containing sample;
- (b) contacting said sample with a ligand of any of the claims from 6 to 8; and
- (c) determining the presence of said ligand bound to said polypeptide.

36. A method for determining the presence or the amount of a transcript or of a nucleic acid encoding the polypeptide of any the claims from 1 to 3 in a sample, the method comprising:

- (a) providing a nucleic acids-containing sample;

- (b) contacting said sample with a nucleic acid of any of the claims 11 to 15;  
and
- (c) determining the hybridization of said nucleic acid with a nucleic acid into the sample.

5

37. Use of the primer sequences containing any of the sequences SEQ ID NO: 41-78 for determining the presence or the amount of a transcript or of a nucleic acid encoding a polypeptide of any the claims from 1 to 4 in a sample by Polymerase Chain Reaction.

10

38. A kit for measuring the activity and/or the presence of the polypeptides of any of the claims from 1 to 3 in a sample comprising one or more of the following reagents: a polypeptide of any of the claims from 1 to 5 or claim 9, a ligand of any of the claims from 6 to 8, a peptide mimetic of claim 10, a nucleic acid of any of the claims from 11 to 15, a cell of claim 17 or 18, a compound of any of the claims from 21 to 23, or a primer sequences containing any of the sequences SEQ ID NO: 41-78.

15

### **ABSTRACT**

The present invention discloses novel open reading frames (ORFs) in human genome encoding for ORFs characterized for polypeptides having at least one activity of human Interferon gamma, and reagents related thereto including variants and fragments of said polypeptides, as well as the encoding nucleic acids and the ligands directed against them. The invention provides methods for identifying and making these molecules, for preparing pharmaceutical compositions containing them, and for using them in the diagnosis, prevention and treatment of diseases.








Figure 1

|          |     |            |            |            |            |            |            |            |            |            |             |     |
|----------|-----|------------|------------|------------|------------|------------|------------|------------|------------|------------|-------------|-----|
| IFNFH01  | 1   | AAC        | ATG        | ACC        | TCA        | CCA        | AAT        | AAA        | CTA        | AAT        | AAG         | 30  |
| pIFNFH01 | 1   |            | <u>Met</u> | <u>Thr</u> | <u>Ser</u> | <u>Phe</u> | <u>Asn</u> | <u>Lys</u> | <u>Leu</u> | <u>Asn</u> | <u>Lys</u>  | 9   |
| IFNFH01  | 31  | CTA        | CCA        | GGG        | ACC        | AAC        | CCT        | GGA        | GAA        | ACA        | GAA         | 60  |
| pIFNFH01 | 10  | <u>Leu</u> | <u>Pro</u> | <u>Gly</u> | <u>Thr</u> | <u>Asn</u> | <u>Pro</u> | <u>Gly</u> | <u>Glu</u> | <u>Thr</u> | <u>Glu</u>  | 19  |
| IFNFH01  | 61  | ATA        | TGT        | GAC        | CTT        | TTA        | GAT        | AGA        | GAA        | TTC        | AAA         | 90  |
| pIFNFH01 | 20  | <u>Ile</u> | <u>Cys</u> | <u>Asp</u> | <u>Leu</u> | <u>Leu</u> | <u>Asp</u> | <u>Arg</u> | <u>Glu</u> | <u>Phe</u> | <u>Lys</u>  | 29  |
| IFNFH01  | 91  | ATA        | GCT        | GTG        | TTG        | AGG        | AAA        | CTC        | AAA        | AAA        | TAT         | 120 |
| pIFNFH01 | 30  | <u>Ile</u> | <u>Ala</u> | <u>Val</u> | <u>Leu</u> | <u>Arg</u> | <u>Lys</u> | <u>Leu</u> | <u>Lys</u> | <u>Lys</u> | <u>Tyr</u>  | 39  |
| IFNFH01  | 121 | CAA        | GAT        | GAT        | ACA        | GAG        | AAG        | AAG        | TTC        | AGA        | ATT         | 150 |
| pIFNFH01 | 40  | <u>Gln</u> | <u>Asp</u> | <u>Asp</u> | <u>Thr</u> | <u>Glu</u> | <u>Lys</u> | <u>Lys</u> | <u>Phe</u> | <u>Arg</u> | <u>Ile</u>  | 49  |
| IFNFH01  | 151 | CTA        | TCA        | GAT        | AAA        | TTT        | AAC        | AAA        | GAG        | ATT        | GAA         | 180 |
| pIFNFH01 | 50  | <u>Leu</u> | <u>Ser</u> | <u>Asp</u> | <u>Lys</u> | <u>Phe</u> | <u>Asn</u> | <u>Lys</u> | <u>Glu</u> | <u>Ile</u> | <u>Glu</u>  | 59  |
| IFNFH01  | 181 | ATA        | TTA        | AAA        | AAT        | AAT        | CAA        | GCA        | GAA        | ATT        | CTG         | 210 |
| pIFNFH01 | 60  | <u>Ile</u> | <u>Leu</u> | <u>Lys</u> | <u>Asn</u> | <u>Asn</u> | <u>Gln</u> | <u>Ala</u> | <u>Glu</u> | <u>Ile</u> | <u>Leu</u>  | 69  |
| IFNFH01  | 211 | GAG        | CTG        | AAA        | AAT        | TTG        | ACT        | GGA        | ATA        | CTG        | AAG         | 240 |
| pIFNFH01 | 70  | <u>Glu</u> | <u>Leu</u> | <u>Lys</u> | <u>Asn</u> | <u>Leu</u> | <u>Thr</u> | <u>Gly</u> | <u>Ile</u> | <u>Leu</u> | <u>Lys</u>  | 79  |
| IFNFH01  | 241 | AAT        | GTG        | CCA        | GGG        | TCT        | TTT        | AAT        | AGC        | AGA        | ATT         | 270 |
| pIFNFH01 | 80  | <u>Asn</u> | <u>Val</u> | <u>Pro</u> | <u>Gly</u> | <u>Ser</u> | <u>Phe</u> | <u>Asn</u> | <u>Ser</u> | <u>Arg</u> | <u>Ile</u>  | 89  |
| IFNFH01  | 271 | GAT        | GGA        | GCA        | AAA        | GGA        | AGA        | ATT        | AGT        | AAG        | CCT         | 300 |
| pIFNFH01 | 90  | <u>Asp</u> | <u>Gly</u> | <u>Ala</u> | <u>Lys</u> | <u>Gly</u> | <u>Arg</u> | <u>Ile</u> | <u>Ser</u> | <u>Lys</u> | <u>Pro</u>  | 99  |
| IFNFH01  | 301 | GAA        | GAC        | AGG        | TTA        | TTT        | GAA        | AAT        | ACA        | CAG        | AGG         | 330 |
| pIFNFH01 | 100 | <u>Glu</u> | <u>Asp</u> | <u>Arg</u> | <u>Leu</u> | <u>Phe</u> | <u>Glu</u> | <u>Asn</u> | <u>Thr</u> | <u>Gln</u> | <u>Arg</u>  | 109 |
| IFNFH01  | 331 | AGA        | CAA        | AAG        | AAA        | AGG        | AAT        | AAA        | AAA        | AAA        | TGA         | 360 |
| pIFNFH01 | 110 | <u>Arg</u> | <u>Gln</u> | <u>Lys</u> | <u>Lys</u> | <u>Arg</u> | <u>Asn</u> | <u>Lys</u> | <u>Lys</u> | <u>Lys</u> | <u>stop</u> | 118 |

Figure 2

|          |     |            |            |            |            |            |            |            |            |            |            |     |
|----------|-----|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|-----|
| IFNFH03  | 1   | AAC        | ATG        | ACA        | TCA        | CCA        | AAT        | GAG        | TTA        | AAT        | GAG        | 30  |
| pIFNFH03 | 1   |            | <u>Met</u> | <u>Thr</u> | <u>Ser</u> | <u>Pro</u> | <u>Asn</u> | <u>Glu</u> | <u>Leu</u> | <u>Asn</u> | <u>Glu</u> | 9   |
| IFNFH03  | 31  | GCA        | GCA        | GGA        | ACT        | ACT        | CCC        | AAA        | GAA        | ACA        | GAG        | 60  |
| pIFNFH03 | 10  | Ala        | Ala        | Gly        | <u>Thr</u> | Thr        | <u>Pro</u> | Lys        | <u>Glu</u> | <u>Thr</u> | <u>Glu</u> | 19  |
| IFNFH03  | 61  | ATA        | TGT        | GAC        | ATT        | TCA        | GAC        | AGA        | GAA        | TTC        | AAA        | 90  |
| pIFNFH03 | 20  | <u>Ile</u> | <u>Cys</u> | <u>Asp</u> | Ile        | <u>Ser</u> | <u>Asp</u> | Arg        | <u>Glu</u> | <u>Phe</u> | <u>Lys</u> | 29  |
| IFNFH03  | 91  | ATA        | GCT        | TTG        | TTG        | AAG        | AAA        | CTC        | AAA        | GAA        | ATT        | 120 |
| pIFNFH03 | 30  | <u>Ile</u> | Ala        | Leu        | <u>Leu</u> | <u>Lys</u> | Lys        | <u>Leu</u> | <u>Lys</u> | <u>Glu</u> | <u>Ile</u> | 39  |
| IFNFH03  | 121 | CAA        | GAT        | AAT        | ACG        | GAG        | AAG        | GAA        | CTC        | AGA        | ATT        | 150 |
| pIFNFH03 | 40  | <u>Gln</u> | <u>Asp</u> | <u>Asn</u> | <u>Thr</u> | <u>Glu</u> | <u>Lys</u> | <u>Glu</u> | Leu        | <u>Arg</u> | <u>Ile</u> | 49  |
| IFNFH03  | 151 | CTA        | TCA        | GAT        | AAA        | TTT        | AAC        | AAG        | GAG        | ATT        | GAA        | 180 |
| pIFNFH03 | 50  | <u>Leu</u> | <u>Ser</u> | <u>Asp</u> | <u>Lys</u> | Phe        | Asn        | <u>Lys</u> | <u>Glu</u> | <u>Ile</u> | <u>Glu</u> | 59  |
| IFNFH03  | 181 | ATG        | ATT        | AAA        | AAG        | AAC        | CAA        | GCA        | GAA        | ATT        | CTG        | 210 |
| pIFNFH03 | 60  | Met        | <u>Ile</u> | <u>Lys</u> | Lys        | <u>Asn</u> | <u>Gln</u> | <u>Ala</u> | <u>Glu</u> | <u>Ile</u> | <u>Leu</u> | 69  |
| IFNFH03  | 211 | GAG        | CTA        | AAA        | AAT        | GCA        | GGT        | GGC        | ATA        | TTG        | AAA        | 240 |
| pIFNFH03 | 70  | <u>Glu</u> | <u>Leu</u> | Lys        | <u>Asn</u> | <u>Ala</u> | Gly        | <u>Gly</u> | Ile        | <u>Leu</u> | Lys        | 79  |
| IFNFH03  | 241 | ATG        | CAT        | CAG        | AGT        | TGG        | CTG        | GGC        | ATG        | GTG        | GCT        | 270 |
| pIFNFH03 | 80  | Met        | His        | Gln        | Ser        | Trp        | Leu        | Gly        | Met        | Val        | Ala        | 89  |
| IFNFH03  | 271 | CAC        | GCC        | TGT        | AAT        | CCC        | AGT        | ACT        | TTG        | GGA        | AGC        | 300 |
| pIFNFH03 | 90  | His        | Ala        | Cys        | Asn        | Pro        | Ser        | Thr        | Leu        | Gly        | Ser        | 99  |
| IFNFH03  | 301 | CGA        | GGT        | GGG        | TGG        | ATC        | ACG        | AGT        | TCA        | GGA        | GTT        | 330 |
| pIFNFH03 | 100 | Arg        | Gly        | Gly        | Trp        | Ile        | Thr        | Ser        | Ser        | Gly        | Val        | 109 |
| IFNFH03  | 331 | CAA        | GAC        | CAG        | CCT        | GGC        | CAA        | GGC        | AGT        | GAA        | ACC        | 360 |
| pIFNFH03 | 110 | Gln        | Asp        | Gln        | Pro        | Gly        | Gln        | Gly        | Ser        | Glu        | Thr        | 119 |
| IFNFH03  | 361 | TCA        | TCT        | CTA        | CTA        | AAA        | ATA        | CAA        | AAA        | TTA        | GCT        | 390 |
| pIFNFH03 | 120 | Ser        | Ser        | Leu        | Leu        | Lys        | Ile        | Gln        | Lys        | Leu        | Ala        | 129 |
| IFNFH03  | 391 | GGG        | TGC        | AGT        | GGC        | AGG        | CAC        | CTG        | TAA        |            |            | 414 |
| pIFNFH03 | 130 | Gly        | Cys        | Ser        | Gly        | Arg        | His        | Leu        | stop       |            |            | 136 |

Figure 3

|          |     |            |            |            |            |            |            |            |            |            |            |     |
|----------|-----|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|-----|
| IFNFH04  | 1   | AAC        | ATG        | ACC        | TCA        | CCA        | AAT        | GAA        | CTA        | AAT        | AAG        | 30  |
| pIFNFH04 | 1   |            | <u>Met</u> | <u>Thr</u> | <u>Ser</u> | <u>Pro</u> | <u>Asn</u> | <u>Glu</u> | <u>Leu</u> | <u>Asn</u> | <u>Lys</u> | 9   |
| IFNFH04  | 31  | GCA        | CCA        | GGG        | ACC        | AAT        | CCT        | GGA        | GAA        | ACA        | GAG        | 60  |
| pIFNFH04 | 10  | Ala        | <u>Pro</u> | <u>Gly</u> | <u>Thr</u> | <u>Asn</u> | <u>Pro</u> | <u>Gly</u> | <u>Glu</u> | <u>Thr</u> | <u>Glu</u> | 19  |
| IFNFH04  | 61  | ATG        | TAT        | GAC        | CTT        | TCA        | GAC        | AGA        | GAA        | TTC        | AAA        | 90  |
| pIFNFH04 | 20  | Met        | Tyr        | <u>Asp</u> | <u>Leu</u> | <u>Ser</u> | <u>Asp</u> | <u>Arg</u> | <u>Glu</u> | <u>Phe</u> | <u>Lys</u> | 29  |
| IFNFH04  | 91  | ACA        | GCT        | ATT        | TTG        | AGG        | AAA        | CTC        | AAA        | GAA        | ATT        | 120 |
| pIFNFH04 | 30  | Thr        | Ala        | Ile        | <u>Leu</u> | Arg        | Lys        | <u>Leu</u> | <u>Lys</u> | <u>Glu</u> | <u>Ile</u> | 39  |
| IFNFH04  | 121 | CAA        | GAT        | AAC        | ACA        | AAG        | AAG        | GAA        | TTC        | AGA        | ATT        | 150 |
| pIFNFH04 | 40  | <u>Gln</u> | <u>Asp</u> | <u>Asn</u> | <u>Thr</u> | Lys        | <u>Lys</u> | <u>Glu</u> | Phe        | <u>Arg</u> | <u>Ile</u> | 49  |
| IFNFH04  | 151 | CTA        | TCA        | GAT        | AAA        | TTT        | AAC        | AAA        | CAG        | ATC        | GAA        | 180 |
| pIFNFH04 | 50  | <u>Leu</u> | <u>Ser</u> | <u>Asp</u> | <u>Lys</u> | Phe        | Asn        | <u>Lys</u> | <u>Gln</u> | <u>Ile</u> | <u>Glu</u> | 59  |
| IFNFH04  | 181 | ATA        | ATT        | AAA        | AAG        | AAT        | CAA        | GCA        | GAA        | ATT        | CTA        | 210 |
| pIFNFH04 | 60  | <u>Ile</u> | <u>Ile</u> | <u>Lys</u> | Lys        | <u>Asn</u> | <u>Gln</u> | <u>Ala</u> | <u>Glu</u> | <u>Ile</u> | <u>Leu</u> | 69  |
| IFNFH04  | 211 | GAG        | CTG        | AAA        | AAT        | GTA        | ATT        | GAT        | ATA        | CTA        | AAG        | 240 |
| pIFNFH04 | 70  | <u>Glu</u> | <u>Leu</u> | Lys        | <u>Asn</u> | Val        | Ile        | Asp        | Ile        | <u>Leu</u> | Lys        | 79  |
| IFNFH04  | 241 | AAT        | GCA        | TCA        | GTC        | TCT        | TGA        |            |            |            |            | 258 |
| pIFNFH04 | 80  | Asn        | Ala        | Ser        | Val        | Ser        | stop       |            |            |            |            | 84  |

4/22

Figure 4

|          |     |            |            |            |            |            |            |            |             |            |            |     |
|----------|-----|------------|------------|------------|------------|------------|------------|------------|-------------|------------|------------|-----|
| IFNFH08  | 1   | AAC        | ATG        | ACC        | TCA        | CCA        | AAT        | GAA        | CTT         | AGT        | AAG        | 30  |
| pIFNFH08 | 1   | <u>Met</u> | <u>Thr</u> | <u>Ser</u> | <u>Pro</u> | <u>Asn</u> | <u>Glu</u> | <u>Leu</u> | <u>Ser</u>  | <u>Lys</u> |            | 9   |
| IFNFH08  | 31  | GCA        | CCA        | GGG        | ACC        | AAT        | CAG        | GGA        | GAA         | ACA        | GAG        | 60  |
| pIFNFH08 | 10  | <u>Ala</u> | <u>Pro</u> | <u>Gly</u> | <u>Thr</u> | <u>Asn</u> | <u>Gln</u> | <u>Gly</u> | <u>Glu</u>  | <u>Thr</u> | <u>Glu</u> | 19  |
| IFNFH08  | 61  | ATA        | TAT        | GAC        | CTT        | TCA        | GAC        | ACA        | GAA         | TTC        | AAA        | 90  |
| pIFNFH08 | 20  | <u>Ile</u> | <u>Tyr</u> | <u>Asp</u> | <u>Leu</u> | <u>Ser</u> | <u>Asp</u> | <u>Thr</u> | <u>Glu</u>  | <u>Phe</u> | <u>Lys</u> | 29  |
| IFNFH08  | 91  | ATA        | GCT        | GTT        | TTG        | AGA        | AAC        | TCA        | AAG         | AAG        | AAA        | 120 |
| pIFNFH08 | 30  | <u>Ile</u> | <u>Ala</u> | <u>Val</u> | <u>Leu</u> | <u>Arg</u> | <u>Asn</u> | <u>Ser</u> | <u>Lys</u>  | <u>Lys</u> | <u>Lys</u> | 39  |
| IFNFH08  | 121 | CTC        | AAA        | GAA        | ATT        | CAG        | GAT        | AAC        | ACA         | GAG        | AAG        | 150 |
| pIFNFH08 | 40  | <u>Leu</u> | <u>Lys</u> | <u>Glu</u> | <u>Ile</u> | <u>Gln</u> | <u>Asp</u> | <u>Asn</u> | <u>Thr</u>  | <u>Glu</u> | <u>Lys</u> | 49  |
| IFNFH08  | 151 | GAA        | TTC        | AGA        | ATT        | CTA        | TCA        | GAT        | AAA         | TTT        | AAC        | 180 |
| pIFNFH08 | 50  | <u>Glu</u> | <u>Phe</u> | <u>Arg</u> | <u>Ile</u> | <u>Leu</u> | <u>Ser</u> | <u>Asp</u> | <u>Lys</u>  | <u>Phe</u> | <u>Asn</u> | 59  |
| IFNFH08  | 181 | AAA        | GAG        | ATT        | GAA        | ATA        | ATT        | AAA        | AAG         | AAT        | CAA        | 210 |
| pIFNFH08 | 60  | <u>Lys</u> | <u>Glu</u> | <u>Ile</u> | <u>Glu</u> | <u>Ile</u> | <u>Ile</u> | <u>Lys</u> | <u>Lys</u>  | <u>Asn</u> | <u>Gln</u> | 69  |
| IFNFH08  | 211 | GCA        | GAA        | ATT        | CTA        | GAG        | TTG        | AAA        | AAT         | GCA        | ATT        | 240 |
| pIFNFH08 | 70  | <u>Ala</u> | <u>Glu</u> | <u>Ile</u> | <u>Leu</u> | <u>Glu</u> | <u>Leu</u> | <u>Lys</u> | <u>Asn</u>  | <u>Ala</u> | <u>Ile</u> | 79  |
| IFNFH08  | 241 | GAC        | ATG        | CTG        | AAT        | AAT        | GCA        | TCA        | GAT         | TAT        | CTT        | 270 |
| pIFNFH08 | 80  | <u>Asp</u> | <u>Met</u> | <u>Leu</u> | <u>Asn</u> | <u>Asn</u> | <u>Ala</u> | <u>Ser</u> | <u>Asp</u>  | <u>Tyr</u> | <u>Leu</u> | 89  |
| IFNFH08  | 271 | CAT        | AGT        | AGA        | ATT        | AAT        | CGG        | AAT        | TAG         |            |            | 294 |
| pIFNFH08 | 90  | <u>His</u> | <u>Ser</u> | <u>Arg</u> | <u>Ile</u> | <u>Asn</u> | <u>Arg</u> | <u>Asn</u> | <u>stop</u> |            |            | 96  |

Figure 5

|          |     |            |            |            |            |            |            |            |            |            |            |     |
|----------|-----|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|-----|
| IFNFH10  | 1   | AAC        | ATG        | ACC        | TCA        | CCA        | AAT        | GAG        | GTA        | AAT        | AAG        | 30  |
| pIFNFH10 | 1   |            | <u>Met</u> | <u>Thr</u> | <u>Ser</u> | <u>Pro</u> | <u>Asn</u> | <u>Glu</u> | Val        | <u>Asn</u> | <u>Lys</u> | 9   |
| IFNFH10  | 31  | GTA        | CCA        | ATG        | ACC        | AAC        | CCT        | GGA        | GAA        | ACG        | GAG        | 60  |
| pIFNFH10 | 10  | Val        | <u>Pro</u> | Met        | <u>Thr</u> | <u>Asn</u> | <u>Pro</u> | <u>Gly</u> | <u>Glu</u> | <u>Thr</u> | <u>Glu</u> | 19  |
| IFNFH10  | 61  | ATA        | TGT        | GAC        | CTT        | TCA        | GAC        | CAA        | AAA        | TTA        | AAA        | 90  |
| pIFNFH10 | 20  | <u>Ile</u> | <u>Cys</u> | <u>Asp</u> | <u>Leu</u> | <u>Ser</u> | <u>Asp</u> | Gln        | Lys        | Leu        | <u>Lys</u> | 29  |
| IFNFH10  | 91  | ATA        | GCT        | GTG        | ATG        | AGG        | AAA        | CTC        | AAA        | GAA        | ATT        | 120 |
| pIFNFH10 | 30  | <u>Ile</u> | Ala        | <u>Val</u> | Met        | Arg        | Lys        | <u>Leu</u> | <u>Lys</u> | <u>Glu</u> | <u>Ile</u> | 39  |
| IFNFH10  | 121 | CAA        | GAT        | AAC        | ACA        | GAG        | AAA        | GAA        | TTC        | AAA        | ATT        | 150 |
| pIFNFH10 | 40  | <u>Gln</u> | <u>Asp</u> | <u>Asn</u> | <u>Thr</u> | <u>Glu</u> | <u>Lys</u> | <u>Glu</u> | Phe        | Lys        | <u>Ile</u> | 49  |
| IFNFH10  | 151 | CTA        | TCA        | CGT        | AAA        | TTT        | AAC        | AAA        | AAG        | ATT        | GGA        | 180 |
| pIFNFH10 | 50  | <u>Leu</u> | <u>Ser</u> | Arg        | <u>Lys</u> | Phe        | Asn        | <u>Lys</u> | Lys        | <u>Ile</u> | Gly        | 59  |
| IFNFH10  | 181 | TTA        | ATT        | GAA        | AAT        | AAT        | CAA        | GCA        | GAA        | ATT        | TTG        | 210 |
| pIFNFH10 | 60  | Leu        | <u>Ile</u> | Glu        | Asn        | <u>Asn</u> | <u>Gln</u> | <u>Ala</u> | <u>Glu</u> | <u>Ile</u> | <u>Leu</u> | 69  |
| IFNFH10  | 211 | GAG        | CTG        | AAA        | AAT        | GCA        | ATT        | GGC        | ATA        | CTG        | AAG        | 240 |
| pIFNFH10 | 70  | <u>Glu</u> | <u>Leu</u> | Lys        | <u>Asn</u> | <u>Ala</u> | Ile        | <u>Gly</u> | Ile        | <u>Leu</u> | Lys        | 79  |
| IFNFH10  | 241 | AAT        | GCA        | TCA        | GAG        | TCC        | TTT        | AAT        | AGC        | AAT        | ATG        | 270 |
| pIFNFH10 | 80  | Asn        | Ala        | Ser        | Glu        | Ser        | Phe        | Asn        | Ser        | Asn        | Met        | 89  |
| IFNFH10  | 271 | TAT        | CAA        | GCA        | GAA        | GAC        | AGA        | ATT        | AGT        | GAG        | CTT        | 300 |
| pIFNFH10 | 90  | Tyr        | Gln        | Ala        | Glu        | Asp        | Arg        | Ile        | Ser        | Glu        | Leu        | 99  |
| IFNFH10  | 301 | AAA        | TAC        | AGG        | CTA        | TTT        | GAA        | AAT        | ACA        | CAG        | TCA        | 330 |
| pIFNFH10 | 100 | Lys        | Tyr        | Arg        | Leu        | Phe        | Glu        | Asn        | Thr        | Gln        | Ser        | 109 |
| IFNFH10  | 331 | GAG        | GAG        | ACC        | AAA        | AAC        | AAC        | AAA        | AAA        | CAA        | TGA        | 360 |
| pIFNFH10 | 110 | Glu        | Glu        | Thr        | Lys        | Asn        | Asn        | Lys        | Lys        | Gln        | stop       | 118 |

6/22

Figure 6

|          |     |            |            |            |            |            |            |            |            |            |            |     |
|----------|-----|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|-----|
| IFNFH11  | 1   | CAC        | ATG        | ACC        | TCA        | GGA        | AAT        | GAA        | GTA        | AAT        | AAG        | 30  |
| pIFNFH11 | 1   |            | <u>Met</u> | <u>Thr</u> | <u>Ser</u> | <u>Gly</u> | <u>Asn</u> | <u>Glu</u> | Val        | <u>Asn</u> | <u>Lys</u> | 9   |
| IFNFH11  | 31  | GCA        | CCA        | GGG        | ACC        | AAT        | CTT        | GGA        | GAA        | ACA        | GAG        | 60  |
| pIFNFH11 | 10  | Ala        | <u>Pro</u> | <u>Gly</u> | <u>Thr</u> | <u>Asn</u> | Leu        | <u>Gly</u> | <u>Glu</u> | <u>Thr</u> | <u>Glu</u> | 19  |
| IFNFH11  | 61  | ATA        | TGT        | GAC        | CTT        | TCA        | GAT        | ACA        | GAA        | CTC        | AGA        | 90  |
| pIFNFH11 | 20  | <u>Ile</u> | <u>Cys</u> | <u>Asp</u> | <u>Leu</u> | <u>Ser</u> | <u>Asp</u> | <u>Thr</u> | <u>Glu</u> | Leu        | Arg        | 29  |
| IFNFH11  | 91  | ATA        | ACT        | GTG        | TTG        | AGG        | AAA        | CTC        | AAT        | GAA        | ATT        | 120 |
| pIFNFH11 | 30  | <u>Ile</u> | Thr        | <u>Val</u> | <u>Leu</u> | Arg        | Lys        | <u>Leu</u> | Asn        | <u>Glu</u> | <u>Ile</u> | 39  |
| IFNFH11  | 121 | AAA        | GAT        | AAC        | ACA        | GAG        | ATG        | GAA        | TTC        | AGA        | ATT        | 150 |
| pIFNFH11 | 40  | Lys        | <u>Asp</u> | <u>Asn</u> | <u>Thr</u> | <u>Glu</u> | Met        | <u>Glu</u> | Phe        | <u>Arg</u> | <u>Ile</u> | 49  |
| IFNFH11  | 151 | TTG        | TCA        | GAT        | AAA        | TTT        | AAG        | AAA        | GAG        | ATT        | GAA        | 180 |
| pIFNFH11 | 50  | <u>Leu</u> | <u>Ser</u> | <u>Asp</u> | <u>Lys</u> | Phe        | <u>Lys</u> | <u>Lys</u> | <u>Glu</u> | <u>Ile</u> | <u>Glu</u> | 59  |
| IFNFH11  | 181 | ATA        | ATT        | AAA        | AGG        | AAT        | CAA        | GCA        | GAA        | ATT        | CTG        | 210 |
| pIFNFH11 | 60  | <u>Ile</u> | <u>Ile</u> | <u>Lys</u> | Arg        | <u>Asn</u> | <u>Gln</u> | <u>Ala</u> | <u>Glu</u> | <u>Ile</u> | <u>Leu</u> | 69  |
| IFNFH11  | 211 | GAG        | CTG        | AAA        | AAT        | GCA        | ATT        | GGC        | ATA        | CTG        | AAG        | 240 |
| pIFNFH11 | 70  | <u>Glu</u> | <u>Leu</u> | Lys        | <u>Asn</u> | <u>Ala</u> | Ile        | <u>Gly</u> | Ile        | <u>Leu</u> | Lys        | 79  |
| IFNFH11  | 241 | AAT        | GCA        | TCA        | GAG        | TTT        | TTA        | AAT        | AGA        | AGA        | ACA        | 270 |
| pIFNFH11 | 80  | Asn        | Ala        | Ser        | Glu        | Phe        | Leu        | Asn        | Arg        | Arg        | Thr        | 89  |
| IFNFH11  | 271 | GAT        | CAA        | GCA        | GCA        | GAA        | AAA        | TCT        | AGT        | GAG        | CCT        | 300 |
| pIFNFH11 | 90  | Asp        | Gln        | Ala        | Ala        | Glu        | Lys        | Ser        | Ser        | Glu        | Pro        | 99  |
| IFNFH11  | 301 | GAA        | GAC        | AGA        | CTA        | TTT        | GAA        | AAT        | ACA        | CAG        | AGG        | 330 |
| pIFNFH11 | 100 | <u>Glu</u> | <u>Asp</u> | <u>Arg</u> | <u>Leu</u> | <u>Phe</u> | <u>Glu</u> | <u>Asn</u> | <u>Thr</u> | <u>Gln</u> | <u>Arg</u> | 109 |
| IFNFH11  | 331 | TCT        | CAA        | AAG        | AAA        | AAG        | AAT        | AAA        | AAA        | CAA        | TAA        | 360 |
| pIFNFH11 | 110 | Ser        | Gln        | Lys        | Lys        | Lys        | Asn        | Lys        | Lys        | Gln        | stop       | 118 |

• • •

[illegible]



8/22

Figure 8

|          |     |            |            |            |            |            |            |            |            |            |            |     |
|----------|-----|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|-----|
| IFNFH13  | 1   | AAC        | ATG        | ACC        | TCA        | CCA        | AAT        | GAA        | CTA        | AAT        | AAG        | 30  |
| pIFNFH13 | 1   |            | <u>Met</u> | <u>Thr</u> | <u>Ser</u> | <u>Pro</u> | <u>Asn</u> | <u>Glu</u> | <u>Leu</u> | <u>Asn</u> | <u>Lys</u> | 9   |
| IFNFH13  | 31  | GCA        | CCA        | GGG        | ACC        | AAT        | CCT        | GGA        | GAA        | ACT        | GAG        | 60  |
| pIFNFH13 | 10  | Ala        | <u>Pro</u> | <u>Gly</u> | <u>Thr</u> | <u>Asn</u> | <u>Pro</u> | <u>Gly</u> | <u>Glu</u> | <u>Thr</u> | <u>Glu</u> | 19  |
| IFNFH13  | 61  | ATA        | TGT        | GAC        | CTT        | TCA        | GAC        | AGA        | AAA        | TTC        | AAA        | 90  |
| pIFNFH13 | 20  | <u>Ile</u> | <u>Cys</u> | <u>Asp</u> | <u>Leu</u> | <u>Ser</u> | <u>Asp</u> | <u>Arg</u> | <u>Lys</u> | <u>Phe</u> | <u>Lys</u> | 29  |
| IFNFH13  | 91  | AGA        | GCT        | GTG        | TTG        | AAG        | AAA        | CTC        | AAA        | GAA        | ATT        | 120 |
| pIFNFH13 | 30  | Arg        | Ala        | <u>Val</u> | <u>Leu</u> | <u>Lys</u> | <u>Lys</u> | <u>Leu</u> | <u>Lys</u> | <u>Glu</u> | <u>Ile</u> | 39  |
| IFNFH13  | 121 | CAA        | AAT        | GTC        | TCA        | AAG        | AAG        | GAA        | TTC        | AGA        | ATT        | 150 |
| pIFNFH13 | 40  | <u>Gln</u> | <u>Asn</u> | <u>Val</u> | <u>Ser</u> | <u>Lys</u> | <u>Lys</u> | <u>Glu</u> | <u>Phe</u> | <u>Arg</u> | <u>Ile</u> | 49  |
| IFNFH13  | 151 | CTA        | TTA        | GAT        | AAA        | TTT        | AAC        | AGA        | CAG        | ATT        | GAA        | 180 |
| pIFNFH13 | 50  | <u>Leu</u> | <u>Leu</u> | <u>Asp</u> | <u>Lys</u> | <u>Phe</u> | <u>Asn</u> | <u>Arg</u> | <u>Gln</u> | <u>Ile</u> | <u>Glu</u> | 59  |
| IFNFH13  | 181 | GTA        | ATT        | AAA        | AAT        | AAT        | CAA        | ACA        | GAA        | ATT        | ATG        | 210 |
| pIFNFH13 | 60  | <u>Val</u> | <u>Ile</u> | <u>Lys</u> | <u>Asn</u> | <u>Asn</u> | <u>Gln</u> | <u>Thr</u> | <u>Glu</u> | <u>Ile</u> | <u>Met</u> | 69  |
| IFNFH13  | 211 | GAG        | CTT        | AAA        | AAC        | GCA        | ATT        | GGC        | ATA        | CTG        | AAA        | 240 |
| pIFNFH13 | 70  | <u>Glu</u> | <u>Leu</u> | <u>Lys</u> | <u>Asn</u> | <u>Ala</u> | <u>Ile</u> | <u>Gly</u> | <u>Ile</u> | <u>Leu</u> | <u>Lys</u> | 79  |
| IFNFH13  | 241 | ATG        | CAT        | CAG        | AGT        | TCT        | TTA        | ATA        | GCA        | GCA        | TTG        | 270 |
| pIFNFH13 | 80  | <u>Met</u> | <u>His</u> | <u>Gln</u> | <u>Ser</u> | <u>Ser</u> | <u>Leu</u> | <u>Ile</u> | <u>Ala</u> | <u>Ala</u> | <u>Leu</u> | 89  |
| IFNFH13  | 271 | ATC        | AAA        | CAG        | AAG        | AAA        | GAA        | TTA        | GTG        | AAC        | CTG        | 300 |
| pIFNFH13 | 90  | <u>Ile</u> | <u>Lys</u> | <u>Gln</u> | <u>Lys</u> | <u>Lys</u> | <u>Glu</u> | <u>Leu</u> | <u>Val</u> | <u>Asn</u> | <u>Leu</u> | 99  |
| IFNFH13  | 301 | AAG        | ACA        | GCC        | TAT        | TTG        | AAA        | ATA        | CAC        | AGA        | GGA        | 330 |
| pIFNFH13 | 100 | <u>Lys</u> | <u>Thr</u> | <u>Ala</u> | <u>Tyr</u> | <u>Leu</u> | <u>Lys</u> | <u>Ile</u> | <u>His</u> | <u>Arg</u> | <u>Gly</u> | 109 |
| IFNFH13  | 331 | GAC        | AAA        | AGA        | AAA        | AAA        | TAT        | AAA        | AGA        | ATG        | AA G       | 360 |
| pIFNFH13 | 110 | <u>Asp</u> | <u>Lys</u> | <u>Arg</u> | <u>Lys</u> | <u>Lys</u> | <u>Tyr</u> | <u>Lys</u> | <u>Arg</u> | <u>Met</u> | <u>Lys</u> | 119 |
| IFNFH13  | 361 | CAC        | ACC        | TAA        |            |            |            |            |            |            |            | 369 |
| pIFNFH13 | 120 | <u>His</u> | <u>Thr</u> | stop       |            |            |            |            |            |            |            | 121 |

9/22

Figure 9

|          |     |            |            |            |            |            |            |            |            |            |            |     |
|----------|-----|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|-----|
| IFNFH14  | 1   | AAC        | ATG        | ACA        | TCA        | ACA        | AAG        | GAA        | CTA        | AAT        | AAG        | 30  |
| pIFNFH14 | 1   |            | <u>Met</u> | <u>Thr</u> | <u>Ser</u> | <u>Thr</u> | <u>Lys</u> | <u>Glu</u> | <u>Leu</u> | <u>Asn</u> | <u>Lys</u> | 9   |
| IFNFH14  | 31  | GCA        | CCA        | GTA        | AAC        | AAT        | CCT        | GGA        | GAA        | ACA        | GAA        | 60  |
| pIFNFH14 | 10  | Ala        | <u>Pro</u> | Val        | Asn        | <u>Asn</u> | <u>Pro</u> | <u>Gly</u> | <u>Glu</u> | <u>Thr</u> | <u>Glu</u> | 19  |
| IFNFH14  | 61  | CTA        | TGT        | GAC        | CTT        | TTA        | GAC        | AAA        | AAA        | TTC        | AAA        | 90  |
| pIFNFH14 | 20  | Leu        | <u>Cys</u> | <u>Asp</u> | <u>Leu</u> | Leu        | <u>Asp</u> | <u>Lys</u> | <u>Lys</u> | <u>Phe</u> | <u>Lys</u> | 29  |
| IFNFH14  | 91  | ATA        | GCA        | GTG        | TTG        | AGG        | AAA        | CTA        | AAA        | GGA        | ATT        | 120 |
| pIFNFH14 | 30  | <u>Ile</u> | Ala        | <u>Val</u> | <u>Leu</u> | Arg        | <u>Lys</u> | <u>Leu</u> | <u>Lys</u> | <u>Gly</u> | <u>Ile</u> | 39  |
| IFNFH14  | 121 | CAA        | AAT        | AAC        | ACA        | GAG        | AAG        | GAA        | TTC        | AGA        | ATT        | 150 |
| pIFNFH14 | 40  | <u>Gln</u> | Asn        | <u>Asn</u> | <u>Thr</u> | <u>Glu</u> | <u>Lys</u> | <u>Glu</u> | Phe        | <u>Arg</u> | <u>Ile</u> | 49  |
| IFNFH14  | 151 | CTA        | TCA        | GAT        | AAA        | TTT        | AAC        | AAA        | GAG        | ATT        | GAA        | 180 |
| pIFNFH14 | 50  | <u>Leu</u> | <u>Ser</u> | <u>Asp</u> | <u>Lys</u> | Phe        | Asn        | <u>Lys</u> | <u>Glu</u> | <u>Ile</u> | <u>Glu</u> | 59  |
| IFNFH14  | 181 | ATA        | ATT        | AAA        | AAG        | AAT        | CAA        | GCA        | GAA        | ACT        | CTG        | 210 |
| pIFNFH14 | 60  | <u>Ile</u> | <u>Ile</u> | <u>Lys</u> | <u>Lys</u> | <u>Asn</u> | <u>Gln</u> | <u>Ala</u> | <u>Glu</u> | <u>Thr</u> | <u>Leu</u> | 69  |
| IFNFH14  | 211 | GAG        | CTA        | AAA        | AAT        | GCA        | GTT        | GGC        | ACA        | CTA        | ACA        | 240 |
| pIFNFH14 | 70  | <u>Glu</u> | <u>Leu</u> | <u>Lys</u> | <u>Asn</u> | <u>Ala</u> | Val        | <u>Gly</u> | <u>Thr</u> | <u>Leu</u> | <u>Thr</u> | 79  |
| IFNFH14  | 241 | AAA        | GCA        | TCA        | CAG        | TCC        | TTT        | AAA        | AGC        | AGA        | ATG        | 270 |
| pIFNFH14 | 80  | Lys        | Ala        | Ser        | Gln        | Ser        | Phe        | Lys        | Ser        | Arg        | Met        | 89  |
| IFNFH14  | 271 | GAT        | ATA        | GCA        | GAA        | AGA        | AGA        | ATT        | AGT        | GAA        | CTT        | 300 |
| pIFNFH14 | 90  | Asp        | Ile        | Ala        | Glu        | Arg        | Arg        | Ile        | Ser        | Glu        | Leu        | 99  |
| IFNFH14  | 301 | AAA        | GAC        | AGG        | CTA        | TTT        | GAA        | AAT        | ACA        | GTC        | AGA        | 330 |
| pIFNFH14 | 100 | Lys        | Asp        | Arg        | Leu        | Phe        | Glu        | Asn        | Thr        | Val        | Arg        | 109 |
| IFNFH14  | 331 | AGA        | GAA        | AAA        | AGA        | ATA        | TAA        |            |            |            |            | 348 |
| pIFNFH14 | 110 | Arg        | Glu        | Lys        | Arg        | Ile        | stop       |            |            |            |            | 114 |

10/22

Figure 10

|          |     |            |            |            |            |            |            |            |            |            |            |     |
|----------|-----|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|-----|
| IFNFH15  | 1   | AAT        | ATG        | ACC        | TCA        | CCA        | AAT        | GAA        | CTA        | AAT        | AAG        | 30  |
| pIFNFH15 | 1   |            | <u>Met</u> | <u>Thr</u> | <u>Ser</u> | <u>Pro</u> | <u>Asn</u> | <u>Glu</u> | <u>Leu</u> | <u>Asn</u> | <u>Lys</u> | 9   |
| IFNFH15  | 31  | GCA        | CCA        | GGG        | ATC        | AAT        | CCT        | GGG        | GAA        | ACA        | GAA        | 60  |
| pIFNFH15 | 10  | Ala        | <u>Pro</u> | <u>Gly</u> | <u>Ile</u> | <u>Asn</u> | <u>Pro</u> | <u>Gly</u> | <u>Glu</u> | <u>Thr</u> | <u>Glu</u> | 19  |
| IFNFH15  | 61  | ATA        | TGT        | GAC        | CTT        | TCA        | GAC        | AGA        | GAA        | TTC        | ACA        | 90  |
| pIFNFH15 | 20  | <u>Ile</u> | <u>Cys</u> | <u>Asp</u> | <u>Leu</u> | <u>Ser</u> | <u>Asp</u> | <u>Arg</u> | <u>Glu</u> | <u>Phe</u> | <u>Thr</u> | 29  |
| IFNFH15  | 91  | ATA        | GCT        | GTT        | TCG        | AGG        | AAG        | CTA        | AAC        | AAA        | ATC        | 120 |
| pIFNFH15 | 30  | <u>Ile</u> | Ala        | <u>Val</u> | Ser        | Arg        | Lys        | <u>Leu</u> | Asn        | Lys        | <u>Ile</u> | 39  |
| IFNFH15  | 121 | CAA        | GAT        | AAC        | ATG        | GAG        | AAG        | GAA        | TTC        | AGA        | ATC        | 150 |
| pIFNFH15 | 40  | <u>Gln</u> | <u>Asp</u> | <u>Asn</u> | Met        | <u>Glu</u> | <u>Lys</u> | <u>Glu</u> | Phe        | <u>Arg</u> | <u>Ile</u> | 49  |
| IFNFH15  | 151 | CTA        | TCA        | GAT        | AAA        | TTT        | AAT        | GAA        | GAG        | ATT        | GAA        | 180 |
| pIFNFH15 | 50  | <u>Leu</u> | <u>Ser</u> | <u>Asp</u> | <u>Lys</u> | Phe        | Asn        | Glu        | Glu        | <u>Ile</u> | <u>Glu</u> | 59  |
| IFNFH15  | 181 | ATA        | ATT        | AAA        | AAG        | AAT        | CAA        | GCA        | GAA        | ATT        | CTG        | 210 |
| pIFNFH15 | 60  | <u>Ile</u> | <u>Ile</u> | <u>Lys</u> | Lys        | <u>Asn</u> | <u>Gln</u> | <u>Ala</u> | <u>Glu</u> | <u>Ile</u> | <u>Leu</u> | 69  |
| IFNFH15  | 211 | GAG        | CTG        | AAA        | AAC        | GCA        | ATT        | GAC        | ATG        | TTG        | AAG        | 240 |
| pIFNFH15 | 70  | <u>Glu</u> | <u>Leu</u> | Lys        | <u>Asn</u> | <u>Ala</u> | Ile        | Asp        | Met        | <u>Leu</u> | Lys        | 79  |
| IFNFH15  | 241 | AAT        | GCA        | TCA        | GAG        | AAT        | CTC        | ACC        | AGC        | AGA        | ACT        | 270 |
| pIFNFH15 | 80  | Asn        | Ala        | Ser        | Glu        | Asn        | Leu        | Thr        | Ser        | Arg        | Thr        | 89  |
| IFNFH15  | 271 | GAT        | CAA        | GCA        | AGA        | GAA        | ATA        | ATT        | AGT        | AAG        | CTT        | 300 |
| pIFNFH15 | 90  | Asp        | Gln        | Ala        | Arg        | Glu        | Ile        | Ile        | Ser        | Lys        | Leu        | 99  |
| IFNFH15  | 301 | GAA        | GAC        | AGG        | CTA        | TTT        | GAA        | AAC        | ACA        | AAG        | TCA        | 330 |
| pIFNFH15 | 100 | Glu        | Asp        | Arg        | Leu        | Phe        | Glu        | Asn        | Thr        | Lys        | Ser        | 109 |
| IFNFH15  | 331 | GAG        | GAG        | ACA        | AAT        | GGA        | AAA        | AGA        | ATA        | AAA        | TGC        | 360 |
| pIFNFH15 | 110 | Glu        | Glu        | Thr        | Asn        | Gly        | Lys        | Arg        | Ile        | Lys        | Cys        | 119 |
| IFNFH15  | 361 | AAT        | GAA        | GCA        | CAC        | CTA        | CAA        | GAA        | CTA        | GAA        | AAT        | 390 |
| pIFNFH15 | 120 | Asn        | Glu        | Ala        | His        | Leu        | Gln        | Glu        | Leu        | Glu        | Asn        | 129 |
| IFNFH15  | 391 | AGC        | TTC        | AAA        | ATG        | GGA        | AAT        | CTA        | AAA        | GTT        | ATT        | 420 |
| pIFNFH15 | 130 | Ser        | Phe        | Lys        | Met        | Gly        | Asn        | Leu        | Lys        | Val        | Ile        | 139 |
| IFNFH15  | 421 | GGC        | CTT        | AAA        | TAG        |            |            |            |            |            |            | 432 |
| pIFNFH15 | 140 | Gly        | Leu        | Lys        | stop       |            |            |            |            |            |            | 142 |

11/22

Figure 11

|          |     |            |            |            |            |            |            |            |            |            |            |     |
|----------|-----|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|-----|
| IFNFH20  | 1   | AAC        | ATG        | CCC        | TTA        | CCA        | AAT        | GAG        | CTA        | AAT        | AAG        | 30  |
| pIFNFH20 | 1   |            | <u>Met</u> | <u>Pro</u> | <u>Leu</u> | <u>Pro</u> | <u>Asn</u> | <u>Glu</u> | <u>Leu</u> | <u>Asn</u> | <u>Lys</u> | 9   |
| IFNFH20  | 31  | GCG        | CCA        | GGG        | ACC        | AAT        | CCT        | GGA        | GAA        | ACA        | GAG        | 60  |
| pIFNFH20 | 10  | Ala        | <u>Pro</u> | <u>Gly</u> | <u>Thr</u> | <u>Asn</u> | <u>Pro</u> | <u>Gly</u> | <u>Glu</u> | <u>Thr</u> | <u>Glu</u> | 19  |
| IFNFH20  | 61  | ACA        | TGT        | GAC        | CTT        | TCA        | GAC        | AGA        | GAA        | TTC        | AAA        | 90  |
| pIFNFH20 | 20  | Thr        | <u>Cys</u> | <u>Asp</u> | <u>Leu</u> | <u>Ser</u> | <u>Asp</u> | <u>Arg</u> | <u>Glu</u> | <u>Phe</u> | <u>Lys</u> | 29  |
| IFNFH20  | 91  | ATA        | GCT        | GTG        | TTG        | AGA        | AAA        | CTC        | AAA        | GAA        | ATT        | 120 |
| pIFNFH20 | 30  | <u>Ile</u> | Ala        | <u>Val</u> | <u>Leu</u> | Arg        | Lys        | <u>Leu</u> | <u>Lys</u> | <u>Glu</u> | <u>Ile</u> | 39  |
| IFNFH20  | 121 | CAA        | GAG        | AAT        | ACA        | GAC        | AAG        | GAA        | TTG        | AGA        | ATT        | 150 |
| pIFNFH20 | 40  | <u>Gln</u> | <u>Glu</u> | <u>Asn</u> | <u>Thr</u> | Asp        | <u>Lys</u> | <u>Glu</u> | Leu        | <u>Arg</u> | <u>Ile</u> | 49  |
| IFNFH20  | 151 | CTA        | TCA        | GAT        | AAA        | TTT        | AAC        | AAA        | GAA        | ATC        | AAA        | 180 |
| pIFNFH20 | 50  | <u>Leu</u> | <u>Ser</u> | <u>Asp</u> | <u>Lys</u> | Phe        | Asn        | <u>Lys</u> | <u>Glu</u> | <u>Ile</u> | Lys        | 59  |
| IFNFH20  | 181 | ATA        | ATG        | AAA        | AAG        | AAT        | CAA        | GCA        | GAA        | ATT        | CTG        | 210 |
| pIFNFH20 | 60  | <u>Ile</u> | Met        | <u>Lys</u> | <u>Lys</u> | <u>Asn</u> | <u>Gln</u> | <u>Ala</u> | <u>Glu</u> | <u>Ile</u> | <u>Leu</u> | 69  |
| IFNFH20  | 211 | AAG        | CTG        | AAA        | AAT        | TCA        | ATT        | AGT        | ATA        | ATG        | AAG        | 240 |
| pIFNFH20 | 70  | Lys        | <u>Leu</u> | <u>Lys</u> | <u>Asn</u> | Ser        | Ile        | Ser        | Ile        | Met        | Lys        | 79  |
| IFNFH20  | 241 | AAT        | GCA        | TCA        | TAG        |            |            |            |            |            |            | 252 |
| pIFNFH20 | 80  | Asn        | Ala        | Ser        | stop       |            |            |            |            |            |            | 82  |

12/22

Figure 12

|          |     |            |            |            |            |            |            |            |            |            |            |     |
|----------|-----|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|-----|
| IFNFH23  | 1   | AAC        | ATG        | ACC        | TCA        | CCA        | AAT        | GAA        | CTG        | AAT        | AAG        | 30  |
| pIFNFH23 | 1   | <u>Met</u> | <u>Thr</u> | <u>Ser</u> | <u>Pro</u> | <u>Asn</u> | <u>Glu</u> | <u>Leu</u> | <u>Asn</u> | <u>Lys</u> | 9          |     |
| IFNFH23  | 31  | GCA        | CCA        | GGG        | ACG        | AAT        | TTA        | GGA        | GAA        | ACA        | GAG        | 60  |
| pIFNFH23 | 10  | Ala        | <u>Pro</u> | Gly        | <u>Thr</u> | <u>Asn</u> | Leu        | <u>Gly</u> | <u>Glu</u> | <u>Thr</u> | <u>Glu</u> | 19  |
| IFNFH23  | 61  | ATT        | TGT        | GAC        | CTT        | TCA        | GAC        | AGA        | GAA        | TTC        | AAG        | 90  |
| pIFNFH23 | 20  | <u>Ile</u> | <u>Cys</u> | <u>Asp</u> | <u>Leu</u> | <u>Ser</u> | <u>Asp</u> | <u>Arg</u> | <u>Glu</u> | <u>Phe</u> | <u>Lys</u> | 29  |
| IFNFH23  | 91  | AAA        | GCT        | GTG        | TTG        | CAG        | AAG        | CTC        | AAA        | GAA        | ATT        | 120 |
| PIFNFH23 | 30  | Lys        | Ala        | <u>Val</u> | <u>Leu</u> | Gln        | Lys        | <u>Leu</u> | <u>Lys</u> | <u>Glu</u> | <u>Ile</u> | 39  |
| IFNFH23  | 121 | CAA        | GAT        | AAC        | ACA        | GAG        | AAG        | GAG        | TTC        | AGA        | ATT        | 150 |
| pIFNFH23 | 40  | <u>Gln</u> | <u>Asp</u> | <u>Asn</u> | <u>Thr</u> | <u>Glu</u> | <u>Lys</u> | <u>Glu</u> | Phe        | <u>Arg</u> | <u>Ile</u> | 49  |
| IFNFH23  | 151 | CTA        | TTA        | CAT        | AAA        | TTT        | AAC        | AAA        | GAG        | ATT        | AAA        | 180 |
| pIFNFH23 | 50  | <u>Leu</u> | Leu        | His        | <u>Lys</u> | Phe        | Asn        | <u>Lys</u> | Glu        | <u>Ile</u> | Lys        | 59  |
| IFNFH23  | 181 | ATA        | ATT        | AAA        | AAG        | AAT        | CAA        | GCA        | GAA        | ATT        | CTA        | 210 |
| pIFNFH23 | 60  | <u>Ile</u> | <u>Ile</u> | <u>Lys</u> | Lys        | <u>Asn</u> | <u>Gln</u> | <u>Ala</u> | <u>Glu</u> | <u>Ile</u> | <u>Leu</u> | 69  |
| IFNFH23  | 211 | GAA        | GCA        | AAA        | AAT        | GCA        | ACT        | GAC        | ATA        | CTG        | ATG        | 240 |
| pIFNFH23 | 70  | <u>Glu</u> | Ala        | Lys        | <u>Asn</u> | <u>Ala</u> | Thr        | Asp        | Ile        | <u>Leu</u> | Met        | 79  |
| IFNFH23  | 241 | AAT        | GCA        | TCA        | GAC        | CCT        | ATT        | AAT        | AGC        | ACA        | ATT        | 270 |
| pIFNFH   | 80  | Asn        | Ala        | Ser        | Asp        | Pro        | Ile        | Asn        | Ser        | Thr        | Ile        | 89  |
| IFNFH23  | 271 | GAT        | GAA        | GCA        | GAA        | GAA        | AGA        | ATT        | AGT        | GAG        | CTT        | 300 |
| pIFNFH   | 90  | Asp        | Glu        | Ala        | Glu        | Glu        | Arg        | Ile        | Ser        | Glu        | Leu        | 99  |
| IFNFH23  | 301 | GAA        | GAC        | AGG        | CTA        | TTT        | GAA        | AGT        | ATA        | TAG        |            | 327 |
| pIFNFH23 | 100 | Glu        | Asp        | Arg        | Leu        | Phe        | Glu        | Ser        | Ile        | stop       |            | 107 |

Figure 13

|          |     |            |            |            |            |             |            |            |            |            |            |     |
|----------|-----|------------|------------|------------|------------|-------------|------------|------------|------------|------------|------------|-----|
| IFNFH25  | 1   | AAC        | ATG        | GCC        | TCA        | CCA         | AAC        | AAA        | CTA        | AAT        | AAG        | 30  |
| pIFNFH25 | 1   | <u>Met</u> | <u>Ala</u> | <u>Ser</u> | <u>Pro</u> | <u>Asn</u>  | <u>Lys</u> | <u>Leu</u> | <u>Asn</u> | <u>Lys</u> |            | 9   |
| IFNFH25  | 31  | GCA        | CCA        | GAA        | ACC        | AAT         | CCC        | AAA        | GAG        | ACA        | GAG        | 60  |
| pIFNFH25 | 10  | <u>Ala</u> | <u>Pro</u> | <u>Glu</u> | <u>Thr</u> | <u>Asn</u>  | <u>Pro</u> | <u>Lys</u> | <u>Glu</u> | <u>Thr</u> | <u>Glu</u> | 19  |
| IFNFH25  | 61  | GTA        | TGT        | GAC        | CTT        | TCA         | GAC        | AGA        | GAA        | CTC        | AAA        | 90  |
| pIFNFH25 | 20  | <u>Val</u> | <u>Cys</u> | <u>Asp</u> | <u>Leu</u> | <u>Ser</u>  | <u>Asp</u> | <u>Arg</u> | <u>Glu</u> | <u>Leu</u> | <u>Lys</u> | 29  |
| IFNFH25  | 91  | ATA        | CCT        | GTT        | TTG        | AGG         | AAG        | TTC        | AAT        | GAA        | ATT        | 120 |
| pIFNFH25 | 30  | <u>Ile</u> | <u>Pro</u> | <u>Val</u> | <u>Leu</u> | <u>Arg</u>  | <u>Lys</u> | <u>Phe</u> | <u>Asn</u> | <u>Glu</u> | <u>Ile</u> | 39  |
| IFNFH25  | 121 | CAA        | GAT        | AAC        | ACA        | GAG         | AAG        | GAA        | TTC        | AGA        | ATT        | 150 |
| pIFNFH25 | 40  | <u>Gln</u> | <u>Asp</u> | <u>Asn</u> | <u>Thr</u> | <u>Glu</u>  | <u>Lys</u> | <u>Glu</u> | <u>Phe</u> | <u>Arg</u> | <u>Ile</u> | 49  |
| IFNFH25  | 151 | CTA        | TCA        | GAT        | AAA        | TTT         | AAC        | AAA        | GAG        | ATT        | GAA        | 180 |
| pIFNFH25 | 50  | <u>Leu</u> | <u>Ser</u> | <u>Asp</u> | <u>Lys</u> | <u>Phe</u>  | <u>Asn</u> | <u>Lys</u> | <u>Glu</u> | <u>Ile</u> | <u>Glu</u> | 59  |
| IFNFH25  | 181 | ATA        | ATT        | AAA        | AAG        | AAT         | CAA        | GCG        | GAA        | ATT        | CCG        | 210 |
| pIFNFH25 | 60  | <u>Ile</u> | <u>Ile</u> | <u>Lys</u> | <u>Lys</u> | <u>Asn</u>  | <u>Gln</u> | <u>Ala</u> | <u>Glu</u> | <u>Ile</u> | <u>Pro</u> | 69  |
| IFNFH25  | 211 | GAA        | GTG        | AAA        | AAT        | GCA         | ATT        | AAT        | ACA        | CTG        | AAG        | 240 |
| pIFNFH25 | 70  | <u>Glu</u> | <u>Val</u> | <u>Lys</u> | <u>Asn</u> | <u>Ala</u>  | <u>Ile</u> | <u>Asn</u> | <u>Thr</u> | <u>Leu</u> | <u>Lys</u> | 79  |
| IFNFH25  | 241 | AAT        | TCA        | TCA        | GAG        | TCT         | CTT        | AAT        | AGC        | AGA        | ATT        | 270 |
| pIFNFH25 | 80  | <u>Asn</u> | <u>Ser</u> | <u>Ser</u> | <u>Glu</u> | <u>Ser</u>  | <u>Leu</u> | <u>Asn</u> | <u>Ser</u> | <u>Arg</u> | <u>Ile</u> | 89  |
| IFNFH25  | 271 | GAT        | CAA        | GCA        | GAA        | TAA         |            |            |            |            |            | 285 |
| pIFNFH25 | 90  | <u>Asp</u> | <u>Gln</u> | <u>Ala</u> | <u>Glu</u> | <u>stop</u> |            |            |            |            |            | 93  |

Figure 14

|          |     |            |            |            |            |            |            |            |            |            |            |     |
|----------|-----|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|-----|
| IFNFH27  | 1   | AAC        | ATG        | ACC        | TCG        | CCT        | AAT        | GAA        | CTA        | AAT        | GAA        | 30  |
| pIFNFH27 | 1   |            | <u>Met</u> | <u>Thr</u> | <u>Ser</u> | <u>Pro</u> | <u>Asn</u> | <u>Glu</u> | <u>Leu</u> | <u>Asn</u> | <u>Glu</u> | 9   |
| IFNFH27  | 31  | GCA        | CCA        | GGG        | ACC        | AAT        | CCT        | GCA        | GAG        | ACA        | GAG        | 60  |
| pIFNFH27 | 10  | Ala        | <u>Pro</u> | <u>Gly</u> | <u>Thr</u> | <u>Asn</u> | <u>Pro</u> | Ala        | <u>Glu</u> | <u>Thr</u> | <u>Glu</u> | 19  |
| IFNFH27  | 61  | ATA        | TGT        | AAC        | ATT        | TTA        | GAC        | AGA        | GAA        | TTC        | AAA        | 90  |
| pIFNFH27 | 20  | <u>Ile</u> | <u>Cys</u> | <u>Asn</u> | <u>Ile</u> | <u>Leu</u> | <u>Asp</u> | <u>Arg</u> | <u>Glu</u> | <u>Phe</u> | <u>Lys</u> | 29  |
| IFNFH27  | 91  | ATA        | GCT        | GTT        | TTG        | AGG        | AAA        | CTC        | AAT        | GAA        | ATT        | 120 |
| pIFNFH27 | 30  | <u>Ile</u> | Ala        | <u>Val</u> | <u>Leu</u> | <u>Arg</u> | <u>Lys</u> | <u>Leu</u> | <u>Asn</u> | <u>Glu</u> | <u>Ile</u> | 39  |
| IFNFH27  | 121 | CAA        | GAT        | AAC        | ACA        | GAG        | AAG        | GAA        | TTG        | AAG        | GTT        | 150 |
| pIFNFH27 | 40  | <u>Gln</u> | <u>Asp</u> | <u>Asn</u> | <u>Thr</u> | <u>Glu</u> | <u>Lys</u> | <u>Glu</u> | Leu        | Lys        | Val        | 49  |
| IFNFH27  | 151 | CTC        | TCA        | GAT        | AAA        | ATT        | ATC        | AAA        | GAG        | ATT        | GAA        | 180 |
| pIFNFH27 | 50  | <u>Leu</u> | <u>Ser</u> | <u>Asp</u> | <u>Lys</u> | <u>Ile</u> | <u>Ile</u> | <u>Lys</u> | <u>Glu</u> | <u>Ile</u> | <u>Glu</u> | 59  |
| IFNFH27  | 181 | ATA        | ATT        | AAA        | ATG        | AAT        | CAA        | GCA        | GAA        | ATT        | CTG        | 210 |
| pIFNFH27 | 60  | <u>Ile</u> | <u>Ile</u> | <u>Lys</u> | <u>Met</u> | <u>Asn</u> | <u>Gln</u> | <u>Ala</u> | <u>Glu</u> | <u>Ile</u> | <u>Leu</u> | 69  |
| IFNFH27  | 211 | GAG        | TTG        | AAA        | AAT        | GCA        | ACT        | GAC        | ATA        | CGG        | AAG        | 240 |
| pIFNFH27 | 70  | <u>Glu</u> | <u>Leu</u> | <u>Lys</u> | <u>Asn</u> | <u>Ala</u> | <u>Thr</u> | <u>Asp</u> | <u>Ile</u> | <u>Arg</u> | <u>Lys</u> | 79  |
| IFNFH27  | 241 | AAT        | GCA        | TCG        | GGG        | TCT        | CTT        | AAC        | AAG        | AGA        | CTT        | 270 |
| pIFNFH27 | 80  | Asn        | Ala        | Ser        | <u>Gly</u> | Ser        | Leu        | Asn        | Lys        | Arg        | Leu        | 89  |
| IFNFH27  | 271 | AAT        | CTT        | TCA        | GAA        | GAA        | AGA        | ATT        | AGT        | GAG        | CTC        | 300 |
| pIFNFH27 | 90  | Asn        | Leu        | Ser        | <u>Glu</u> | <u>Glu</u> | <u>Arg</u> | <u>Ile</u> | Ser        | <u>Glu</u> | Leu        | 99  |
| IFNFH27  | 301 | GGA        | GAT        | AGC        | CTA        | TTT        | GAC        | AAT        | ATA        | CAG        | TCA        | 330 |
| pIFNFH27 | 100 | <u>Gly</u> | <u>Asp</u> | <u>Ser</u> | <u>Leu</u> | <u>Phe</u> | <u>Asp</u> | <u>Asn</u> | <u>Ile</u> | <u>Gln</u> | <u>Ser</u> | 109 |
| IFNFH27  | 331 | GAG        | GAA        | GCA        | AAC        | TAA        |            |            |            |            |            | 345 |
| pIFNFH27 | 110 | <u>Glu</u> | <u>Glu</u> | <u>Ala</u> | <u>Asn</u> | stop       |            |            |            |            |            | 113 |

Figure 15

|          |     |            |            |            |            |            |            |            |            |            |            |     |
|----------|-----|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|-----|
| IFNFH31  | 1   | AAT        | ATG        | ACC        | TCA        | CCA        | AAT        | GAA        | CTA        | AAT        | AAG        | 30  |
| pIFNFH31 | 1   |            | <u>Met</u> | <u>Thr</u> | <u>Ser</u> | <u>Pro</u> | <u>Asn</u> | <u>Glu</u> | <u>Leu</u> | <u>Asn</u> | <u>Lys</u> | 9   |
| IFNFH31  | 31  | GTA        | CCA        | GGG        | GCC        | AAT        | CCT        | GGA        | GAA        | ACA        | GAG        | 60  |
| pIFNFH31 | 10  | Val        | <u>Pro</u> | Gly        | Ala        | <u>Asn</u> | <u>Pro</u> | <u>Gly</u> | <u>Glu</u> | <u>Thr</u> | <u>Glu</u> | 19  |
| IFNFH31  | 61  | ATT        | TGT        | GAT        | CAT        | TCA        | GAA        | AGA        | GAA        | TTC        | AAA        | 90  |
| pIFNFH31 | 20  | <u>Ile</u> | <u>Cys</u> | <u>Asp</u> | His        | <u>Ser</u> | Glu        | Arg        | <u>Glu</u> | <u>Phe</u> | <u>Lys</u> | 29  |
| IFNFH31  | 91  | ATA        | ACT        | GTC        | TTG        | AGG        | AAA        | CTC        | AAA        | GAC        | ATT        | 120 |
| pIFNFH31 | 30  | <u>Ile</u> | Thr        | <u>Val</u> | <u>Leu</u> | Arg        | Lys        | <u>Leu</u> | <u>Lys</u> | Asp        | <u>Ile</u> | 39  |
| IFNFH31  | 121 | CAT        | GAT        | AAC        | ACA        | GAG        | AAG        | ACA        | ATC        | AGA        | ATT        | 150 |
| pIFNFH31 | 40  | His        | <u>Asp</u> | <u>Asn</u> | <u>Thr</u> | <u>Glu</u> | <u>Lys</u> | Thr        | Ile        | <u>Arg</u> | <u>Ile</u> | 49  |
| IFNFH31  | 151 | CTA        | TCA        | GAT        | AAA        | TTT        | AAC        | AAA        | GAT        | ATT        | GAA        | 180 |
| pIFNFH31 | 50  | <u>Leu</u> | <u>Ser</u> | <u>Asp</u> | <u>Lys</u> | Phe        | Asn        | <u>Lys</u> | Asp        | <u>Ile</u> | <u>Glu</u> | 59  |
| IFNFH31  | 181 | ATA        | ATT        | TTA        | AAA        | AAT        | CAA        | GAT        | GAT        | ATT        | CTG        | 210 |
| pIFNFH31 | 60  | <u>Ile</u> | <u>Ile</u> | Leu        | Lys        | <u>Asn</u> | <u>Gln</u> | Asp        | Asp        | <u>Ile</u> | <u>Leu</u> | 69  |
| IFNFH31  | 211 | GAG        | CTG        | GAA        | AAT        | GCA        | ATT        | GGT        | GTA        | CTG        | AAG        | 240 |
| pIFNFH31 | 70  | <u>Glu</u> | <u>Leu</u> | Glu        | <u>Asn</u> | <u>Ala</u> | Ile        | <u>Gly</u> | Val        | <u>Leu</u> | Lys        | 79  |
| IFNFH31  | 241 | AAT        | GAA        | TCA        | GGG        | TTC        | TTT        | AAT        | AGC        | AGG        | ATG        | 270 |
| pIFNFH31 | 80  | Asn        | Glu        | Ser        | Gly        | Phe        | Phe        | Asn        | Ser        | Arg        | Met        | 89  |
| IFNFH31  | 271 | GAT        | GAA        | GCA        | GAA        | GAA        | ATA        | ATT        | AGA        | AAG        | CTT        | 300 |
| pIFNFH31 | 90  | Asp        | Glu        | Ala        | Glu        | Glu        | Ile        | Ile        | Arg        | Lys        | Leu        | 99  |
| IFNFH31  | 301 | GAA        | GAC        | AGT        | TTA        | TTT        | GAA        | AAT        | ATA        | CAG        | TCA        | 330 |
| pIFNFH31 | 100 | Glu        | Asp        | Ser        | Leu        | Phe        | Glu        | Asn        | Ile        | Gln        | Ser        | 109 |
| IFNFH31  | 331 | GAG        | AAG        | AAA        | GCG        | AAA        | AAA        | GTA        | AAA        | CAA        | ACA        | 360 |
| pIFNFH31 | 110 | Glu        | Lys        | Lys        | Ala        | Lys        | Lys        | Val        | Lys        | Gln        | Thr        | 119 |
| IFNFH31  | 361 | AAC        | AAA        | AAA        | AGA        | AGC        | ATG        | TAT        | TAG        |            |            | 384 |
| pIFNFH31 | 120 | Asn        | Lys        | Lys        | Arg        | Ser        | Met        | Tyr        | stop       |            |            | 126 |



Figure 16

|          |     |            |            |            |            |            |            |            |            |            |            |     |
|----------|-----|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|-----|
| IFNFH32  | 1   | AAC        | ATG        | ACC        | TCA        | CCA        | AAT        | AAA        | CTT        | AAA        | AAG        | 30  |
| pIFNFH32 | 1   |            | <u>Met</u> | <u>Thr</u> | <u>Ser</u> | <u>Pro</u> | <u>Asn</u> | <u>Lys</u> | <u>Leu</u> | <u>Lys</u> | <u>Lys</u> | 9   |
| IFNFH32  | 31  | GCA        | CCA        | GGG        | ACC        | AAT        | CCT        | GGA        | GAA        | ACA        | GAA        | 60  |
| pIFNFH32 | 10  | Ala        | <u>Pro</u> | <u>Gly</u> | <u>Thr</u> | <u>Asn</u> | <u>Pro</u> | <u>Gly</u> | <u>Glu</u> | <u>Thr</u> | <u>Glu</u> | 19  |
| IFNFH32  | 61  | ACA        | TGT        | GGA        | CTT        | TCA        | CAG        | AGA        | GAA        | TTC        | AAA        | 90  |
| pIFNFH32 | 20  | Thr        | <u>Cys</u> | <u>Gly</u> | <u>Leu</u> | <u>Ser</u> | <u>Gln</u> | <u>Arg</u> | <u>Glu</u> | <u>Phe</u> | <u>Lys</u> | 29  |
| IFNFH32  | 91  | GTA        | GCT        | GTG        | TTG        | AGG        | AAA        | CTC        | AAA        | GAA        | ATT        | 120 |
| pIFNFH32 | 30  | Val        | Ala        | <u>Val</u> | <u>Leu</u> | <u>Arg</u> | <u>Lys</u> | <u>Leu</u> | <u>Lys</u> | <u>Glu</u> | <u>Ile</u> | 39  |
| IFNFH32  | 121 | CAA        | GAT        | AAC        | AGA        | GAG        | AAG        | GAA        | TTC        | AGA        | ATT        | 150 |
| pIFNFH32 | 40  | <u>Gln</u> | <u>Asp</u> | <u>Asn</u> | <u>Arg</u> | <u>Glu</u> | <u>Lys</u> | <u>Glu</u> | <u>Phe</u> | <u>Arg</u> | <u>Ile</u> | 49  |
| IFNFH32  | 151 | GTA        | TCA        | GAT        | AAA        | TTT        | AAC        | AAA        | GAG        | ATT        | GAA        | 180 |
| pIFNFH32 | 50  | Val        | <u>Ser</u> | <u>Asp</u> | <u>Lys</u> | <u>Phe</u> | <u>Asn</u> | <u>Lys</u> | <u>Glu</u> | <u>Ile</u> | <u>Glu</u> | 59  |
| IFNFH32  | 181 | ATA        | ATT        | AAA        | AAG        | AAT        | CAG        | GCA        | GAA        | ATA        | CTG        | 210 |
| pIFNFH32 | 60  | <u>Ile</u> | <u>Ile</u> | <u>Lys</u> | <u>Lys</u> | <u>Asn</u> | <u>Gln</u> | <u>Ala</u> | <u>Glu</u> | <u>Ile</u> | <u>Leu</u> | 69  |
| IFNFH32  | 211 | GAG        | CTG        | AAA        | AAT        | CAA        | CTG        | GCA        | TAC        | TGA        |            | 237 |
| pIFNFH32 | 70  | <u>Glu</u> | <u>Leu</u> | <u>Lys</u> | <u>Asn</u> | <u>Gln</u> | <u>Leu</u> | <u>Ala</u> | <u>Tyr</u> | stop       |            | 77  |

Figure 17

|          |     |            |            |            |            |            |            |            |            |            |            |     |
|----------|-----|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|-----|
| IFNFH36  | 1   | AAC        | ATG        | ACC        | TCA        | CCA        | AAC        | AAA        | CTA        | AAT        | AAG        | 30  |
| pIFNFH36 | 1   |            | <u>Met</u> | <u>Thr</u> | <u>Ser</u> | <u>Pro</u> | <u>Asn</u> | <u>Lys</u> | <u>Leu</u> | <u>Asn</u> | <u>Lys</u> | 9   |
| IFNFH36  | 31  | GCA        | CCC        | AGG        | GCC        | AAT        | TCT        | GGA        | GAA        | ACA        | GAG        | 60  |
| pIFNFH36 | 10  | Ala        | <u>Pro</u> | Arg        | Ala        | <u>Asn</u> | Ser        | <u>Gly</u> | <u>Glu</u> | <u>Thr</u> | <u>Glu</u> | 19  |
| IFNFH36  | 61  | ATA        | CGT        | AAA        | CTT        | TCA        | AAC        | ACA        | GAA        | ATC        | AAG        | 90  |
| pIFNFH36 | 20  | <u>Ile</u> | Arg        | Lys        | <u>Leu</u> | <u>Ser</u> | Asn        | <u>Thr</u> | <u>Glu</u> | Ile        | <u>Lys</u> | 29  |
| IFNFH36  | 91  | ATA        | GCT        | GTG        | TTG        | AGA        | AAA        | CTC        | AAA        | GAA        | ATT        | 120 |
| pIFNFH36 | 30  | <u>Ile</u> | Ala        | <u>Val</u> | <u>Leu</u> | Arg        | Lys        | <u>Leu</u> | <u>Lys</u> | <u>Glu</u> | <u>Ile</u> | 39  |
| IFNFH36  | 121 | CAA        | GAT        | AAC        | ACA        | GAG        | AAA        | GAA        | TTC        | AGA        | ATT        | 150 |
| pIFNFH36 | 40  | <u>Gln</u> | <u>Asp</u> | <u>Asn</u> | <u>Thr</u> | <u>Glu</u> | <u>Lys</u> | <u>Glu</u> | Phe        | <u>Arg</u> | <u>Ile</u> | 49  |
| IFNFH36  | 151 | CTA        | TCA        | GAT        | AAA        | TTT        | AAC        | AAA        | GAG        | ATT        | GAA        | 180 |
| pIFNFH36 | 50  | <u>Leu</u> | <u>Ser</u> | <u>Asp</u> | <u>Lys</u> | Phe        | Asn        | <u>Lys</u> | Glu        | <u>Ile</u> | <u>Glu</u> | 59  |
| IFNFH36  | 181 | ATA        | ACT        | AAA        | AAG        | AAT        | CAA        | GCA        | GAA        | ATT        | CTG        | 210 |
| pIFNFH36 | 60  | <u>Ile</u> | Thr        | <u>Lys</u> | Lys        | <u>Asn</u> | <u>Gln</u> | <u>Ala</u> | <u>Glu</u> | <u>Ile</u> | <u>Leu</u> | 69  |
| IFNFH36  | 211 | GAG        | CTG        | AGA        | AAT        | GCA        | ATT        | GAC        | ATA        | CTG        | AAG        | 240 |
| pIFNFH36 | 70  | <u>Glu</u> | <u>Leu</u> | <u>Arg</u> | <u>Asn</u> | <u>Ala</u> | Ile        | Asp        | Ile        | <u>Leu</u> | Lys        | 79  |
| IFNFH36  | 241 | AAT        | GCA        | TCA        | GGG        | TCT        | TTT        | AAT        | AGC        | AGA        | ATT        | 270 |
| pIFNFH36 | 80  | Asn        | Ala        | Ser        | Gly        | Ser        | Phe        | Asn        | Ser        | Arg        | Ile        | 89  |
| IFNFH36  | 271 | GAG        | CAA        | GCA        | GAA        | TAA        |            |            |            |            |            | 285 |
| pIFNFH36 | 90  | Glu        | Gln        | Ala        | Glu        | stop       |            |            |            |            |            | 93  |

Figure 18

|          |     |            |            |            |            |            |            |            |            |            |            |     |
|----------|-----|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|-----|
| IFNFH37  | 1   | AAC        | ATG        | ACC        | TCA        | CTA        | AAT        | GAA        | CTA        | AAT        | AAG        | 30  |
| pIFNFH37 | 1   |            | <u>Met</u> | <u>Thr</u> | <u>Ser</u> | Leu        | <u>Asn</u> | <u>Glu</u> | <u>Leu</u> | <u>Asn</u> | <u>Lys</u> | 9   |
| IFNFH37  | 31  | GCA        | CCA        | GGG        | GCC        | AAC        | CCT        | GGA        | GAA        | ACA        | GAG        | 60  |
| pIFNFH37 | 10  | Ala        | <u>Pro</u> | Gly        | Ala        | <u>Asn</u> | <u>Pro</u> | <u>Gly</u> | <u>Glu</u> | <u>Thr</u> | <u>Glu</u> | 19  |
| IFNFH37  | 61  | ATA        | TGC        | GAC        | CTT        | TCA        | GAC        | AGA        | GAA        | TTC        | AAA        | 90  |
| pIFNFH37 | 20  | <u>Ile</u> | <u>Cys</u> | <u>Asp</u> | <u>Leu</u> | <u>Ser</u> | <u>Asp</u> | Arg        | <u>Glu</u> | <u>Phe</u> | <u>Lys</u> | 29  |
| IFNFH37  | 91  | ATA        | GCT        | GTG        | TTG        | GGG        | AAA        | TTC        | AAA        | GAT        | AAC        | 120 |
| pIFNFH37 | 30  | <u>Ile</u> | Ala        | <u>Val</u> | <u>Leu</u> | Gly        | <u>Lys</u> | Phe        | Lys        | <u>Asp</u> | <u>Asn</u> | 39  |
| IFNFH37  | 121 | ACA        | GAG        | AAG        | GAA        | TTC        | AGA        | ATT        | CTA        | TCA        | GAT        | 150 |
| pIFNFH37 | 40  | <u>Thr</u> | <u>Glu</u> | <u>Lys</u> | <u>Glu</u> | Phe        | <u>Arg</u> | <u>Ile</u> | <u>Leu</u> | <u>Ser</u> | <u>Asp</u> | 49  |
| IFNFH37  | 151 | AAA        | TTT        | AAC        | AAA        | GAG        | ATT        | GAA        | ATA        | ATT        | AAA        | 180 |
| pIFNFH37 | 50  | <u>Lys</u> | Phe        | Asn        | <u>Lys</u> | Glu        | <u>Ile</u> | <u>Glu</u> | <u>Ile</u> | <u>Ile</u> | <u>Lys</u> | 59  |
| IFNFH37  | 181 | AAG        | AAT        | CAA        | GCA        | GAA        | ATT        | CTG        | GAG        | CTG        | AAA        | 210 |
| pIFNFH37 | 60  | Lys        | <u>Asn</u> | <u>Gln</u> | <u>Ala</u> | <u>Glu</u> | <u>Ile</u> | <u>Leu</u> | <u>Glu</u> | <u>Leu</u> | Lys        | 69  |
| IFNFH37  | 211 | AAT        | GCA        | ATT        | GCC        | ACA        | TTA        | AAG        | AAT        | GCA        | TTA        | 240 |
| pIFNFH37 | 70  | <u>Asn</u> | <u>Ala</u> | Ile        | Ala        | <u>Thr</u> | <u>Leu</u> | Lys        | Asn        | Ala        | Leu        | 79  |
| IFNFH37  | 241 | GAG        | TTT        | TTT        | AAT        | AGC        | AGA        | ATT        | TAT        | GGA        | GCA        | 270 |
| pIFNFH37 | 80  | Glu        | Phe        | Phe        | Asn        | Ser        | Arg        | Ile        | Tyr        | Gly        | Ala        | 89  |
| IFNFH37  | 271 | GAA        | AAA        | AAG        | AAT        | TAG        |            |            |            |            |            | 285 |
| pIFNFH37 | 90  | Glu        | Lys        | Lys        | Asn        | stop       |            |            |            |            |            | 93  |

Figure 19

|          |     |            |            |            |            |            |            |            |            |            |            |     |
|----------|-----|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|-----|
| IFNFH39  | 1   | TCA        | ATG        | GCC        | AGA        | CAC        | CTA        | CAA        | ACA        | TCC        | ACT        | 30  |
| pIFNFH39 | 1   | Met        | Ala        | Arg        | His        | Leu        | Gln        | Thr        | Ser        | Thr        |            | 9   |
| IFNFH39  | 31  | AGC        | ATC        | AAG        | ACC        | ATC        | CAG        | GAA        | AAT        | AGG        | ACC        | 60  |
| pIFNFH39 | 10  | Ser        | Ile        | Lys        | Thr        | Ile        | Gln        | Glu        | Asn        | Arg        | Thr        | 19  |
| IFNFH39  | 61  | TCA        | CCA        | AGT        | GAA        | CTA        | AAT        | AAG        | GCA        | CCA        | GGG        | 90  |
| pIFNFH39 | 20  | <u>Ser</u> | <u>Pro</u> | <u>Ser</u> | <u>Glu</u> | <u>Leu</u> | <u>Asn</u> | <u>Lys</u> | <u>Ala</u> | <u>Pro</u> | <u>Gly</u> | 29  |
| IFNFH39  | 91  | GCC        | AGT        | CTT        | GGA        | GAA        | ACA        | GAG        | ATA        | TGT        | GAT        | 120 |
| pIFNFH39 | 30  | Ala        | Ser        | Leu        | <u>Gly</u> | <u>Glu</u> | <u>Thr</u> | <u>Glu</u> | <u>Ile</u> | <u>Cys</u> | <u>Asp</u> | 39  |
| IFNFH39  | 121 | CTT        | TCA        | AAC        | AGA        | GAA        | TTG        | AAA        | ATA        | GCT        | GTT        | 150 |
| pIFNFH39 | 40  | <u>Leu</u> | <u>Ser</u> | Asn        | Arg        | <u>Glu</u> | Leu        | <u>Lys</u> | <u>Ile</u> | <u>Ala</u> | <u>Val</u> | 49  |
| IFNFH39  | 151 | TTG        | AGG        | AAA        | CTC        | AAA        | GAA        | ATT        | CAA        | GAT        | AGC        | 180 |
| pIFNFH39 | 50  | <u>Leu</u> | Arg        | Lys        | <u>Leu</u> | <u>Lys</u> | <u>Glu</u> | <u>Ile</u> | <u>Gln</u> | <u>Asp</u> | Ser        | 59  |
| IFNFH39  | 181 | ACA        | GAG        | AAG        | GAA        | TTC        | AGA        | ATC        | CTA        | TCA        | GAT        | 210 |
| pIFNFH39 | 60  | <u>Thr</u> | <u>Glu</u> | <u>Lys</u> | <u>Glu</u> | Phe        | <u>Arg</u> | <u>Ile</u> | <u>Leu</u> | <u>Ser</u> | <u>Asp</u> | 69  |
| IFNFH39  | 211 | AAA        | TTT        | AAC        | AAA        | CAA        | ATT        | GAA        | ATA        | ATT        | AAA        | 240 |
| pIFNFH39 | 70  | <u>Lys</u> | Phe        | Asn        | <u>Lys</u> | <u>Gln</u> | <u>Ile</u> | <u>Glu</u> | <u>Ile</u> | <u>Ile</u> | <u>Lys</u> | 79  |
| IFNFH39  | 241 | AAC        | AGT        | CAA        | GCA        | GAA        | ATT        | CTG        | GAG        | CTG        | AAA        | 270 |
| pIFNFH39 | 80  | Asn        | Ser        | <u>Gln</u> | <u>Ala</u> | <u>Glu</u> | <u>Ile</u> | <u>Leu</u> | <u>Glu</u> | <u>Leu</u> | Lys        | 89  |
| IFNFH39  | 271 | AAT        | GCA        | ATT        | GAC        | TTA        | CTG        | AAG        | AAT        | GCA        | TCA        | 300 |
| pIFNFH39 | 90  | <u>Asn</u> | <u>Ala</u> | Ile        | Asp        | Leu        | <u>Leu</u> | Lys        | Asn        | Ala        | Ser        | 99  |
| IFNFH39  | 301 | GAA        | TCT        | CCT        | AAT        | AGT        | AGA        | ATT        | AAT        | CAA        | GTA        | 330 |
| pIFNFH39 | 100 | <u>Glu</u> | <u>Ser</u> | Pro        | Asn        | Ser        | Arg        | Ile        | Asn        | Gln        | Val        | 109 |
| IFNFH39  | 331 | GAA        | GAA        | TGA        |            |            |            |            |            |            |            | 339 |
| pIFNFH39 | 110 | Glu        | Glu        | stop       |            |            |            |            |            |            |            | 111 |

Figure 20

|          |     |            |            |            |            |            |            |            |            |            |            |     |
|----------|-----|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|-----|
| IFNFH42  | 1   | TCA        | ATG        | CCA        | AGA        | CAC        | CAA        | AGA        | ACA        | CCT        | ACT        | 30  |
| pIFNFH42 | 1   |            | Met        | Pro        | Arg        | His        | Gln        | Arg        | Thr        | Pro        | Thr        | 9   |
| IFNFH42  | 31  | AGA        | ATC        | AAC        | ACC        | ATC        | CAG        | GAA        | AAC        | ACG        | ACC        | 60  |
| pIFNFH42 | 10  | Arg        | Ile        | Asn        | Thr        | Ile        | Gln        | Glu        | Asn        | Thr        | <u>Thr</u> | 19  |
| IFNFH42  | 61  | TCA        | TCA        | AAT        | GAG        | CTA        | AAT        | GAG        | GCA        | CCA        | GGG        | 90  |
| pIFNFH42 | 20  | <u>Ser</u> | Ser        | <u>Asn</u> | <u>Glu</u> | <u>Leu</u> | <u>Asn</u> | Glu        | Ala        | <u>Pro</u> | Gly        | 29  |
| IFNFH42  | 91  | ATC        | ACT        | CCT        | GGA        | GAA        | ACA        | GAG        | ATA        | TGT        | GAC        | 120 |
| pIFNFH42 | 30  | Ile        | Thr        | <u>Pro</u> | <u>Gly</u> | <u>Glu</u> | <u>Thr</u> | <u>Glu</u> | <u>Ile</u> | <u>Cys</u> | <u>Asp</u> | 39  |
| IFNFH42  | 121 | CTT        | TCA        | GAC        | AGA        | GAA        | TTC        | AAA        | GTA        | GCT        | GTG        | 150 |
| pIFNFH42 | 40  | <u>Leu</u> | <u>Ser</u> | <u>Asp</u> | Arg        | <u>Glu</u> | <u>Phe</u> | <u>Lys</u> | Val        | Ala        | <u>Val</u> | 49  |
| IFNFH42  | 151 | TTG        | AGA        | GAG        | CTC        | AAA        | GAA        | ATT        | CAA        | GAT        | AAC        | 180 |
| pIFNFH42 | 50  | <u>Leu</u> | Arg        | Glu        | <u>Leu</u> | <u>Lys</u> | <u>Glu</u> | <u>Ile</u> | <u>Gln</u> | <u>Asp</u> | <u>Asn</u> | 59  |
| IFNFH42  | 181 | ACA        | GAG        | AAG        | AAA        | TTC        | AGA        | ATT        | CTA        | CCA        | GAT        | 210 |
| pIFNFH42 | 60  | <u>Thr</u> | <u>Glu</u> | <u>Lys</u> | Lys        | Phe        | <u>Arg</u> | <u>Ile</u> | <u>Leu</u> | Pro        | <u>Asp</u> | 69  |
| IFNFH42  | 211 | AAA        | TTT        | ATC        | AAA        | GAG        | ATT        | GAA        | ATA        | ATT        | AAA        | 240 |
| pIFNFH42 | 70  | <u>Lys</u> | Phe        | Ile        | <u>Lys</u> | Glu        | <u>Ile</u> | <u>Glu</u> | <u>Ile</u> | <u>Ile</u> | <u>Lys</u> | 79  |
| IFNFH42  | 241 | AAG        | AAT        | CAA        | TCA        | GAA        | ATT        | CTG        | GAG        | CTG        | AAA        | 270 |
| pIFNFH42 | 80  | Lys        | <u>Asn</u> | <u>Gln</u> | Ser        | <u>Glu</u> | <u>Ile</u> | <u>Leu</u> | <u>Glu</u> | <u>Leu</u> | Lys        | 89  |
| IFNFH42  | 271 | AAC        | CCA        | ACT        | GCT        | GTA        | CTG        | AAG        | AAT        | GCA        | TCA        | 300 |
| pIFNFH42 | 90  | <u>Asn</u> | Pro        | Thr        | Ala        | Val        | <u>Leu</u> | Lys        | Asn        | Ala        | Ser        | 99  |
| IFNFH42  | 301 | GAG        | TCC        | CTT        | AAT        | AGC        | AGA        | ATG        | GAT        | CGA        | GTA        | 330 |
| pIFNFH42 | 100 | Glu        | Ser        | Leu        | Asn        | Ser        | Arg        | Met        | Asp        | Arg        | Val        | 109 |
| IFNFH42  | 331 | GAA        | AAG        | AAG        | AAT        | TAG        |            |            |            |            |            | 345 |
| pIFNFH42 | 110 | Glu        | Lys        | Lys        | Asn        | stop       |            |            |            |            |            | 113 |

### Figure 21

INSP037

pIFNFH04  
pIFNFH08  
pIFNFH32  
pIFNFH20  
pIFNFH12  
pIFNFH25  
pIFNFH36  
pIFNFH37  
pIFNFH39  
pIFNFH42  
pIFNFH23  
pIFNFH27  
pIFNFH14  
pIFNFH01  
pIFNFH10  
pIFNFH11  
pIFNFH13  
pIFNFH31  
pIFNFH03  
pIFNFH15

MTSPNELNKLKLPWTNPGETEICDLSDETFKISVLKN ---- LKEI  
 MTSPNELNKAPGTNPGETEMYDLSDREFKTAI LRK ---- LKEI  
 MTSPNELSKAPGTNQGETEIDYDLSDTEFKIAVLRNSKKK LKEI  
 MTSPNKLKKA PGTNPGETETCGLSQREFKVAVL RK ---- LKEI  
 MPLPNELNKAPGTNPGETETCDLSDREFKIAVL RK ---- LKEI  
 MTSPNELNKPFGTNPGETEICDLSDEKFIAVLK K ---- LNEA  
 MASPNKLKKAPE TNPKETEVCDSLSDRELKIPVLRK ---- FNEI  
 MTSPNKLNKAPRANSGETEIRKLSNTEIKIAVL RK ---- LKEI  
 MTSLNELNKAPGANPGETEICDLSDEFKIAVLGKF ----  
 MARHLQTSTSIKTIQENR TSPSELNKAPGASLGETEICDLSNRELKIAVL RK ---- LKEI  
 MPRHQRTPTPRINTIQENT TSSNELNEAPGITGETEICDLSDEFFKVAVLRE ---- LKEI  
 MTSPNELNKAPGTNLGETEICDLSDEFFKKA VLOK ---- LKEI  
 MTSPNELNEAPGTNPAETEICNILDREFKIAVL RK ---- LNEI  
 MTSTKELNKAPVNNPGETELCDLLDKKFKIAVL RK ---- LKGI  
 MTSPNKLNKLPGTNPGETEICDL LDREFKIAVL RK ---- LKKY  
 MTSPNEVNKVPMTNPGETEICDLSDEQKLKIAVMRK ---- LKEI  
 MTSGNEVNKA PGTNLGETEICDLSDELRITVLRK ---- LNEI  
 MTSPNELNKAPGTNPGETEICDLSDEKFKRAVLK K ---- LKEI  
 MTSPNELNKPVGANPGETEICDHSEREFKITVLRK ---- LKDI  
 MTSPNELNEAGTTPKETEICDISDREFKIALKK ---- LKEI  
 MTSPNELNKAPGINPGETEICDLSDEFTIAVSRK ---- LNKI

INSP037


pIFNFH04  
pIFNFH08  
pIFNFH32  
pIFNFH20  
pIFNFH12  
pIFNFH25  
pIFNFH36  
pIFNFH37  
pIFNFH39  
pIFNFH42  
pIFNFH23  
pIFNFH27  
pIFNFH14  
pIFNFH01  
pIFNFH10  
pIFNFH11  
pIFNFH13  
pIFNFH31  
pIFNFH03  
pIFNFH15

QDNTEKESRILSDKYKKQIEIIEIKGNQAEIIELRNADGTL  
QDNTKKEFRILSDKFNKQIEIIEIKKNQAEIIELEKNVIDIIEKNASVS  
QDNTEKEFRILSDKFNKQIEIIEIKKNQAEIIELEKNAIDMINNASDYLHSRINRN  
QDNREKEFRIVSDKFNKQIEIIEIKKNQAEIIELEKNQLAY  
QENTDKELRILSDKFNKQIEIKMKKNQAEIIELEKLNKSNISIMKNAS  
QDSTEKEFRILSDKCNKDIKIEIKKNQAEIIELEKNAIDGILKDAEFFNSRDT  
QDNTEKEFRILSDKFNKQIEIIEIKKNQAEIIEPEVKNAINTEKLNSSSLNSRIDQAE  
QDNTEKEFRILSDKFNKQIEIIEIKKNQAEIIELELRNADIDIEKNASGSFNSRIEQAE  
KDNTEKEFRILSDKFNKQIEIIEIKKNQAEIIELEKNAIATIEKNALEFFNSRIYGAEKKN  
QDSTEKEFRILSDKFNKQIEIIEIKKNQAEIIELEKNAIDIEKNASESPNSRINQVEE  
QDNTEKFRILPDKFKIEIEIIEIKKNQAEIIELEKNPTAVIEKNASESPNSRMDRVEKKN  
QDNTEKEFRILHKKFNKQIEIIEIKKNQAEIIELEKNAIDIEKNASDPINSTIDEAERISEL  
QDNTEKELEKVLSDKIEIIEIIEIKKNQAEIIELEKNAIDIRKNASQSLNKLNDSEERISEL  
QNNTEKEFRILSDKFNKQIEIIEIKKNQAEIIELEKNVGTIEKNASQSFKSRMDIAERISEL  
QDDTEKKFRILSDKFNKQIEIIEIKKNQAEIIELEKNLTGIEKNVPGSFNSRIDGAKGRISKP  
QDNTEKEFKILSRKFNKKIIEIENQAEIIELEKNAIGIEKNASESFNSNMYQAEDRISEL  
KDNTEMEFRILSDKFKKQIEIIEIKKNQAEIIELEKNAIGIEKNASEFLNRRTDQAAEKSSP  
QNVSKKEFRILLDKFNQRQIEVIKKNQTEIMELKNAIGIEKNHQSSLIAALIKKQKLELVNL  
HDNTEKTRILSDKFNKQIEIIEIKKNQADILEENAGVIEKNSSGFFNSRMDQAEIIEIRKL  
QDNTEKELELRILSDKFNKQIEIIEIKKNQAEIIELEKNAGGIEKNQSWGLGSMVAHACNPSTLGS  
QDNMEKEFRILSDKFNEEIEIIEIKKNQAEIIELEKNAIDIEKNASENLTSRTDQAREIISKL

PIFNFH23  
PIFNFH27  
PIFNFH14  
PIFNFH01  
PIFNFH10  
PIFNFH11  
PIFNFH13  
PIFNFH31  
PIFNFH03  
PIFNFH15

EDRLFESI  
GDSLFDNIQSEAN  
KDRLFENTVRREKRI  
EDRLFENTQRRQKKRNKKK  
KYRLFENTQSEETKNNKKQ  
EDRLFENTQRSQKKNNKKQ  
KTAYLKIERGDKRKKYKRMKHT  
EDSLFENIQSEKKAKKVQTNKKRSMY  
RGGWITSSGVQDQPGQGSSETSSLLKIQKLAG CSGRHL  
DRLFENTKSEETNGKRIKCNHAHLQELENSFKMGNLKVIGLK

Figure 22



800.ST25.txt  
SEQUENCE LISTING

<110> Applied Research Systems ARS holding N.V.  
<120> Novel IFNgamma-like ORFs  
<130> 0800Z  
<160> 155  
<170> PatentIn version 3.0  
<210> 1  
<211> 360  
<212> DNA  
<213> Homo sapiens

<400> 1  
aacatgacct caccaaataa actaaataag ctaccagggg ccaaccctgg agaaacagaa  
60

atatgtgacc ttttagatag agaattcaaa atagctgtgt tgaggaaact caaaaaatat 1  
20

caagatgata cagagaagaa gttcagaatt ctatcagata aatttaacaa agagattgaa 1  
80

atattaaaaa ataatcaagc agaaattctg gagctgaaaa atttgactgg aatactgaag 2  
40

aatgtgccag ggtcttttaa tagcagaatt gatggagcaa aaggaagaat tagtaagcct 3  
00

gaagacaggt tatttgaaaa tacacagagg agacaaaaga aaaggaataa aaaaaaatga 3  
60

<210> 2  
<211> 118  
<212> PRT  
<213> Homo sapiens

<400> 2

Met Thr Ser Pro Asn Lys Leu Asn Lys Leu Pro Gly Thr Asn Pro Gly  
1 5 10 15

Glu Thr Glu Ile Cys Asp Leu Leu Asp Arg Glu Phe Lys Ile Ala Val



## 800.ST25.txt

20

25

30

Leu Arg Lys Leu Lys Lys Tyr Gln Asp Asp Thr Glu Lys Lys Phe Arg  
35 40 45

Ile Leu Ser Asp Lys Phe Asn Lys Glu Ile Glu Ile Leu Lys Asn Asn  
50 55 60

Gln Ala Glu Ile Leu Glu Leu Lys Asn Leu Thr Gly Ile Leu Lys Asn  
65 70 75 80

Val Pro Gly Ser Phe Asn Ser Arg Ile Asp Gly Ala Lys Gly Arg Ile  
85 90 95

Ser Lys Pro Glu Asp Arg Leu Phe Glu Asn Thr Gln Arg Arg Gln Lys  
100 105 110

Lys Arg Asn Lys Lys Lys  
115

&lt;210&gt; 3

&lt;211&gt; 414

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 3

aacatgacat caccaaata gttaaatgag gcagcaggaa ctactcccaa agaaacagag  
60

atatgtgaca tttcagacag agaattcaaa atagctttgt tgaagaaact caaagaaatt 1  
20

caagataata cggagaagga actcagaatt ctatcagata aatttaacaa ggagattgaa 1  
80

atgattaataa agaaccaagc agaaattctg gagctaaaaa atgcaggtgg catattgaaa 2  
40

atgcatcaga gttggctggg catggtggct cagcctgta atcccagtac tttgggaagc 3  
00

cgaggtgggt ggatcacgag ttcaggagtt caagaccagc ctggccaagg cagtgaacc 3  
60

tcatctctac taaaaatata aaaattagct ggggtgcagtg gcaggcacct gtaa 4  
14

800.ST25.txt

<210> 4  
 <211> 136  
 <212> PRT  
 <213> Homo sapiens

<400> 4

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Thr | Ser | Pro | Asn | Glu | Leu | Asn | Glu | Ala | Ala | Gly | Thr | Thr | Pro | Lys |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |
| Glu | Thr | Glu | Ile | Cys | Asp | Ile | Ser | Asp | Arg | Glu | Phe | Lys | Ile | Ala | Leu |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |
| Leu | Lys | Lys | Leu | Lys | Glu | Ile | Gln | Asp | Asn | Thr | Glu | Lys | Glu | Leu | Arg |
|     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |
| Ile | Leu | Ser | Asp | Lys | Phe | Asn | Lys | Glu | Ile | Glu | Met | Ile | Lys | Lys | Asn |
|     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |
| Gln | Ala | Glu | Ile | Leu | Glu | Leu | Lys | Asn | Ala | Gly | Gly | Ile | Leu | Lys | Met |
| 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |
| His | Gln | Ser | Trp | Leu | Gly | Met | Val | Ala | His | Ala | Cys | Asn | Pro | Ser | Thr |
|     |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |
| Leu | Gly | Ser | Arg | Gly | Gly | Trp | Ile | Thr | Ser | Ser | Gly | Val | Gln | Asp | Gln |
|     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |
| Pro | Gly | Gln | Gly | Ser | Glu | Thr | Ser | Ser | Leu | Leu | Lys | Ile | Gln | Lys | Leu |
|     |     | 115 |     |     |     |     | 120 |     |     |     |     | 125 |     |     |     |
| Ala | Gly | Cys | Ser | Gly | Arg | His | Leu |     |     |     |     |     |     |     |     |
|     | 130 |     |     |     |     | 135 |     |     |     |     |     |     |     |     |     |

<210> 5  
 <211> 258  
 <212> DNA  
 <213> Homo sapiens

<400> 5

aacatgacct caccaaatag actaaataag gcaccaggga ccaatcctgg agaaacagag  
 60

atgtatgacc tttcagacag agaattcaaa acagctatatt tgaggaaact caaagaaatt 1  
 20

caagataaca caaagaagga attcagaatt ctatcagata aatttaacaa acagatcgaa 1  
 80

800.ST25.txt

ataattaaaa agaatcaagc agaaattcta gagctgaaaa atgtaattga tataactaaag 2  
40

aatgcatcag tctcttga 2  
58

<210> 6  
<211> 84  
<212> PRT  
<213> Homo sapiens

<400> 6

Met Thr Ser Pro Asn Glu Leu Asn Lys Ala Pro Gly Thr Asn Pro Gly  
1 5 10 15

Glu Thr Glu Met Tyr Asp Leu Ser Asp Arg Glu Phe Lys Thr Ala Ile  
20 25 30

Leu Arg Lys Leu Lys Glu Ile Gln Asp Asn Thr Lys Lys Glu Phe Arg  
35 40 45

Ile Leu Ser Asp Lys Phe Asn Lys Gln Ile Glu Ile Ile Lys Lys Asn  
50 55 60

Gln Ala Glu Ile Leu Glu Leu Lys Asn Val Ile Asp Ile Leu Lys Asn  
65 70 75 80

Ala Ser Val Ser

<210> 7  
<211> 294  
<212> DNA  
<213> Homo sapiens

<400> 7

aacatgacct caccaaata acttagtaag gcaccaggga ccaatcaggg agaaacagag  
60

atatatgacc tttcagacac agaattcaaa atagctgttt tgagaaactc aaagaagaaa 1  
20

ctcaaagaaa ttcaggataa cacagagaag gaattcagaa ttctatcaga taaatttaac 1  
80

800.ST25.txt

aaagagattg aaataattaa aaagaatcaa gcagaaattc tagagttgaa aaatgcaatt 2  
40

gacatgctga ataatgcac agattatctt catagtagaa ttaatcggaa ttag 2  
94

<210> 8  
<211> 96  
<212> PRT  
<213> Homo sapiens

<400> 8

Met Thr Ser Pro Asn Glu Leu Ser Lys Ala Pro Gly Thr Asn Gln Gly  
1 5 10 15

Glu Thr Glu Ile Tyr Asp Leu Ser Asp Thr Glu Phe Lys Ile Ala Val  
20 25 30

Leu Arg Asn Ser Lys Lys Lys Leu Lys Glu Ile Gln Asp Asn Thr Glu  
35 40 45

Lys Glu Phe Arg Ile Leu Ser Asp Lys Phe Asn Lys Glu Ile Glu Ile  
50 55 60

Ile Lys Lys Asn Gln Ala Glu Ile Leu Glu Leu Lys Asn Ala Ile Asp  
65 70 75 80

Met Leu Asn Asn Ala Ser Asp Tyr Leu His Ser Arg Ile Asn Arg Asn  
85 90 95

<210> 9  
<211> 360  
<212> DNA  
<213> Homo sapiens

<400> 9

aacatgacct caccaaatga ggtaaataag gtaccaatga ccaaccctgg agaaacggag  
60

atatgtgacc tttcagacca aaaattaaaa atagctgtga tgaggaaact caaagaaatt 1  
20

caagataaca cagagaaaga attcaaaatt ctatcacgta aatttaacaa aaagattgga 1  
80

ttaattgaaa ataatcaagc agaaattttg gagctgaaaa atgcaattgg cataactgaag 2

800.ST25.txt

40

aatgcatcag agtccttttaa tagcaatatg tatcaagcag aagacagaat tagtgagctt  
00

aaatacaggc tatttgaaaa tacacagtca gaggagacca aaaacaacaa aaaacaatga  
60

<210> 10  
<211> 118  
<212> PRT  
<213> Homo sapiens

<400> 10

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Thr | Ser | Pro | Asn | Glu | Val | Asn | Lys | Val | Pro | Met | Thr | Asn | Pro | Gly |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Glu | Thr | Glu | Ile | Cys | Asp | Leu | Ser | Asp | Gln | Lys | Leu | Lys | Ile | Ala | Val |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Arg | Lys | Leu | Lys | Glu | Ile | Gln | Asp | Asn | Thr | Glu | Lys | Glu | Phe | Lys |
|     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Leu | Ser | Arg | Lys | Phe | Asn | Lys | Lys | Ile | Gly | Leu | Ile | Glu | Asn | Asn |
| 50  |     |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gln | Ala | Glu | Ile | Leu | Glu | Leu | Lys | Asn | Ala | Ile | Gly | Ile | Leu | Lys | Asn |
| 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Ser | Glu | Ser | Phe | Asn | Ser | Asn | Met | Tyr | Gln | Ala | Glu | Asp | Arg | Ile |
|     |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Glu | Leu | Lys | Tyr | Arg | Leu | Phe | Glu | Asn | Thr | Gln | Ser | Glu | Glu | Thr |
|     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |

|     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|
| Lys | Asn | Asn | Lys | Lys | Gln |
|     |     |     | 115 |     |     |

<210> 11  
<211> 360  
<212> DNA  
<213> Homo sapiens

<400> 11  
cacatgacct caggaaatga agtaaataag gcaccaggga ccaatcttgg agaaacagag  
60

800.ST25.txt

atatgtgacc tttcagatac agaactcaga ataactgtgt tgaggaaact caatgaaatt 1  
20

aaagataaca cagagatgga attcagaatt ttgtcagata aatttaagaa agagattgaa 1  
80

ataattaaaa ggaatcaagc agaaattctg gagctgaaaa atgcaattgg cataactgaag 2  
40

aatgcatcag agttttttaa tagaagaaca gatcaagcag cagaaaaatc tagtgagcct 3  
00

gaagacagac tatttgaaaa tacacagagg tctcaaaaga aaaagaataa aaaacaataa 3  
60

<210> 12  
<211> 118  
<212> PRT  
<213> Homo sapiens

<400> 12

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |    |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|
| Met | Thr | Ser | Gly | Asn | Glu | Val | Asn | Lys | Ala | Pro | Gly | Thr | Asn | Leu | Gly | 1   | 5   | 10  | 15 |
| Glu | Thr | Glu | Ile | Cys | Asp | Leu | Ser | Asp | Thr | Glu | Leu | Arg | Ile | Thr | Val | 20  | 25  | 30  |    |
| Leu | Arg | Lys | Leu | Asn | Glu | Ile | Lys | Asp | Asn | Thr | Glu | Met | Glu | Phe | Arg | 35  | 40  | 45  |    |
| Ile | Leu | Ser | Asp | Lys | Phe | Lys | Lys | Glu | Ile | Glu | Ile | Ile | Lys | Arg | Asn | 50  | 55  | 60  |    |
| Gln | Ala | Glu | Ile | Leu | Glu | Leu | Lys | Asn | Ala | Ile | Gly | Ile | Leu | Lys | Asn | 65  | 70  | 75  | 80 |
| Ala | Ser | Glu | Phe | Leu | Asn | Arg | Arg | Thr | Asp | Gln | Ala | Ala | Glu | Lys | Ser | 85  | 90  | 95  |    |
| Ser | Glu | Pro | Glu | Asp | Arg | Leu | Phe | Glu | Asn | Thr | Gln | Arg | Ser | Gln | Lys | 100 | 105 | 110 |    |
| Lys | Lys | Asn | Lys | Lys | Gln |     |     |     |     |     |     |     |     |     |     | 115 |     |     |    |

800.ST25.txt

<210> 13  
 <211> 276  
 <212> DNA  
 <213> Homo sapiens

<400> 13  
 aacatgacct caccaaatga actgaataag ccaccaggga ccaatcctgg agaaacagaa  
 60

atatgtgacc tttcagacaa agaattcaaa atagctgtgt tgaagaaact caacgaagct 1  
 20

caagatagca cagagaagga attcagaatt ctatcagata aatgtaacaa agacattaaa 1  
 80

ataattaaaa agaatcaagc agaatttctg aagctgaaag atgcaattgg aatactgaag 2  
 40

gatgcattcag agtttttttaa tagcagaact gattga 2  
 76

<210> 14  
 <211> 90  
 <212> PRT  
 <213> Homo sapiens

<400> 14

Met Thr Ser Pro Asn Glu Leu Asn Lys Pro Pro Gly Thr Asn Pro Gly  
 1 5 10 15

Glu Thr Glu Ile Cys Asp Leu Ser Asp Lys Glu Phe Lys Ile Ala Val  
 20 25 30

Leu Lys Lys Leu Asn Glu Ala Gln Asp Ser Thr Glu Lys Glu Phe Arg  
 35 40 45

Ile Leu Ser Asp Lys Cys Asn Lys Asp Ile Lys Ile Ile Lys Lys Asn  
 50 55 60

Gln Ala Glu Phe Leu Lys Leu Lys Asp Ala Ile Gly Ile Leu Lys Asp  
 65 70 75 80

Ala Ser Glu Phe Phe Asn Ser Arg Thr Asp  
 85 90

<210> 15

800.ST25.txt

<211> 369  
 <212> DNA  
 <213> Homo sapiens

<400> 15  
 aacatgacct caccaaatga actaaataag gcaccaggga ccaatcctgg agaaactgag . . . 1  
 60  
 atatgtgacc tttcagacag aaaattcaaa agagctgtgt tgaagaaact caaagaaatt . . 1  
 20  
 caaaatgtct caaagaagga attcagaatt ctattagata aatttaacag acagattgaa . . 1  
 80  
 gtaattaaaa ataatcaaac agaaattatg gagcttaaaa acgcaattgg cataactgaaa . 2  
 40  
 atgcatcaga gttctttaat agcagcattg atcaaacaga agaaagaatt agtgaacctg . 3  
 00  
 aagacagcct atttgaaaat acacagagga gacaaaagaa aaaaatataa aagaatgaag . 3  
 60  
 cacacctaa . . . 3  
 69

<210> 16  
 <211> 121  
 <212> PRT  
 <213> Homo sapiens

<400> 16

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Thr | Ser | Pro | Asn | Glu | Leu | Asn | Lys | Ala | Pro | Gly | Thr | Asn | Pro | Gly |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |
| Glu | Thr | Glu | Ile | Cys | Asp | Leu | Ser | Asp | Arg | Lys | Phe | Lys | Arg | Ala | Val |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |
| Leu | Lys | Lys | Leu | Lys | Glu | Ile | Gln | Asn | Val | Ser | Lys | Lys | Glu | Phe | Arg |
|     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |
| Ile | Leu | Leu | Asp | Lys | Phe | Asn | Arg | Gln | Ile | Glu | Val | Ile | Lys | Asn | Asn |
|     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |
| Gln | Thr | Glu | Ile | Met | Glu | Leu | Lys | Asn | Ala | Ile | Gly | Ile | Leu | Lys | Met |
| 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |



800.ST25.txt

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| His | Gln | Ser | Ser | Leu | Ile | Ala | Ala | Leu | Ile | Lys | Gln | Lys | Lys | Glu | Leu |
|     |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |
| Val | Asn | Leu | Lys | Thr | Ala | Tyr | Leu | Lys | Ile | His | Arg | Gly | Asp | Lys | Arg |
|     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |
| Lys | Lys | Tyr | Lys | Arg | Met | Lys | His | Thr |     |     |     |     |     |     |     |
|     |     | 115 |     |     |     |     | 120 |     |     |     |     |     |     |     |     |

<210> 17

<211> 348

<212> DNA.....

<213> Homo sapiens

<400> 17

aacatgacat caacaaagga actaaataag gcaccagtaa acaatcctgg agaaacagaa  
60

ctatgtgacc ttttagacaa aaaattcaaa atagcagtgt tgaggaaact aaaaggaatt 1  
20

caaaataaca cagagaagga attcagaatt ctatcagata aatttaacaa agagattgaa 1  
80

ataattaaaa agaatacaagc agaaactctg gagctaaaaa atgcagttgg cacactaaca 2  
40

aaagcatcac agtccttttaa aagcagaatg gatatagcag aaagaagaat tagtgaactt 3  
00

aaagacaggc tatttgaaaa tacagtcaga agagaaaaaa gaatataa 3  
48

<210> 18

<211> 114

<212> PRT

<213> Homo sapiens

<400> 18

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Thr | Ser | Thr | Lys | Glu | Leu | Asn | Lys | Ala | Pro | Val | Asn | Asn | Pro | Gly |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Glu | Thr | Glu | Leu | Cys | Asp | Leu | Leu | Asp | Lys | Lys | Phe | Lys | Ile | Ala | Val |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |

800.ST25.txt

Leu Arg Lys Leu Lys Gly Ile Gln Asn Asn Thr Glu Lys Glu Phe Arg  
35 40 45

Ile Leu Ser Asp Lys Phe Asn Lys Glu Ile Glu Ile Ile Lys Lys Asn  
50 55 60

Gln Ala Glu Thr Leu Glu Leu Lys Asn Ala Val Gly Thr Leu Thr Lys  
65 70 75 80

Ala Ser Gln Ser Phe Lys Ser Arg Met Asp Ile Ala Glu Arg Arg Ile  
85 90 95

Ser Glu Leu Lys Asp Arg Leu Phe Glu Asn Thr Val Arg Arg Glu Lys  
100 105 110

Arg Ile

<210> 19  
<211> 432  
<212> DNA  
<213> Homo sapiens

<400> 19  
aatatgacct caccaaatag actaaataag gcaccaggga tcaatcctgg ggaaacagaa  
60

atatgtgacc tttcagacag agaattcaca atagctgttt cgaggaagct aaacaaaatc 1  
20

caagataaca tggagaagga attcagaatc ctatcagata aatttaatag agagattgaa 1  
80

ataattaaaa agaatcaagc agaaattctg gagctgaaaa acgcaattga catgttgaag 2  
40

aatgcatcag agaatctcac cagcagaact gatcaagcaa gagaaataat tagtaagctt 3  
00

gaagacaggc tatttgaaaa cacaaagtca gagagagaaa atggaaaaag aataaaatgc 3  
60

aatgaagcac acctacaaga actagaaaat agcttcaaaa tgggaaatct aaaagttatt 4  
20

ggccttaaat ag 4  
32

800.ST25.txt

<210> 20  
 <211> 142  
 <212> PRT  
 <213> Homo sapiens

<400> 20

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Thr | Ser | Pro | Asn | Glu | Leu | Asn | Lys | Ala | Pro | Gly | Ile | Asn | Pro | Gly |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |
| Glu | Thr | Glu | Ile | Cys | Asp | Leu | Ser | Asp | Arg | Glu | Phe | Thr | Ile | Ala | Val |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |
| Ser | Arg | Lys | Leu | Asn | Lys | Ile | Gln | Asp | Asn | Met | Glu | Lys | Glu | Phe | Arg |
|     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |
| Ile | Leu | Ser | Asp | Lys | Phe | Asn | Glu | Glu | Ile | Glu | Ile | Ile | Lys | Lys | Asn |
|     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |
| Gln | Ala | Glu | Ile | Leu | Glu | Leu | Lys | Asn | Ala | Ile | Asp | Met | Leu | Lys | Asn |
| 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |
| Ala | Ser | Glu | Asn | Leu | Thr | Ser | Arg | Thr | Asp | Gln | Ala | Arg | Glu | Ile | Ile |
|     |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |
| Ser | Lys | Leu | Glu | Asp | Arg | Leu | Phe | Glu | Asn | Thr | Lys | Ser | Glu | Glu | Thr |
|     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |
| Asn | Gly | Lys | Arg | Ile | Lys | Cys | Asn | Glu | Ala | His | Leu | Gln | Glu | Leu | Glu |
|     |     | 115 |     |     |     |     | 120 |     |     |     |     | 125 |     |     |     |
| Asn | Ser | Phe | Lys | Met | Gly | Asn | Leu | Lys | Val | Ile | Gly | Leu | Lys |     |     |
|     | 130 |     |     |     |     | 135 |     |     |     |     | 140 |     |     |     |     |

<210> 21  
 <211> 252  
 <212> DNA  
 <213> Homo sapiens

<400> 21

aacatgccct taccaaata gctaaataag gcgccaggga ccaatcctgg agaaacagag  
 60

acatgtgacc tttcagacag agaattcaaa atagctgtgt tgagaaaact caaagaaatt  
 20

caagagaata cagacaagga attgagaatt ctatcagata aatttaacaa agaaatcaaa  
 1

800.ST25.txt

80

ataatgaaaa agaatcaagc agaaattctg aagctgaaaa attcaattag tataatgaag 2  
40

aatgcatcat ag 2  
52

<210> 22  
<211> 82  
<212> PRT  
<213> Homo sapiens

<400> 22

Met Pro Leu Pro Asn Glu Leu Asn Lys Ala Pro Gly Thr Asn Pro Gly  
1 5 10 15

Glu Thr Glu Thr Cys Asp Leu Ser Asp Arg Glu Phe Lys Ile Ala Val  
20 25 30

Leu Arg Lys Leu Lys Glu Ile Gln Glu Asn Thr Asp Lys Glu Leu Arg  
35 40 45

Ile Leu Ser Asp Lys Phe Asn Lys Glu Ile Lys Ile Met Lys Lys Asn  
50 55 60

Gln Ala Glu Ile Leu Lys Leu Lys Asn Ser Ile Ser Ile Met Lys Asn  
65 70 75 80

Ala Ser

<210> 23  
<211> 327  
<212> DNA  
<213> Homo sapiens

<400> 23

aacatgacct caccaaataga actgaataag gcaccaggga cgaatttagg agaaacagag  
60

atttgtgacc tttcagacag agaattcaag aaagctgtgt tgcagaagct caaagaaatt 1  
20

caagataaca cagagaagga gttcagaatt ctattacata aatttaacaa agagattaaa 1  
80

800.ST25.txt

ataattaaaa agaatcaagc agaaattcta gaagcaaaaa atgcaactga catactgatg  
40

aatgcatcag accctattaa tagcacaatt gatgaagcag aagaaagaat tagtgagctt  
00

gaagacaggc tatttgaaag tatatag  
27

<210> 24

<211> 107

<212> PRT

<213> Homo sapiens

<400> 24

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Thr | Ser | Pro | Asn | Glu | Leu | Asn | Lys | Ala | Pro | Gly | Thr | Asn | Leu | Gly |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Glu | Thr | Glu | Ile | Cys | Asp | Leu | Ser | Asp | Arg | Glu | Phe | Lys | Lys | Ala | Val |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Gln | Lys | Leu | Lys | Glu | Ile | Gln | Asp | Asn | Thr | Glu | Lys | Glu | Phe | Arg |
|     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Leu | Leu | His | Lys | Phe | Asn | Lys | Glu | Ile | Lys | Ile | Ile | Lys | Lys | Asn |
|     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gln | Ala | Glu | Ile | Leu | Glu | Ala | Lys | Asn | Ala | Thr | Asp | Ile | Leu | Met | Asn |
| 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Ser | Asp | Pro | Ile | Asn | Ser | Thr | Ile | Asp | Glu | Ala | Glu | Glu | Arg | Ile |
|     |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |

|     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Glu | Leu | Glu | Asp | Arg | Leu | Phe | Glu | Ser | Ile |
|     |     |     | 100 |     |     |     |     | 105 |     |     |

<210> 25

<211> 285

<212> DNA

<213> Homo sapiens

<400> 25

aacatggcct caccaaacia actaaataag gcaccagaaa ccaatcccaa agagacagag  
60

800.ST25.txt

gtatgtgacc tttcagacag agaactcaaa atacctgttt tgaggaagtt caatgaaatt 1  
20

caagataaca cagagaagga attcagaatt ctatcagata aatttaacaa agagattgaa 1  
80

ataattaaaa agaatcaagc ggaaattccg gaagtgaaaa atgcaattaa tacactgaag 2  
40

aattcatcag agtctcttaa tagcagaatt gatcaagcag aataa 2  
85

<210> 26  
<211> 93  
<212> PRT  
<213> Homo sapiens

<400> 26

Met Ala Ser Pro Asn Lys Leu Asn Lys Ala Pro Glu Thr Asn Pro Lys  
1 5 10 15

Glu Thr Glu Val Cys Asp Leu Ser Asp Arg Glu Leu Lys Ile Pro Val  
20 25 30

Leu Arg Lys Phe Asn Glu Ile Gln Asp Asn Thr Glu Lys Glu Phe Arg  
35 40 45

Ile Leu Ser Asp Lys Phe Asn Lys Glu Ile Glu Ile Ile Lys Lys Asn  
50 55 60

Gln Ala Glu Ile Pro Glu Val Lys Asn Ala Ile Asn Thr Leu Lys Asn  
65 70 75 80

Ser Ser Glu Ser Leu Asn Ser Arg Ile Asp Gln Ala Glu  
85 90

<210> 27  
<211> 345  
<212> DNA  
<213> Homo sapiens

<400> 27

aacatgacct cgcctaata ga actaaatgaa gcaccaggga ccaatcctgc agagacagag  
60

atatgtaaca ttttagacag agaattcaaa atagctgttt tgaggaaact caatgaaatt 1

800.ST25.txt

20

caagataaca cagagaagga attgaaggtt ctctcagata aaattatcaa agagattgaa  
80

ataattaataa tgaatcaagc agaaattctg gagttgaaaa atgcaactga catacgggaag  
40

aatgcatcgg ggtctcttaa caagagactt aatctttcag aagaaagaat tagtgagctc  
00

ggagatagcc tatttgacaa tatacagtca gaggaagcaa actaa  
45

<210> 28  
<211> 113  
<212> PRT  
<213> Homo sapiens

<400> 28

Met Thr Ser Pro Asn Glu Leu Asn Glu Ala Pro Gly Thr Asn Pro Ala  
1 5 10 15

Glu Thr Glu Ile Cys Asn Ile Leu Asp Arg Glu Phe Lys Ile Ala Val  
20 25 30

Leu Arg Lys Leu Asn Glu Ile Gln Asp Asn Thr Glu Lys Glu Leu Lys  
35 40 45

Val Leu Ser Asp Lys Ile Ile Lys Glu Ile Glu Ile Ile Lys Met Asn  
50 55 60

Gln Ala Glu Ile Leu Glu Leu Lys Asn Ala Thr Asp Ile Arg Lys Asn  
65 70 75 80

Ala Ser Gly Ser Leu Asn Lys Arg Leu Asn Leu Ser Glu Glu Arg Ile  
85 90 95

Ser Glu Leu Gly Asp Ser Leu Phe Asp Asn Ile Gln Ser Glu Glu Ala  
100 105 110

Asn

<210> 29  
<211> 384

800.ST25.txt

<212> DNA

<213> Homo sapiens

<400> 29

aatatgacct caccaaatga actaaataag gtaccagggg ccaatectgg agaaacagag  
60

atttgtgatc attcagaaag agaattcaaa ataactgtct tgaggaaact caaagacatt 1  
20

catgataaca cagagaagac aatcagaatt ctatcagata aattttaacaa agatattgaa 1  
80

ataatttttaa aaaatcaaga tgatattctg gagctggaaa atgcaattgg tgtactgaag 2  
40

aatgaatcag ggttcttttaa tagcaggatg gatgaagcag aagaaataat tagaaagctt 3  
00

gaagacagtt tatttgaaaa tatacagtca gagaagaaag cgaaaaaagt aaaacaaaca 3  
60

aacaaaaaaaa gaagcatgta ttag 3  
84

<210> 30

<211> 126

<212> PRT

<213> Homo sapiens

<400> 30

Met Thr Ser Pro Asn Glu Leu Asn Lys Val Pro Gly Ala Asn Pro Gly  
1 5 10 15

Glu Thr Glu Ile Cys Asp His Ser Glu Arg Glu Phe Lys Ile Thr Val  
20 25 30

Leu Arg Lys Leu Lys Asp Ile His Asp Asn Thr Glu Lys Thr Ile Arg  
35 40 45

Ile Leu Ser Asp Lys Phe Asn Lys Asp Ile Glu Ile Ile Leu Lys Asn  
50 55 60

Gln Asp Asp Ile Leu Glu Leu Glu Asn Ala Ile Gly Val Leu Lys Asn  
65 70 75 80



800.ST25.txt

Glu Ser Gly Phe Phe Asn Ser Arg Met Asp Glu Ala Glu Glu Ile Ile  
85 90 95

Arg Lys Leu Glu Asp Ser Leu Phe Glu Asn Ile Gln Ser Glu Lys Lys  
100 105 110

Ala Lys Lys Val Lys Gln Thr Asn Lys Lys Arg Ser Met Tyr  
115 120 125

<210> 31

<211> 237

<212> DNA

<213> Homo sapiens

<400> 31

aacatgacct caccaaataa acttaaaaag gcaccaggga ccaatcctgg agaaacagaa  
60

acatgtggac tttcacagag agaattcaaa gtagctgtgt tgaggaaact caaagaaatt 1  
20

caagataaca gagagaagga attcagaatt gtatcagata aatttaacaa agagattgaa 1  
80

ataattaaaa agaatcaggc agaaatactg gagctgaaaa atcaactggc atactga 2  
37

<210> 32

<211> 77

<212> PRT

<213> Homo sapiens

<400> 32

Met Thr Ser Pro Asn Lys Leu Lys Lys Ala Pro Gly Thr Asn Pro Gly  
1 5 10 15

Glu Thr Glu Thr Cys Gly Leu Ser Gln Arg Glu Phe Lys Val Ala Val  
20 25 30

Leu Arg Lys Leu Lys Glu Ile Gln Asp Asn Arg Glu Lys Glu Phe Arg  
35 40 45

Ile Val Ser Asp Lys Phe Asn Lys Glu Ile Glu Ile Ile Lys Lys Asn  
50 55 60

Gln Ala Glu Ile Leu Glu Leu Lys Asn Gln Leu Ala Tyr

800.ST25.txt

65

70

75

<210> 33  
<211> 285  
<212> DNA  
<213> Homo sapiens

<400> 33  
aacatgacct caccaaaca actaaataag gcacccaggg ccaattctgg agaaacagag  
60

atacgtaaac tttcaaacac agaaatcaag atagctgtgt tgagaaaact caaagaaatt 1  
20

caagataaca cagagaaaga attcagaatt ctatcagata aatttaacaa agagattgaa 1  
80

ataactaaaa agaatcaagc agaaattctg gagctgagaa atgcaattga cataactgaag 2  
40

aatgcatcag ggtcttttaa tagcagaatt gagcaagcag aataa 2  
85

<210> 34  
<211> 93  
<212> PRT  
<213> Homo sapiens

<400> 34

Met Thr Ser Pro Asn Lys Leu Asn Lys Ala Pro Arg Ala Asn Ser Gly  
1 5 10 15

Glu Thr Glu Ile Arg Lys Leu Ser Asn Thr Glu Ile Lys Ile Ala Val  
20 25 30

Leu Arg Lys Leu Lys Glu Ile Gln Asp Asn Thr Glu Lys Glu Phe Arg  
35 40 45

Ile Leu Ser Asp Lys Phe Asn Lys Glu Ile Glu Ile Thr Lys Lys Asn  
50 55 60

Gln Ala Glu Ile Leu Glu Leu Arg Asn Ala Ile Asp Ile Leu Lys Asn  
65 70 75 80

Ala Ser Gly Ser Phe Asn Ser Arg Ile Glu Gln Ala Glu  
85 90

800.ST25.txt

<210> 35  
 <211> 285  
 <212> DNA  
 <213> Homo sapiens

<400> 35  
 aacatgacct cactaaatga actaaataag gcaccagggg ccaaccctgg agaaacagag  
 60  
 atatgcgacc tttcagacag agaattcaaa atagctgtgt tggggaaatt caaagataac  
 20  
 acagagaagg aattcagaat tctatcagat aaatttaaca aagagattga aataattaaa  
 80  
 aagaatcaag cagaaattct ggagctgaaa aatgcaattg ccacattaaa gaatgcatta  
 40  
 gagtttttta atagcagaat ttatggagca gaaaaaaaga attag  
 85

<210> 36  
 <211> 93  
 <212> PRT  
 <213> Homo sapiens

<400> 36  
 Met Thr Ser Leu Asn Glu Leu Asn Lys Ala Pro Gly Ala Asn Pro Gly  
 1 5 10 15  
 Glu Thr Glu Ile Cys Asp Leu Ser Asp Arg Glu Phe Lys Ile Ala Val  
 20 25 30  
 Leu Gly Lys Phe Lys Asp Asn Thr Glu Lys Glu Phe Arg Ile Leu Ser  
 35 40 45  
 Asp Lys Phe Asn Lys Glu Ile Glu Ile Ile Lys Lys Asn Gln Ala Glu  
 50 55 60  
 Ile Leu Glu Leu Lys Asn Ala Ile Ala Thr Leu Lys Asn Ala Leu Glu  
 65 70 75 80  
 Phe Phe Asn Ser Arg Ile Tyr Gly Ala Glu Lys Lys Asn  
 85 90

800.ST25.txt

<210> 37  
 <211> 339  
 <212> DNA  
 <213> Homo sapiens

<400> 37  
 tcaatggcca gacacctaca aacatccact agcatcaaga ccatccagga aataggacc  
 60

tcaccaagtg aactaaataa ggcaccaggg gccagtcttg gagaaacaga gatatgtgat. 1  
 20

ctttcaaaca gagaattgaa aatagctgtt ttgaggaaac tcaaagaaat tcaagatagc 1  
 80

acagagaagg aattcagaat cctatcagat aaatttaaca aacaaattga aataattaaa 2  
 40

aacagtcaag cagaaattct ggagctgaaa aatgcaattg acttactgaa gaatgcatca 3  
 00

gaatctccta atagtagaat taatcaagta gaagaatga 3  
 39

<210> 38  
 <211> 111  
 <212> PRT  
 <213> Homo sapiens

<400> 38

Met Ala Arg His Leu Gln Thr Ser Thr Ser Ile Lys Thr Ile Gln Glu  
 1 5 10 15

Asn Arg Thr Ser Pro Ser Glu Leu Asn Lys Ala Pro Gly Ala Ser Leu  
 20 25 30

Gly Glu Thr Glu Ile Cys Asp Leu Ser Asn Arg Glu Leu Lys Ile Ala  
 35 40 45

Val Leu Arg Lys Leu Lys Glu Ile Gln Asp Ser Thr Glu Lys Glu Phe  
 50 55 60

Arg Ile Leu Ser Asp Lys Phe Asn Lys Gln Ile Glu Ile Ile Lys Asn  
 65 70 75 80

Ser Gln Ala Glu Ile Leu Glu Leu Lys Asn Ala Ile Asp Leu Leu Lys

## 800.ST25.txt

85

90

95

Asn Ala Ser Glu Ser Pro Asn Ser Arg Ile Asn Gln Val Glu Glu  
 100 105 110

<210> 39  
 <211> 345  
 <212> DNA  
 <213> Homo sapiens

<400> 39  
 tcaatgccaa gacaccaaag aacacctact agaatcaaca ccatccagga aaacacgacc  
 60

tcatcaaattg agctaaatga ggcaccaggg atcactcctg gagaaacaga gatattgtgac 1  
 20

ctttcagaca gagaattcaa agtagctgtg ttgagagagc tcaaagaaat tcaagataac 1  
 80

acagagaaga aattcagaat tctaccagat aaatttatca aagagattga aataattaaa 2  
 40

aagaatcaat cagaaattct ggagctgaaa aaccaactg ctgtactgaa gaatgcatca 3  
 00

gagtccctta atagcagaat ggatcgagta gaaaagaaga attag 3  
 45

<210> 40  
 <211> 113  
 <212> PRT  
 <213> Homo sapiens

<400> 40

Met Pro Arg His Gln Arg Thr Pro Thr Arg Ile Asn Thr Ile Gln Glu  
 1 5 10 15

Asn Thr Thr Ser Ser Asn Glu Leu Asn Glu Ala Pro Gly Ile Thr Pro  
 20 25 30

Gly Glu Thr Glu Ile Cys Asp Leu Ser Asp Arg Glu Phe Lys Val Ala  
 35 40 45

Val Leu Arg Glu Leu Lys Glu Ile Gln Asp Asn Thr Glu Lys Lys Phe  
 50 55 60

800.ST25.txt

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Ile | Leu | Pro | Asp | Lys | Phe | Ile | Lys | Glu | Ile | Glu | Ile | Ile | Lys | Lys | ... |
| 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |     |
| Asn | Gln | Ser | Glu | Ile | Leu | Glu | Leu | Lys | Asn | Pro | Thr | Ala | Val | Leu | Lys | ... |
|     |     |     | 85  |     |     |     |     |     | 90  |     |     |     |     |     | 95  |     |
| Asn | Ala | Ser | Glu | Ser | Leu | Asn | Ser | Arg | Met | Asp | Arg | Val | Glu | Lys | Lys | ... |
|     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |     |

Asn

<210> 41  
 <211> 22  
 <212> DNA  
 <213> synthetic construct

<400> 41  
 aacatgacct caccaaataa ac  
 22

<210> 42  
 <211> 21  
 <212> DNA  
 <213> synthetic construct

<400> 42  
 aacatgacat caccaaatga g  
 21

<210> 43  
 <211> 29  
 <212> DNA  
 <213> synthetic construct

<400> 43  
 tcattttttt ttattccttt tcttttgtc  
 29

<210> 44  
 <211> 22  
 <212> DNA  
 <213> synthetic construct

800.ST25.txt

<400> 44

ttacaggtgc ctgccactgc ac

22

<210> 45

<211> 22

<212> DNA

<213> synthetic construct

<400> 45

aacatgacct caccaa'atga ac

22

<210> 46

<211> 24

<212> DNA

<213> synthetic construct

<400> 46

tcaagagact gatgcattct ttag

24

<210> 47

<211> 22

<212> DNA

<213> synthetic construct

<400> 47

aacatgacct caccaa'atga ac

22

<210> 48

<211> 24

<212> DNA

<213> synthetic construct

<400> 48

ctaattccga ttaattctac tatg

24

<210> 49

<211> 21

<212> DNA

<213> synthetic construct

<400> 49

aacatgacct caccaaatga g

21

<210> 50

<211> 25

<212> DNA

<213> synthetic construct

<400> 50

tcattgtttt ttgttgtttt tggtc

25

<210> 51

<211> 22

<212> DNA

<213> synthetic construct

<400> 51

cacatgacct caggaaatga ag

22

<210> 52

<211> 27

<212> DNA

<213> synthetic construct

<400> 52

ttattgtttt ttattctttt tcttttg

27

<210> 53

<211> 22

<212> DNA

<213> synthetic construct

<400> 53

aacatgacct caccaaatga ac

22

<210> 54



---

800.ST25.txt

<211> 27  
<212> DNA  
<213> synthetic construct

<400> 54  
tcaatcagtt ctgctattaa aaaactc  
27

<210> 55  
<211> 22  
<212> DNA  
<213> synthetic construct

<400> 55  
aacatgacct caccaaatga ac  
22

<210> 56  
<211> 30  
<212> DNA  
<213> synthetic construct

<400> 56  
ttaggtgtgc ttcattcttt tatatTTTTT  
30

<210> 57  
<211> 22  
<212> DNA  
<213> synthetic construct

<400> 57  
aacatgacat caacaaagga ac  
22

<210> 58  
<211> 26  
<212> DNA  
<213> synthetic construct

<400> 58  
ttatattctt ttttctcttc tgactg  
26

800.ST25.txt

<210> 59  
<211> 22  
<212> DNA  
<213> synthetic construct

<400> 59  
aatatgacct caccaaatga ac  
22

<210> 60  
<211> 24  
<212> DNA  
<213> synthetic construct

<400> 60  
ctatttaagg ccaataactt ttag  
24

<210> 61  
<211> 22  
<212> DNA  
<213> synthetic construct

<400> 61  
aacatgccct taccaaatga gc  
22

<210> 62  
<211> 23  
<212> DNA  
<213> synthetic construct

<400> 62  
ctatgatgca ttcttcatta tac  
23

<210> 63  
<211> 22  
<212> DNA  
<213> synthetic construct

<400> 63  
aacatgacct caccaaatga ac

800.ST25.txt

22

<210> 64  
<211> 24  
<212> DNA  
<213> synthetic construct

<400> 64  
ctatatactt tcaaatagcc tgtc  
24

<210> 65  
<211> 22  
<212> DNA  
<213> synthetic construct

<400> 65  
aacatgacct cgcctaatga ac  
22

<210> 66  
<211> 21  
<212> DNA  
<213> synthetic construct

<400> 66  
ttagtttgct tcctctgact g  
21

<210> 67  
<211> 22  
<212> DNA  
<213> synthetic construct

<400> 67  
aatatgacct caccaaatac ac  
22

<210> 68  
<211> 26  
<212> DNA  
<213> synthetic construct

<400> 68  
ctaatacatg cttctttttt tgtttg  
26

<210> 69  
<211> 22  
<212> DNA  
<213> synthetic construct

<400> 69  
aacatgacct caccaaataa ac  
22

<210> 70  
<211> 25  
<212> DNA  
<213> synthetic construct

<400> 70  
tcagtatgcc agttgatttt tcagc  
25

<210> 71  
<211> 22  
<212> DNA  
<213> synthetic construct

<400> 71  
aacatgacct caccaaacia ac  
22

<210> 72  
<211> 23  
<212> DNA  
<213> synthetic construct

<400> 72  
ttattctgct tgctcaattc tgc  
23

<210> 73  
<211> 22  
<212> DNA

800.ST25.txt

<213> synthetic construct

<400> 73

aacatgacct cactaaatga ac

22

<210> 74

<211> 29

<212> DNA

<213> synthetic construct

<400> 74

ctaattcttt ttttctgctc cataaatte

29

<210> 75

<211> 23

<212> DNA

<213> synthetic construct

<400> 75

tcaatggcca gacacctaca aac

23

<210> 76

<211> 26

<212> DNA

<213> synthetic construct

<400> 76

tcattcttct acttgattaa ttctac

26

<210> 77

<211> 23

<212> DNA

<213> synthetic construct

<400> 77

tcaatgccaa gacaccaaag aac

23

<210> 78

800.ST25.txt

<211> 25  
<212> DNA  
<213> synthetic construct

<400> 78  
ctaattcttc ttttctactc gatcc  
25

<210> 79  
<211> 39  
<212> DNA  
<213> synthetic construct

<400> 79  
aagcaggctt cgccaccaac atgacctcac caaataaac  
39

<210> 80  
<211> 41  
<212> DNA  
<213> synthetic construct

<400> 80  
gtgatggtga tgggtgtttt ttttattcct tttcttttgt c  
41

<210> 81  
<211> 38  
<212> DNA  
<213> synthetic construct

<400> 81  
aagcaggctt cgccaccaac atgacatcac caaatgag  
38

<210> 82  
<211> 34  
<212> DNA  
<213> synthetic construct

<400> 82  
gtgatggtga tgggtgcaggt gcctgccact gcac  
34

800.ST25.txt

<210> 83  
<211> 36  
<212> DNA  
<213> synthetic construct

<400> 83  
aagcaggctt cgccaccatg acctcaccaa atgaac  
36

<210> 84  
<211> 36  
<212> DNA  
<213> synthetic construct

<400> 84  
gtgatggtga tggtagagaga ctgatgcatt ctttag  
36

<210> 85  
<211> 39  
<212> DNA  
<213> synthetic construct

<400> 85  
aagcaggctt cgccaccaac atgacctcac caaatgaac  
39

<210> 86  
<211> 36  
<212> DNA  
<213> synthetic construct

<400> 86  
gtgatggtga tggtagattcc gattaattct actatg  
36

<210> 87  
<211> 38  
<212> DNA  
<213> synthetic construct

<400> 87  
aagcaggctt cgccaccaac atgacctcac caaatgag

38

<210> 88  
<211> 37  
<212> DNA  
<213> synthetic construct

<400> 88  
gtgatgggtga tgggtgttggt ttttggttggt ttgggtc  
37

<210> 89  
<211> 39  
<212> DNA  
<213> synthetic construct

<400> 89  
aagcaggctt cgccaccac atgacctcag gaaatgaag  
39

<210> 90  
<211> 39  
<212> DNA  
<213> synthetic construct

<400> 90  
gtgatgggtga tgggtgttggt ttttattcctt tttcttttg  
39

<210> 91  
<211> 39  
<212> DNA  
<213> synthetic construct

<400> 91  
aagcaggctt cgccaccaac atgacctcac caaatgaac  
39

<210> 92  
<211> 39  
<212> DNA  
<213> synthetic construct



800.ST25.txt

<400> 92  
gtgatggtga tggatgatcag ttctgctatt aaaaaactc  
39

<210> 93  
<211> 39  
<212> DNA  
<213> synthetic construct

<400> 93  
aagcaggctt cgccaccaac atgacctcac caaatgaac  
39

<210> 94  
<211> 42  
<212> DNA  
<213> synthetic construct

<400> 94  
gtgatggtga tggatgggtgt gcttcattct tttatatattt tt  
42

<210> 95  
<211> 39  
<212> DNA  
<213> synthetic construct

<400> 95  
aagcaggctt cgccaccaac atgacatcaa caaaggaac  
39

<210> 96  
<211> 38  
<212> DNA  
<213> synthetic construct

<400> 96  
gtgatggtga tggatgtattc ttttttctct tctgactg  
38

<210> 97  
<211> 39  
<212> DNA

800.ST25.txt

<213> synthetic construct

<400> 97

aagcaggctt cgccaccaat atgacctcac caaatgaac  
39

<210> 98

<211> 36

<212> DNA

<213> synthetic construct

<400> 98

gtgatggtga tgggtgtttaa ggccaataac ttttag  
36

<210> 99

<211> 39

<212> DNA

<213> synthetic construct

<400> 99

aagcaggctt cgccaccaac atgcccttac caaatgagc  
39

<210> 100

<211> 35

<212> DNA

<213> synthetic construct

<400> 100

gtgatggtga tgggtgtgatg cattcttcat tatac  
35

<210> 101

<211> 39

<212> DNA

<213> synthetic construct

<400> 101

aagcaggctt cgccaccaac atgacctcac caaatgaac  
39

<210> 102

800.ST25.txt

<211> 36  
<212> DNA  
<213> synthetic construct

<400> 102  
gtgatggtga tgggtgtatac tttcaaatac cctgtc  
36

<210> 103  
<211> 39  
<212> DNA  
<213> synthetic construct

<400> 103  
aagcaggctt cgccaccaac atgacctcgc ctaatgaac  
39

<210> 104  
<211> 33  
<212> DNA  
<213> synthetic construct

<400> 104  
gtgatggtga tgggtgggttg cttcctctga ctg  
33

<210> 105  
<211> 39  
<212> DNA  
<213> synthetic construct

<400> 105  
aagcaggctt cgccaccaat atgacctcac caaatgaac  
39

<210> 106  
<211> 38  
<212> DNA  
<213> synthetic construct

<400> 106  
gtgatggtga tgggtgataca tgcttctttt tttgtttg  
38

800.ST25.txt

<210> 107  
<211> 39  
<212> DNA  
<213> synthetic construct

<400> 107  
aagcaggctt cgccaccaac atgacctcac caaataaac  
39

<210> 108  
<211> 37  
<212> DNA  
<213> synthetic construct

<400> 108  
gtgatggtga tggatggtatg ccagttgatt tttcagc  
37

<210> 109  
<211> 39  
<212> DNA  
<213> synthetic construct

<400> 109  
aagcaggctt cgccaccaac atgacctcac caaacaac  
39

<210> 110  
<211> 35  
<212> DNA  
<213> synthetic construct

<400> 110  
gtgatggtga tggatggtctg cttgctcaat tctgc  
35

<210> 111  
<211> 39  
<212> DNA  
<213> synthetic construct

<400> 111  
aagcaggctt cgccaccaac atgacctcac taaatgaac

---

800.ST25.txt

39

<210> 112  
<211> 41  
<212> DNA  
<213> synthetic construct

<400> 112  
gtgatggtga tggatgattct ttttttctgc tccataaatt c  
41

<210> 113  
<211> 40  
<212> DNA  
<213> synthetic construct

<400> 113  
aagcaggctt cgccacctca atggccagac acctacaaac  
40

<210> 114  
<211> 38  
<212> DNA  
<213> synthetic construct

<400> 114  
gtgatggtga tggatgttctt ctacttgatt aattctac  
38

<210> 115  
<211> 40  
<212> DNA  
<213> synthetic construct

<400> 115  
aagcaggctt cgccacctca atgccaagac accaaagaac  
40

<210> 116  
<211> 37  
<212> DNA  
<213> synthetic construct

800.ST25.txt

<400> 116  
gtgatggatga tggatgattct tcttttctac tcatcc  
37

<210> 117  
<211> 59  
<212> DNA  
<213> synthetic construct

<400> 117  
ggggacaagt ttgtacaaaa aagcaggctt cgccaccaac atgacctcac caataaac  
59

<210> 118  
<211> 77  
<212> DNA  
<213> synthetic construct

<400> 118  
ggggaccact ttgtacaaga aagctggggt tcaatggatga tggatgaggt gttttttttt  
60

attccttttc ttttgtc  
77

<210> 119  
<211> 58  
<212> DNA  
<213> synthetic construct

<400> 119  
ggggacaagt ttgtacaaaa aagcaggctt cgccaccaac atgacatcac caaatgag  
58

<210> 120  
<211> 70  
<212> DNA  
<213> synthetic construct

<400> 120  
ggggaccact ttgtacaaga aagctggggt tcaatggatga tggatgaggt gcaggatgct  
60

gccactgcac

800.ST25.txt

70

<210> 121  
<211> 59  
<212> DNA  
<213> synthetic construct

<400> 121  
ggggacaagt ttgtacaaaa aagcaggctt cgccaccaac atgacctcac caaatgaac  
59

<210> 122  
<211> 72  
<212> DNA  
<213> synthetic construct

<400> 122  
ggggaccact ttgtacaaga aagctggggt tcaatgggtga tggatgatggt gagagactga  
60

tgcattcttt ag  
72

<210> 123  
<211> 59  
<212> DNA  
<213> synthetic construct

<400> 123  
ggggacaagt ttgtacaaaa aagcaggctt cgccaccaac atgacctcac caaatgaac  
59

<210> 124  
<211> 72  
<212> DNA  
<213> synthetic construct

<400> 124  
ggggaccact ttgtacaaga aagctggggt tcaatgggtga tggatgatggt gattccgatt  
60

aattctacta tg  
72

800.ST25.txt

<210> 125  
<211> 58  
<212> DNA  
<213> synthetic construct

<400> 125  
ggggacaagt ttgtacaaaa aagcagggtt cgccaccaac atgacctcac caaatgag  
58

<210> 126  
<211> 73  
<212> DNA  
<213> synthetic construct

<400> 126  
ggggaccact ttgtacaaga aagctgggtt tcaatgggtga tggatgatggt gttgtttttt  
60

gttgtttttg gtc  
73

<210> 127  
<211> 59  
<212> DNA  
<213> synthetic construct

<400> 127  
ggggacaagt ttgtacaaaa aagcagggtt cgccaccac atgacctcag gaaatgaag  
59

<210> 128  
<211> 75  
<212> DNA  
<213> synthetic construct

<400> 128  
ggggaccact ttgtacaaga aagctgggtt tcaatgggtga tggatgatggt gttgtttttt  
60

attctttttc ttttg  
75

<210> 129



800.ST25.txt

<211> 59  
<212> DNA  
<213> synthetic construct

<400> 129  
ggggacaagt ttgtacaaaa aagcaggctt cgccaccaac atgacctcac caaatgaac  
59

<210> 130  
<211> 75  
<212> DNA  
<213> synthetic construct

<400> 130  
ggggaccact ttgtacaaga aagctgggtt tcaatggtga tggatgatggt gatcagttct  
60

gctattaaaa aactc  
75

<210> 131  
<211> 59  
<212> DNA  
<213> synthetic construct

<400> 131  
ggggacaagt ttgtacaaaa aagcaggctt cgccaccaac atgacctcac caaatgaac  
59

<210> 132  
<211> 78  
<212> DNA  
<213> synthetic construct

<400> 132  
ggggaccact ttgtacaaga aagctgggtt tcaatggtga tggatgatggt gggatgatggt  
60

cattctttta tatttttt  
78

<210> 133  
<211> 59  
<212> DNA

800.ST25.txt

<213> synthetic construct

<400> 133

ggggacaagt ttgtacaaaa aagcaggctt cgccaccaac atgacatcaa caaaggaac  
59

<210> 134

<211> 74

<212> DNA

<213> synthetic construct

<400> 134

ggggaccact ttgtacaaga aagctggggt tcaatgggtga tggatgatggt gtattctttt  
60

ttctcttctg actg

74

<210> 135

<211> 59

<212> DNA

<213> synthetic construct

<400> 135

ggggacaagt ttgtacaaaa aagcaggctt cgccaccaat atgacctcac caaatgaac  
59

<210> 136

<211> 72

<212> DNA

<213> synthetic construct

<400> 136

ggggaccact ttgtacaaga aagctggggt tcaatgggtga tggatgatggt gtttaaggcc  
60

aataactttt ag

72

<210> 137

<211> 59

<212> DNA

<213> synthetic construct

800.ST25.txt

<400> 137

ggggacaagt ttgtacaaaa aagcaggctt cgccaccaac atgoccttac caaatgagc  
59

<210> 138

<211> 71

<212> DNA

<213> synthetic construct

<400> 138

ggggaccact ttgtacaaga aagctggggt tcaatgggtga tggatgatggt gtgatgcatt  
60

cttcattata c

71

<210> 139

<211> 59

<212> DNA

<213> synthetic construct

<400> 139

ggggacaagt ttgtacaaaa aagcaggctt cgccaccaac atgacctcac caaatgaac  
59

<210> 140

<211> 72

<212> DNA

<213> synthetic construct

<400> 140

ggggaccact ttgtacaaga aagctggggt tcaatgggtga tggatgatggt gtatactttc  
60

aaatagcctg tc

72

<210> 141

<211> 59

<212> DNA

<213> synthetic construct

<400> 141

ggggacaagt ttgtacaaaa aagcaggctt cgccaccaac atgacctcgc ctaatgaac

59

<210> 142  
<211> 69  
<212> DNA  
<213> synthetic construct

<400> 142  
ggggaccact ttgtacaaga aagctggggt tcaatgggtga tggatgatggg gggttgcttc  
60

ctctgactg  
69

<210> 143  
<211> 59  
<212> DNA  
<213> synthetic construct

<400> 143  
ggggacaagt ttgtacaaaa aagcagggtt cgccaccaat atgacctcac caaatgaac  
59

<210> 144  
<211> 74  
<212> DNA  
<213> synthetic construct

<400> 144  
ggggaccact ttgtacaaga aagctggggt tcaatgggtga tggatgatggg gatacatgct  
60

tcttttttttg ttg  
74

<210> 145  
<211> 59  
<212> DNA  
<213> synthetic construct

<400> 145  
ggggacaagt ttgtacaaaa aagcagggtt cgccaccaac atgacctcac caataaac  
59

800.ST25.txt

<210> 146  
<211> 73  
<212> DNA  
<213> synthetic construct

<400> 146  
ggggaccact ttgtacaaga aagctggggt tcaatgggtga tggatgatggt ggtatgccag  
60  
ttgatattttc agc  
73

<210> 147  
<211> 59  
<212> DNA  
<213> synthetic construct

<400> 147  
ggggacaagt ttgtacaaaa aagcagggtt cgccaccaac atgacctcac caaacaac  
59

<210> 148  
<211> 71  
<212> DNA  
<213> synthetic construct

<400> 148  
ggggaccact ttgtacaaga aagctggggt tcaatgggtga tggatgatggt gttctgcttg  
60  
ctcaattctg c  
71

<210> 149  
<211> 59  
<212> DNA  
<213> synthetic construct

<400> 149  
ggggacaagt ttgtacaaaa aagcagggtt cgccaccaac atgacctcac taaatgaac  
59

<210> 150

800.ST25.txt

<211> 77  
<212> DNA  
<213> synthetic construct

<400> 150  
ggggaccact ttgtacaaga aagctggggt tcaatgggtga tggatgatggt gattcttttt  
60

ttctgctcca taaattc  
77

<210> 151  
<211> 60  
<212> DNA  
<213> synthetic construct

<400> 151  
ggggacaagt ttgtacaaaa aagcaggctt cgccacctca atggccagac acctacaaac  
60

<210> 152  
<211> 74  
<212> DNA  
<213> synthetic construct

<400> 152  
ggggaccact ttgtacaaga aagctggggt tcaatgggtga tggatgatggt gttcttctac  
60

ttgattaatt ctac  
74

<210> 153  
<211> 60  
<212> DNA  
<213> synthetic construct

<400> 153  
ggggacaagt ttgtacaaaa aagcaggctt cgccacctca atgccaagac accaaagaac  
60

<210> 154  
<211> 73  
<212> DNA

800.ST25.txt

<213> synthetic construct

<400> 154

ggggaccact ttgtacaaga aagctggggt tcaatgggtga tggatgatggt gattcttctt  
60

ttctactcga tcc  
73

<210> 155

<211> 78

<212> PRT

<213> Homo sapiens

<400> 155

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Thr | Ser | Pro | Asn | Glu | Leu | Asn | Lys | Leu | Pro | Trp | Thr | Asn | Pro | Gly |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Glu | Thr | Glu | Ile | Cys | Asp | Leu | Ser | Asp | Thr | Glu | Phe | Lys | Ile | Ser | Val |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Lys | Asn | Leu | Lys | Glu | Ile | Gln | Asp | Asn | Thr | Glu | Lys | Glu | Ser | Arg |
|     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Leu | Ser | Asp | Lys | Tyr | Lys | Lys | Gln | Ile | Glu | Ile | Ile | Lys | Gly | Asn |
|     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gln | Ala | Glu | Ile | Leu | Glu | Leu | Arg | Asn | Ala | Asp | Gly | Thr | Leu |
| 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**